[
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Alprenolol </protein> and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the <chemical> beta 1-adrenoceptors </chemical> of rat left atria.",
    "original_text": " Alprenolol  and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the  beta 1-adrenoceptors  of rat left atria.",
    "entity1": "Alprenolol",
    "entity2": "beta 1-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Alprenolol and <protein> bromoacetylalprenololmenthane </protein> are competitive slowly reversible antagonists at the <chemical> beta 1-adrenoceptors </chemical> of rat left atria.",
    "original_text": "Alprenolol and  bromoacetylalprenololmenthane  are competitive slowly reversible antagonists at the  beta 1-adrenoceptors  of rat left atria.",
    "entity1": "bromoacetylalprenololmenthane",
    "entity2": "beta 1-adrenoceptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Alprenolol and BAAM also caused surmountable antagonism of <protein> isoprenaline </protein> responses, and this <chemical> beta 1-adrenoceptor </chemical> antagonism was slowly reversible.",
    "original_text": "Alprenolol and BAAM also caused surmountable antagonism of  isoprenaline  responses, and this  beta 1-adrenoceptor  antagonism was slowly reversible.",
    "entity1": "isoprenaline",
    "entity2": "beta 1-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Alprenolol </protein> and BAAM also caused surmountable antagonism of isoprenaline responses, and this <chemical> beta 1-adrenoceptor </chemical> antagonism was slowly reversible.",
    "original_text": " Alprenolol  and BAAM also caused surmountable antagonism of isoprenaline responses, and this  beta 1-adrenoceptor  antagonism was slowly reversible.",
    "entity1": "Alprenolol",
    "entity2": "beta 1-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Alprenolol and <protein> BAAM </protein> also caused surmountable antagonism of isoprenaline responses, and this <chemical> beta 1-adrenoceptor </chemical> antagonism was slowly reversible.",
    "original_text": "Alprenolol and  BAAM  also caused surmountable antagonism of isoprenaline responses, and this  beta 1-adrenoceptor  antagonism was slowly reversible.",
    "entity1": "BAAM",
    "entity2": "beta 1-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We conclude that <protein> alprenolol </protein> and BAAM are competitive slowly reversible <chemical> beta 1-adrenoceptor </chemical> antagonists on rat left atria.",
    "original_text": "We conclude that  alprenolol  and BAAM are competitive slowly reversible  beta 1-adrenoceptor  antagonists on rat left atria.",
    "entity1": "alprenolol",
    "entity2": "beta 1-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We conclude that alprenolol and <protein> BAAM </protein> are competitive slowly reversible <chemical> beta 1-adrenoceptor </chemical> antagonists on rat left atria.",
    "original_text": "We conclude that alprenolol and  BAAM  are competitive slowly reversible  beta 1-adrenoceptor  antagonists on rat left atria.",
    "entity1": "BAAM",
    "entity2": "beta 1-adrenoceptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Discovery and optimization of <protein> anthranilic acid sulfonamides </protein> as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of <chemical> albumin </chemical> binding.",
    "original_text": "Discovery and optimization of  anthranilic acid sulfonamides  as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of  albumin  binding.",
    "entity1": "anthranilic acid sulfonamides",
    "entity2": "albumin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Adenine phosphoribosyltransferase </protein> plays a role in purine salvage by catalyzing the direct conversion of <chemical> adenine </chemical> to adenosine monophosphate.",
    "original_text": " Adenine phosphoribosyltransferase  plays a role in purine salvage by catalyzing the direct conversion of  adenine  to adenosine monophosphate.",
    "entity1": "Adenine phosphoribosyltransferase",
    "entity2": "adenine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of <protein> acetylcholine </protein>, an important neurotransmitter associated with memory, by blocking the enzyme <chemical> acetylcholinesterase </chemical>.",
    "original_text": "BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of  acetylcholine , an important neurotransmitter associated with memory, by blocking the enzyme  acetylcholinesterase .",
    "entity1": "acetylcholine",
    "entity2": "acetylcholinesterase"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell <protein> K(ATP) channel </protein>, and suggest that <chemical> mitiglinide </chemical> may be a clinically useful anti-diabetic drug.",
    "original_text": "These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell  K(ATP) channel , and suggest that  mitiglinide  may be a clinically useful anti-diabetic drug.",
    "entity1": "K(ATP) channel",
    "entity2": "mitiglinide"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly <protein> telmisartan </protein>, are partial agonists at <chemical> peroxisome proliferator-activated receptor-\u03b3 </chemical>.",
    "original_text": "Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly  telmisartan , are partial agonists at  peroxisome proliferator-activated receptor-\u03b3 .",
    "entity1": "telmisartan",
    "entity2": "peroxisome proliferator-activated receptor-\u03b3"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Although generally highly specific for <protein> angiotensin II type 1 receptors </protein>, some ARBs, particularly <chemical> telmisartan </chemical>, are partial agonists at peroxisome proliferator-activated receptor-\u03b3.",
    "original_text": "Although generally highly specific for  angiotensin II type 1 receptors , some ARBs, particularly  telmisartan , are partial agonists at peroxisome proliferator-activated receptor-\u03b3.",
    "entity1": "angiotensin II type 1 receptors",
    "entity2": "telmisartan"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Direct-acting <protein> CB1 </protein> agonists, including <chemical> \u0394(9)-tetrahydrocannabinol </chemical>, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "original_text": "Direct-acting  CB1  agonists, including  \u0394(9)-tetrahydrocannabinol , WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "entity1": "CB1",
    "entity2": "\u0394(9)-tetrahydrocannabinol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Direct-acting <protein> CB1 </protein> agonists, including \u0394(9)-tetrahydrocannabinol, <chemical> WIN 55,212 </chemical> [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "original_text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol,  WIN 55,212  [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "entity1": "CB1",
    "entity2": "WIN 55,212"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Direct-acting <protein> CB1 </protein> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 <chemical>[ R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate </chemical>], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "original_text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [ R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate ], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "entity1": "CB1",
    "entity2": "[ R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Direct-acting <protein> CB1 </protein> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], <chemical> AM2389 </chemical> [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "original_text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate],  AM2389  [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "entity1": "CB1",
    "entity2": "AM2389"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Direct-acting <protein> CB1 </protein> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 <chemical>[ 9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol </chemical>], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "original_text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [ 9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol ], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "entity1": "CB1",
    "entity2": "[ 9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Direct-acting <protein> CB1 </protein> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and <chemical> AM4054 </chemical> [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "original_text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and  AM4054  [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "entity1": "CB1",
    "entity2": "AM4054"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Direct-acting <protein> CB1 </protein> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 <chemical>[ 9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol </chemical>], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "original_text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [ 9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol ], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
    "entity1": "CB1",
    "entity2": "[ 9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <protein> CB2 </protein> agonist <chemical> AM1241 </chemical> [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.",
    "original_text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the  CB2  agonist  AM1241  [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.",
    "entity1": "CB2",
    "entity2": "AM1241"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <protein> CB2 </protein> agonist AM1241 <chemical>[ 1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole </chemical>], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.",
    "original_text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the  CB2  agonist AM1241 [ 1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole ], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.",
    "entity1": "CB2",
    "entity2": "[ 1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <protein> CB2 </protein> agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor <chemical> AM404 </chemical>, and the CB antagonist rimonabant did not have diuretic effects.",
    "original_text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the  CB2  agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor  AM404 , and the CB antagonist rimonabant did not have diuretic effects.",
    "entity1": "CB2",
    "entity2": "AM404"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In further studies, the diuretic effects of the <protein> CB1 </protein> agonist <chemical> AM4054 </chemical> were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
    "original_text": "In further studies, the diuretic effects of the  CB1  agonist  AM4054  were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
    "entity1": "CB1",
    "entity2": "AM4054"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of <protein> WIN 55,212 </protein> antagonized by the <chemical> CB2 </chemical> antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
    "original_text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of  WIN 55,212  antagonized by the  CB2  antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
    "entity1": "WIN 55,212",
    "entity2": "CB2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In further studies, the diuretic effects of the <protein> CB1 </protein> agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with <chemical> rimonabant </chemical>, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
    "original_text": "In further studies, the diuretic effects of the  CB1  agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with  rimonabant , but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
    "entity1": "CB1",
    "entity2": "rimonabant"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the <protein> vanilloid receptor type I </protein> antagonist <chemical> capsazepine </chemical>, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
    "original_text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the  vanilloid receptor type I  antagonist  capsazepine , nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
    "entity1": "vanilloid receptor type I",
    "entity2": "capsazepine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the <protein> CB2 </protein> antagonist <chemical> AM630 </chemical> [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
    "original_text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the  CB2  antagonist  AM630  [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
    "entity1": "CB2",
    "entity2": "AM630"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the <protein> CB2 </protein> antagonist AM630 <chemical>[ (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone) </chemical>].",
    "original_text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the  CB2  antagonist AM630 [ (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone) ].",
    "entity1": "CB2",
    "entity2": "[ (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Mutation of arginine 228 to <protein> lysine </protein> enhances the <chemical> glucosyltransferase </chemical> activity of bovine beta-1,4-galactosyltransferase I.",
    "original_text": "Mutation of arginine 228 to  lysine  enhances the  glucosyltransferase  activity of bovine beta-1,4-galactosyltransferase I.",
    "entity1": "lysine",
    "entity2": "glucosyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from <protein> UDP-Glc </protein> to GlcNAc (<chemical> Glc-T </chemical> activity), albeit at only 0.3% efficiency.",
    "original_text": "Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from  UDP-Glc  to GlcNAc ( Glc-T  activity), albeit at only 0.3% efficiency.",
    "entity1": "UDP-Glc",
    "entity2": "Glc-T"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Beta-1,4-galactosyltransferase I </protein> (beta4Gal-T1) normally transfers Gal from <chemical> UDP-Gal </chemical> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.",
    "original_text": " Beta-1,4-galactosyltransferase I  (beta4Gal-T1) normally transfers Gal from  UDP-Gal  to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.",
    "entity1": "Beta-1,4-galactosyltransferase I",
    "entity2": "UDP-Gal"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from <protein> UDP-Gal </protein> to GlcNAc in the presence of Mn(2+) ion (<chemical> Gal-T </chemical> activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.",
    "original_text": "Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from  UDP-Gal  to GlcNAc in the presence of Mn(2+) ion ( Gal-T  activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.",
    "entity1": "UDP-Gal",
    "entity2": "Gal-T"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Beta-1,4-galactosyltransferase I (<protein> beta4Gal-T1 </protein>) normally transfers Gal from <chemical> UDP-Gal </chemical> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.",
    "original_text": "Beta-1,4-galactosyltransferase I ( beta4Gal-T1 ) normally transfers Gal from  UDP-Gal  to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.",
    "entity1": "beta4Gal-T1",
    "entity2": "UDP-Gal"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The selective <protein> betaAR </protein> agonist <chemical> isoproterenol </chemical> caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region.",
    "original_text": "The selective  betaAR  agonist  isoproterenol  caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region.",
    "entity1": "betaAR",
    "entity2": "isoproterenol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The selective <protein> beta1AR </protein> antagonists atenolol and metoprolol blocked <chemical> isoproterenol </chemical>-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",
    "original_text": "The selective  beta1AR  antagonists atenolol and metoprolol blocked  isoproterenol -induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",
    "entity1": "beta1AR",
    "entity2": "isoproterenol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The selective <protein> beta1AR </protein> antagonists <chemical> atenolol </chemical> and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",
    "original_text": "The selective  beta1AR  antagonists  atenolol  and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",
    "entity1": "beta1AR",
    "entity2": "atenolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The selective <protein> beta1AR </protein> antagonists atenolol and <chemical> metoprolol </chemical> blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",
    "original_text": "The selective  beta1AR  antagonists atenolol and  metoprolol  blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",
    "entity1": "beta1AR",
    "entity2": "metoprolol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In contrast, the selective <protein> beta2AR </protein> antagonists ICI-118,551 and butoxamine inhibited <chemical> isoproterenol </chemical>-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",
    "original_text": "In contrast, the selective  beta2AR  antagonists ICI-118,551 and butoxamine inhibited  isoproterenol -mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",
    "entity1": "beta2AR",
    "entity2": "isoproterenol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In contrast, the selective <protein> beta2AR </protein> antagonists ICI-118,551 and <chemical> butoxamine </chemical> inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",
    "original_text": "In contrast, the selective  beta2AR  antagonists ICI-118,551 and  butoxamine  inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",
    "entity1": "beta2AR",
    "entity2": "butoxamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In contrast, the selective <protein> beta2AR </protein> antagonists <chemical> ICI-118,551 </chemical> and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",
    "original_text": "In contrast, the selective  beta2AR  antagonists  ICI-118,551  and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",
    "entity1": "beta2AR",
    "entity2": "ICI-118,551"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model, <protein> beta1AR </protein> activation is responsible for the enhanced hippocampal CA3 network activity initiated by <chemical> isoproterenol </chemical>.",
    "original_text": "Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model,  beta1AR  activation is responsible for the enhanced hippocampal CA3 network activity initiated by  isoproterenol .",
    "entity1": "beta1AR",
    "entity2": "isoproterenol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> P2Y(2) receptor </protein> agonist <chemical> INS37217 </chemical> enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.",
    "original_text": " P2Y(2) receptor  agonist  INS37217  enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.",
    "entity1": "P2Y(2) receptor",
    "entity2": "INS37217"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Selective antagonism of <protein> GluR5 </protein> kainate-receptor-mediated synaptic currents by <chemical> topiramate </chemical> in rat basolateral amygdala neurons.",
    "original_text": "Selective antagonism of  GluR5  kainate-receptor-mediated synaptic currents by  topiramate  in rat basolateral amygdala neurons.",
    "entity1": "GluR5",
    "entity2": "topiramate"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Selective antagonism of GluR5 <protein> kainate-receptor </protein>-mediated synaptic currents by <chemical> topiramate </chemical> in rat basolateral amygdala neurons.",
    "original_text": "Selective antagonism of GluR5  kainate-receptor -mediated synaptic currents by  topiramate  in rat basolateral amygdala neurons.",
    "entity1": "kainate-receptor",
    "entity2": "topiramate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Density functional theory calculations using the hybrid functional B3LYP have been performed to study the <protein> methyl </protein> transfer step in <chemical> glycine N-methyltransferase </chemical> (GNMT).",
    "original_text": "Density functional theory calculations using the hybrid functional B3LYP have been performed to study the  methyl  transfer step in  glycine N-methyltransferase  (GNMT).",
    "entity1": "methyl",
    "entity2": "glycine N-methyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Density functional theory calculations using the hybrid functional B3LYP have been performed to study the <protein> methyl </protein> transfer step in glycine N-methyltransferase (<chemical> GNMT </chemical>).",
    "original_text": "Density functional theory calculations using the hybrid functional B3LYP have been performed to study the  methyl  transfer step in glycine N-methyltransferase ( GNMT ).",
    "entity1": "methyl",
    "entity2": "GNMT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The starting point for the calculations is the recent X-ray crystal structure of <protein> GNMT </protein> complexed with <chemical> SAM </chemical> and acetate.",
    "original_text": "The starting point for the calculations is the recent X-ray crystal structure of  GNMT  complexed with  SAM  and acetate.",
    "entity1": "GNMT",
    "entity2": "SAM"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Dopamine D(2) receptor-induced <protein> COX-2 </protein>-mediated production of <chemical> prostaglandin E(2) </chemical> in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.",
    "original_text": "Dopamine D(2) receptor-induced  COX-2 -mediated production of  prostaglandin E(2)  in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.",
    "entity1": "COX-2",
    "entity2": "prostaglandin E(2)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The effect was counteracted by the <protein> D(2) </protein> antagonist <chemical> eticlopride </chemical>, pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA.",
    "original_text": "The effect was counteracted by the  D(2)  antagonist  eticlopride , pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA.",
    "entity1": "D(2)",
    "entity2": "eticlopride"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "A high throughput assay for the glucuronidation of <protein> 7-hydroxy-4-trifluoromethylcoumarin </protein> by recombinant <chemical> human UDP-glucuronosyltransferases </chemical> and liver microsomes.",
    "original_text": "A high throughput assay for the glucuronidation of  7-hydroxy-4-trifluoromethylcoumarin  by recombinant  human UDP-glucuronosyltransferases  and liver microsomes.",
    "entity1": "7-hydroxy-4-trifluoromethylcoumarin",
    "entity2": "human UDP-glucuronosyltransferases"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of <protein> 7-hydroxy-4-trifluoromethylcoumarin </protein> (HFC) for several <chemical> UGTs </chemical>.",
    "original_text": "2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of  7-hydroxy-4-trifluoromethylcoumarin  (HFC) for several  UGTs .",
    "entity1": "7-hydroxy-4-trifluoromethylcoumarin",
    "entity2": "UGTs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (<protein> HFC </protein>) for several <chemical> UGTs </chemical>.",
    "original_text": "2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin ( HFC ) for several  UGTs .",
    "entity1": "HFC",
    "entity2": "UGTs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "3.\u2002 We have used this method to screen 11 recombinant <protein> human UGTs </protein> for <chemical> HFC </chemical> glucuronidation activity and studied the reaction kinetics with the most active enzymes.",
    "original_text": "3.\u2002 We have used this method to screen 11 recombinant  human UGTs  for  HFC  glucuronidation activity and studied the reaction kinetics with the most active enzymes.",
    "entity1": "human UGTs",
    "entity2": "HFC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <protein> HFC </protein> glucuronidation catalysts were <chemical> UGT1A10 </chemical> followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
    "original_text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were  UGT1A10  followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
    "entity1": "HFC",
    "entity2": "UGT1A10"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <protein> HFC </protein> glucuronidation catalysts were UGT1A10 followed by <chemical> UGT1A6 </chemical> >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
    "original_text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were UGT1A10 followed by  UGT1A6  >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
    "entity1": "HFC",
    "entity2": "UGT1A6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <protein> HFC </protein> glucuronidation catalysts were UGT1A10 followed by UGT1A6 ><chemical> UGT1A7 </chemical> >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
    "original_text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were UGT1A10 followed by UGT1A6 > UGT1A7  >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
    "entity1": "HFC",
    "entity2": "UGT1A7"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <protein> HFC </protein> glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 ><chemical> UGT2A1 </chemical>, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
    "original_text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 > UGT2A1 , whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
    "entity1": "HFC",
    "entity2": "UGT2A1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <protein> HFC </protein> glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M <chemical> UGT1A6 </chemical> was about 10 times better catalyst than the other recombinant UGTs.",
    "original_text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M  UGT1A6  was about 10 times better catalyst than the other recombinant UGTs.",
    "entity1": "HFC",
    "entity2": "UGT1A6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <protein> HFC </protein> glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant <chemical> UGTs </chemical>.",
    "original_text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant  UGTs .",
    "entity1": "HFC",
    "entity2": "UGTs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both <protein> HFC </protein> and UDP-glucuronic acid than the other <chemical> UGTs </chemical>.",
    "original_text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both  HFC  and UDP-glucuronic acid than the other  UGTs .",
    "entity1": "HFC",
    "entity2": "UGTs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> UGT1A6 </protein> exhibited a significantly higher Vmax and Km values toward both <chemical> HFC </chemical> and UDP-glucuronic acid than the other UGTs.",
    "original_text": " UGT1A6  exhibited a significantly higher Vmax and Km values toward both  HFC  and UDP-glucuronic acid than the other UGTs.",
    "entity1": "UGT1A6",
    "entity2": "HFC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and <protein> UDP </protein>-glucuronic acid than the other <chemical> UGTs </chemical>.",
    "original_text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and  UDP -glucuronic acid than the other  UGTs .",
    "entity1": "UDP",
    "entity2": "UGTs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> UGT1A6 </protein> exhibited a significantly higher Vmax and Km values toward both HFC and <chemical> UDP </chemical>-glucuronic acid than the other UGTs.",
    "original_text": " UGT1A6  exhibited a significantly higher Vmax and Km values toward both HFC and  UDP -glucuronic acid than the other UGTs.",
    "entity1": "UGT1A6",
    "entity2": "UDP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-<protein> glucuronic acid </protein> than the other <chemical> UGTs </chemical>.",
    "original_text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP- glucuronic acid  than the other  UGTs .",
    "entity1": "glucuronic acid",
    "entity2": "UGTs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> UGT1A6 </protein> exhibited a significantly higher Vmax and Km values toward both HFC and UDP-<chemical> glucuronic acid </chemical> than the other UGTs.",
    "original_text": " UGT1A6  exhibited a significantly higher Vmax and Km values toward both HFC and UDP- glucuronic acid  than the other UGTs.",
    "entity1": "UGT1A6",
    "entity2": "glucuronic acid"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "This inhibition was blocked when mice were pretreated with the selective <protein> H3R </protein> agonist <chemical> R-(alpha)-methyl-histamine </chemical> (10\u00a0mg/kg).",
    "original_text": "This inhibition was blocked when mice were pretreated with the selective  H3R  agonist  R-(alpha)-methyl-histamine  (10\u00a0mg/kg).",
    "entity1": "H3R",
    "entity2": "R-(alpha)-methyl-histamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the <protein> 5-HT(1A/1B)-receptor </protein> antagonist <chemical> (-)-propranolol </chemical> and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.",
    "original_text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the  5-HT(1A/1B)-receptor  antagonist  (-)-propranolol  and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.",
    "entity1": "5-HT(1A/1B)-receptor",
    "entity2": "(-)-propranolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the <protein> 5-HT(3/4)-receptor </protein> antagonist <chemical> tropisetron </chemical> did not affect it.",
    "original_text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the  5-HT(3/4)-receptor  antagonist  tropisetron  did not affect it.",
    "entity1": "5-HT(3/4)-receptor",
    "entity2": "tropisetron"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the <protein> 5-HT(2A/2B/2C)-receptor </protein> antagonist <chemical> LY 53857 </chemical> enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.",
    "original_text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the  5-HT(2A/2B/2C)-receptor  antagonist  LY 53857  enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.",
    "entity1": "5-HT(2A/2B/2C)-receptor",
    "entity2": "LY 53857"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The <protein> 5-HT(2B/2C)-receptor </protein> antagonist <chemical> SB 206553 </chemical> facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect.",
    "original_text": "The  5-HT(2B/2C)-receptor  antagonist  SB 206553  facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect.",
    "entity1": "5-HT(2B/2C)-receptor",
    "entity2": "SB 206553"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the <protein> 5-HT(2A) </protein>-receptor antagonist <chemical> ketanserin </chemical> was without effect.",
    "original_text": "The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the  5-HT(2A) -receptor antagonist  ketanserin  was without effect.",
    "entity1": "5-HT(2A)",
    "entity2": "ketanserin"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> PKC </protein> isoforms did show different sensitivity and selectivity for down-regulation by <chemical> I3A </chemical> and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells.",
    "original_text": " PKC  isoforms did show different sensitivity and selectivity for down-regulation by  I3A  and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells.",
    "entity1": "PKC",
    "entity2": "I3A"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> PKC </protein> isoforms did show different sensitivity and selectivity for down-regulation by I3A and <chemical> phorbol 12-myristate 13-acetate </chemical> (PMA) in WEHI-231, HOP-92, and Colo-205 cells.",
    "original_text": " PKC  isoforms did show different sensitivity and selectivity for down-regulation by I3A and  phorbol 12-myristate 13-acetate  (PMA) in WEHI-231, HOP-92, and Colo-205 cells.",
    "entity1": "PKC",
    "entity2": "phorbol 12-myristate 13-acetate"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> PKC </protein> isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (<chemical> PMA </chemical>) in WEHI-231, HOP-92, and Colo-205 cells.",
    "original_text": " PKC  isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate ( PMA ) in WEHI-231, HOP-92, and Colo-205 cells.",
    "entity1": "PKC",
    "entity2": "PMA"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The results suggested that both the EtOAc extract and berberine were able to activate PPAR\u03b1/\u03b2/\u03b3, and Rhizoma Coptis contains potential natural agonists of <protein> PPARs </protein> besides <chemical> berberine </chemical>.",
    "original_text": "The results suggested that both the EtOAc extract and berberine were able to activate PPAR\u03b1/\u03b2/\u03b3, and Rhizoma Coptis contains potential natural agonists of  PPARs  besides  berberine .",
    "entity1": "PPARs",
    "entity2": "berberine"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> CGP 12177A </protein> mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor; however, it has recently been reported that disruption of the <chemical> beta(1)-adrenoceptor </chemical> gene abolishes this effect.",
    "original_text": " CGP 12177A  mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor; however, it has recently been reported that disruption of the  beta(1)-adrenoceptor  gene abolishes this effect.",
    "entity1": "CGP 12177A",
    "entity2": "beta(1)-adrenoceptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results suggest that PDE4B mediates the antipsychotic effects of rolipram in CAR and that the <protein> PDE4B </protein>-regulated <chemical> cyclic adenosine monophosphate </chemical> signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.",
    "original_text": "These results suggest that PDE4B mediates the antipsychotic effects of rolipram in CAR and that the  PDE4B -regulated  cyclic adenosine monophosphate  signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.",
    "entity1": "PDE4B",
    "entity2": "cyclic adenosine monophosphate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Cat-1 </protein>, the transporter for the essential <chemical> amino acids </chemical>, arginine and lysine, is one of the up-regulated genes.",
    "original_text": " Cat-1 , the transporter for the essential  amino acids , arginine and lysine, is one of the up-regulated genes.",
    "entity1": "Cat-1",
    "entity2": "amino acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Cat-1 </protein>, the transporter for the essential amino acids, <chemical> arginine </chemical> and lysine, is one of the up-regulated genes.",
    "original_text": " Cat-1 , the transporter for the essential amino acids,  arginine  and lysine, is one of the up-regulated genes.",
    "entity1": "Cat-1",
    "entity2": "arginine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Cat-1 </protein>, the transporter for the essential amino acids, arginine and <chemical> lysine </chemical>, is one of the up-regulated genes.",
    "original_text": " Cat-1 , the transporter for the essential amino acids, arginine and  lysine , is one of the up-regulated genes.",
    "entity1": "Cat-1",
    "entity2": "lysine"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "On the basis of data obtained in rabbits, the imidazoline receptor ligand <protein> rilmenidine </protein> has been suggested to decrease blood pressure in humans by activating central <chemical> alpha(2A)-adrenoceptors </chemical>.",
    "original_text": "On the basis of data obtained in rabbits, the imidazoline receptor ligand  rilmenidine  has been suggested to decrease blood pressure in humans by activating central  alpha(2A)-adrenoceptors .",
    "entity1": "rilmenidine",
    "entity2": "alpha(2A)-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the rabbit pulmonary artery, <protein> rilmenidine </protein> and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <chemical> alpha(2)-autoreceptors </chemical>, sharing this property with rauwolscine, phentolamine, and idazoxan.",
    "original_text": "In the rabbit pulmonary artery,  rilmenidine  and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the  alpha(2)-autoreceptors , sharing this property with rauwolscine, phentolamine, and idazoxan.",
    "entity1": "rilmenidine",
    "entity2": "alpha(2)-autoreceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the rabbit pulmonary artery, rilmenidine and <protein> oxymetazoline </protein> are potent full agonists, whereas in the human atrial appendages they are antagonists at the <chemical> alpha(2)-autoreceptors </chemical>, sharing this property with rauwolscine, phentolamine, and idazoxan.",
    "original_text": "In the rabbit pulmonary artery, rilmenidine and  oxymetazoline  are potent full agonists, whereas in the human atrial appendages they are antagonists at the  alpha(2)-autoreceptors , sharing this property with rauwolscine, phentolamine, and idazoxan.",
    "entity1": "oxymetazoline",
    "entity2": "alpha(2)-autoreceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <protein> alpha(2)-autoreceptors </protein>, sharing this property with <chemical> rauwolscine </chemical>, phentolamine, and idazoxan.",
    "original_text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the  alpha(2)-autoreceptors , sharing this property with  rauwolscine , phentolamine, and idazoxan.",
    "entity1": "alpha(2)-autoreceptors",
    "entity2": "rauwolscine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <protein> alpha(2)-autoreceptors </protein>, sharing this property with rauwolscine, <chemical> phentolamine </chemical>, and idazoxan.",
    "original_text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the  alpha(2)-autoreceptors , sharing this property with rauwolscine,  phentolamine , and idazoxan.",
    "entity1": "alpha(2)-autoreceptors",
    "entity2": "phentolamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <protein> alpha(2)-autoreceptors </protein>, sharing this property with rauwolscine, phentolamine, and <chemical> idazoxan </chemical>.",
    "original_text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the  alpha(2)-autoreceptors , sharing this property with rauwolscine, phentolamine, and  idazoxan .",
    "entity1": "alpha(2)-autoreceptors",
    "entity2": "idazoxan"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with <protein> alpha(2A)-autoreceptors </protein>, at which, however, both rilmenidine and <chemical> oxymetazoline </chemical> exhibit different properties (antagonism and agonism, respectively).",
    "original_text": "The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with  alpha(2A)-autoreceptors , at which, however, both rilmenidine and  oxymetazoline  exhibit different properties (antagonism and agonism, respectively).",
    "entity1": "alpha(2A)-autoreceptors",
    "entity2": "oxymetazoline"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with <protein> alpha(2A)-autoreceptors </protein>, at which, however, both <chemical> rilmenidine </chemical> and oxymetazoline exhibit different properties (antagonism and agonism, respectively).",
    "original_text": "The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with  alpha(2A)-autoreceptors , at which, however, both  rilmenidine  and oxymetazoline exhibit different properties (antagonism and agonism, respectively).",
    "entity1": "alpha(2A)-autoreceptors",
    "entity2": "rilmenidine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The antagonistic property of <protein> rilmenidine </protein> at <chemical> human alpha(2A)-adrenoceptors </chemical> indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved.",
    "original_text": "The antagonistic property of  rilmenidine  at  human alpha(2A)-adrenoceptors  indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved.",
    "entity1": "rilmenidine",
    "entity2": "human alpha(2A)-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <protein> histamine H1-receptor </protein> antagonists <chemical> terfenadine </chemical>, astemizole, loratadine, and acrivastine are reviewed.",
    "original_text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating  histamine H1-receptor  antagonists  terfenadine , astemizole, loratadine, and acrivastine are reviewed.",
    "entity1": "histamine H1-receptor",
    "entity2": "terfenadine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <protein> histamine H1-receptor </protein> antagonists terfenadine, <chemical> astemizole </chemical>, loratadine, and acrivastine are reviewed.",
    "original_text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating  histamine H1-receptor  antagonists terfenadine,  astemizole , loratadine, and acrivastine are reviewed.",
    "entity1": "histamine H1-receptor",
    "entity2": "astemizole"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <protein> histamine H1-receptor </protein> antagonists terfenadine, astemizole, <chemical> loratadine </chemical>, and acrivastine are reviewed.",
    "original_text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating  histamine H1-receptor  antagonists terfenadine, astemizole,  loratadine , and acrivastine are reviewed.",
    "entity1": "histamine H1-receptor",
    "entity2": "loratadine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <protein> histamine H1-receptor </protein> antagonists terfenadine, astemizole, loratadine, and <chemical> acrivastine </chemical> are reviewed.",
    "original_text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating  histamine H1-receptor  antagonists terfenadine, astemizole, loratadine, and  acrivastine  are reviewed.",
    "entity1": "histamine H1-receptor",
    "entity2": "acrivastine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Terfenadine </protein> and astemizole are chemically unrelated to <chemical> histamine H1-receptor </chemical> antagonists such as diphenhydramine and chlorpheniramine.",
    "original_text": " Terfenadine  and astemizole are chemically unrelated to  histamine H1-receptor  antagonists such as diphenhydramine and chlorpheniramine.",
    "entity1": "Terfenadine",
    "entity2": "histamine H1-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Terfenadine and <protein> astemizole </protein> are chemically unrelated to <chemical> histamine H1-receptor </chemical> antagonists such as diphenhydramine and chlorpheniramine.",
    "original_text": "Terfenadine and  astemizole  are chemically unrelated to  histamine H1-receptor  antagonists such as diphenhydramine and chlorpheniramine.",
    "entity1": "astemizole",
    "entity2": "histamine H1-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Terfenadine and astemizole are chemically unrelated to <protein> histamine H1-receptor </protein> antagonists such as <chemical> diphenhydramine </chemical> and chlorpheniramine.",
    "original_text": "Terfenadine and astemizole are chemically unrelated to  histamine H1-receptor  antagonists such as  diphenhydramine  and chlorpheniramine.",
    "entity1": "histamine H1-receptor",
    "entity2": "diphenhydramine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Terfenadine and astemizole are chemically unrelated to <protein> histamine H1-receptor </protein> antagonists such as diphenhydramine and <chemical> chlorpheniramine </chemical>.",
    "original_text": "Terfenadine and astemizole are chemically unrelated to  histamine H1-receptor  antagonists such as diphenhydramine and  chlorpheniramine .",
    "entity1": "histamine H1-receptor",
    "entity2": "chlorpheniramine"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "G6PC2: A Negative Regulator of Basal <protein> Glucose </protein>-Stimulated <chemical> Insulin </chemical> Secretion.",
    "original_text": "G6PC2: A Negative Regulator of Basal  Glucose -Stimulated  Insulin  Secretion.",
    "entity1": "Glucose",
    "entity2": "Insulin"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "G6pc2 deletion resulted in a leftward shift in the dose-response curve for <protein> glucose </protein>-stimulated <chemical> insulin </chemical> secretion (GSIS).",
    "original_text": "G6pc2 deletion resulted in a leftward shift in the dose-response curve for  glucose -stimulated  insulin  secretion (GSIS).",
    "entity1": "glucose",
    "entity2": "insulin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These data suggest that <protein> G6pc2 </protein> represents a novel, negative regulator of basal GSIS that acts by hydrolyzing <chemical> glucose-6-phosphate </chemical>, thereby reducing glycolytic flux.",
    "original_text": "These data suggest that  G6pc2  represents a novel, negative regulator of basal GSIS that acts by hydrolyzing  glucose-6-phosphate , thereby reducing glycolytic flux.",
    "entity1": "G6pc2",
    "entity2": "glucose-6-phosphate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of <protein> [(3)H] dopamine </protein> (DA) uptake and [(3)H]WIN 35428 binding in <chemical> human dopamine transporter </chemical> (DAT) wild-type and mutants with altered conformational equilibria.",
    "original_text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of  [(3)H] dopamine  (DA) uptake and [(3)H]WIN 35428 binding in  human dopamine transporter  (DAT) wild-type and mutants with altered conformational equilibria.",
    "entity1": "[(3)H] dopamine",
    "entity2": "human dopamine transporter"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of <protein> [(3)H] dopamine </protein> (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (<chemical> DAT </chemical>) wild-type and mutants with altered conformational equilibria.",
    "original_text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of  [(3)H] dopamine  (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter ( DAT ) wild-type and mutants with altered conformational equilibria.",
    "entity1": "[(3)H] dopamine",
    "entity2": "DAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (<protein> DA </protein>) uptake and [(3)H]WIN 35428 binding in <chemical> human dopamine transporter </chemical> (DAT) wild-type and mutants with altered conformational equilibria.",
    "original_text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine ( DA ) uptake and [(3)H]WIN 35428 binding in  human dopamine transporter  (DAT) wild-type and mutants with altered conformational equilibria.",
    "entity1": "DA",
    "entity2": "human dopamine transporter"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (<protein> DA </protein>) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (<chemical> DAT </chemical>) wild-type and mutants with altered conformational equilibria.",
    "original_text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine ( DA ) uptake and [(3)H]WIN 35428 binding in human dopamine transporter ( DAT ) wild-type and mutants with altered conformational equilibria.",
    "entity1": "DA",
    "entity2": "DAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "RESULTS: (+/-)-, R-, and S-modafinil bind to the <protein> DAT </protein> and inhibit <chemical> DA </chemical> uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.",
    "original_text": "RESULTS: (+/-)-, R-, and S-modafinil bind to the  DAT  and inhibit  DA  uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.",
    "entity1": "DAT",
    "entity2": "DA"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Apple <protein> polyphenols </protein> suppress antigen presentation of <chemical> ovalbumin </chemical> by THP-1-derived dendritic cells.",
    "original_text": "Apple  polyphenols  suppress antigen presentation of  ovalbumin  by THP-1-derived dendritic cells.",
    "entity1": "polyphenols",
    "entity2": "ovalbumin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of <protein> acetylcholinesterase </protein> (AChE) in the nervous system, which leads to increased synaptic <chemical> acetylcholine </chemical> levels.",
    "original_text": "The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of  acetylcholinesterase  (AChE) in the nervous system, which leads to increased synaptic  acetylcholine  levels.",
    "entity1": "acetylcholinesterase",
    "entity2": "acetylcholine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (<protein> AChE </protein>) in the nervous system, which leads to increased synaptic <chemical> acetylcholine </chemical> levels.",
    "original_text": "The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase ( AChE ) in the nervous system, which leads to increased synaptic  acetylcholine  levels.",
    "entity1": "AChE",
    "entity2": "acetylcholine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired <protein> pyridoxal kinase </protein> for the conversion of <chemical> pyridoxine </chemical> and pyridoxal to PLP.",
    "original_text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired  pyridoxal kinase  for the conversion of  pyridoxine  and pyridoxal to PLP.",
    "entity1": "pyridoxal kinase",
    "entity2": "pyridoxine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired <protein> pyridoxal kinase </protein> for the conversion of pyridoxine and <chemical> pyridoxal </chemical> to PLP.",
    "original_text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired  pyridoxal kinase  for the conversion of pyridoxine and  pyridoxal  to PLP.",
    "entity1": "pyridoxal kinase",
    "entity2": "pyridoxal"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In addition, <protein> ethanol </protein> induced degradation of <chemical> DNA methyltransferases </chemical> (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "original_text": "In addition,  ethanol  induced degradation of  DNA methyltransferases  (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "entity1": "ethanol",
    "entity2": "DNA methyltransferases"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In addition, <protein> ethanol </protein> induced degradation of DNA methyltransferases (<chemical> DNMT- </chemical>1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "original_text": "In addition,  ethanol  induced degradation of DNA methyltransferases ( DNMT- 1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "entity1": "ethanol",
    "entity2": "DNMT-"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In addition, <protein> ethanol </protein> induced degradation of DNA methyltransferases (DNMT-1, <chemical> DNMT-3a </chemical>, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "original_text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1,  DNMT-3a , and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "entity1": "ethanol",
    "entity2": "DNMT-3a"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In addition, <protein> ethanol </protein> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and <chemical> DNMT-3b </chemical>), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "original_text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and  DNMT-3b ), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "entity1": "ethanol",
    "entity2": "DNMT-3b"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In addition, <protein> ethanol </protein> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the <chemical> methyl CpG-binding proteins </chemical> (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "original_text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the  methyl CpG-binding proteins  (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "entity1": "ethanol",
    "entity2": "methyl CpG-binding proteins"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In addition, <protein> ethanol </protein> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (<chemical> MeCP-2 </chemical>, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "original_text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins ( MeCP-2 , MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
    "entity1": "ethanol",
    "entity2": "MeCP-2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In addition, <protein> ethanol </protein> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, <chemical> MBD-2 </chemical> and MBD-3), in MEF cells by the proteasomal pathway.",
    "original_text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2,  MBD-2  and MBD-3), in MEF cells by the proteasomal pathway.",
    "entity1": "ethanol",
    "entity2": "MBD-2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In addition, <protein> ethanol </protein> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and <chemical> MBD-3 </chemical>), in MEF cells by the proteasomal pathway.",
    "original_text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and  MBD-3 ), in MEF cells by the proteasomal pathway.",
    "entity1": "ethanol",
    "entity2": "MBD-3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Methionine synthase reductase (<protein> MTRR </protein>) is an enzyme involved in the conversion of <chemical> Hcy </chemical> to methionine.",
    "original_text": "Methionine synthase reductase ( MTRR ) is an enzyme involved in the conversion of  Hcy  to methionine.",
    "entity1": "MTRR",
    "entity2": "Hcy"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Methionine synthase reductase </protein> (MTRR) is an enzyme involved in the conversion of <chemical> Hcy </chemical> to methionine.",
    "original_text": " Methionine synthase reductase  (MTRR) is an enzyme involved in the conversion of  Hcy  to methionine.",
    "entity1": "Methionine synthase reductase",
    "entity2": "Hcy"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "alpha-Tocopherol transfer protein (<protein> alpha-TTP </protein>), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma <chemical> alpha-tocopherol </chemical> level by mediating the secretion of alpha-tocopherol by the liver.",
    "original_text": "alpha-Tocopherol transfer protein ( alpha-TTP ), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma  alpha-tocopherol  level by mediating the secretion of alpha-tocopherol by the liver.",
    "entity1": "alpha-TTP",
    "entity2": "alpha-tocopherol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> alpha-Tocopherol transfer protein </protein> (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma <chemical> alpha-tocopherol </chemical> level by mediating the secretion of alpha-tocopherol by the liver.",
    "original_text": " alpha-Tocopherol transfer protein  (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma  alpha-tocopherol  level by mediating the secretion of alpha-tocopherol by the liver.",
    "entity1": "alpha-Tocopherol transfer protein",
    "entity2": "alpha-tocopherol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "alpha-Tocopherol transfer protein (<protein> alpha-TTP </protein>), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of <chemical> alpha-tocopherol </chemical> by the liver.",
    "original_text": "alpha-Tocopherol transfer protein ( alpha-TTP ), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of  alpha-tocopherol  by the liver.",
    "entity1": "alpha-TTP",
    "entity2": "alpha-tocopherol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> alpha-Tocopherol transfer protein </protein> (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of <chemical> alpha-tocopherol </chemical> by the liver.",
    "original_text": " alpha-Tocopherol transfer protein  (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of  alpha-tocopherol  by the liver.",
    "entity1": "alpha-Tocopherol transfer protein",
    "entity2": "alpha-tocopherol"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Second, <protein> probucol </protein>, an antiatherogenic compound reported to be an inactivator of <chemical> ABCA1 </chemical> reduced hepatic alpha-tocopherol secretion.",
    "original_text": "Second,  probucol , an antiatherogenic compound reported to be an inactivator of  ABCA1  reduced hepatic alpha-tocopherol secretion.",
    "entity1": "probucol",
    "entity2": "ABCA1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid </protein> (1) is a potent <chemical> AMPA receptor </chemical> agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.",
    "original_text": " 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid  (1) is a potent  AMPA receptor  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.",
    "entity1": "2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid",
    "entity2": "AMPA receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Pranlukast </protein>, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from <chemical> leukotriene receptor </chemical> antagonism.",
    "original_text": " Pranlukast , a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from  leukotriene receptor  antagonism.",
    "entity1": "Pranlukast",
    "entity2": "leukotriene receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Pranlukast </protein>, a <chemical> leukotriene receptor </chemical> antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism.",
    "original_text": " Pranlukast , a  leukotriene receptor  antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism.",
    "entity1": "Pranlukast",
    "entity2": "leukotriene receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "BACKGROUND: <protein> Pranlukast </protein>, a <chemical> cysteinyl leukotriene receptor 1 </chemical> (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.",
    "original_text": "BACKGROUND:  Pranlukast , a  cysteinyl leukotriene receptor 1  (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.",
    "entity1": "Pranlukast",
    "entity2": "cysteinyl leukotriene receptor 1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "BACKGROUND: <protein> Pranlukast </protein>, a cysteinyl leukotriene receptor 1 (<chemical> CysLTR1 </chemical>) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.",
    "original_text": "BACKGROUND:  Pranlukast , a cysteinyl leukotriene receptor 1 ( CysLTR1 ) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.",
    "entity1": "Pranlukast",
    "entity2": "CysLTR1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "CONCLUSION: Our results indicate that <protein> pranlukast </protein> inhibits IL-5 synthesis via a mechanism distinct from <chemical> CysLTR1 </chemical> antagonism.",
    "original_text": "CONCLUSION: Our results indicate that  pranlukast  inhibits IL-5 synthesis via a mechanism distinct from  CysLTR1  antagonism.",
    "entity1": "pranlukast",
    "entity2": "CysLTR1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Phenytoin </protein> is principally metabolized by <chemical> CYP2C9 </chemical>, and both are probable substrates of the drug transporter P-glycoprotein.",
    "original_text": " Phenytoin  is principally metabolized by  CYP2C9 , and both are probable substrates of the drug transporter P-glycoprotein.",
    "entity1": "Phenytoin",
    "entity2": "CYP2C9"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Phenytoin </protein> is principally metabolized by CYP2C9, and both are probable substrates of the <chemical> drug transporter </chemical> P-glycoprotein.",
    "original_text": " Phenytoin  is principally metabolized by CYP2C9, and both are probable substrates of the  drug transporter  P-glycoprotein.",
    "entity1": "Phenytoin",
    "entity2": "drug transporter"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Phenytoin </protein> is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter <chemical> P-glycoprotein </chemical>.",
    "original_text": " Phenytoin  is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter  P-glycoprotein .",
    "entity1": "Phenytoin",
    "entity2": "P-glycoprotein"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "To further our understanding of how <protein> fisetin </protein> negatively regulates <chemical> mTORC1 </chemical> signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in fisetin-treated TSC2-knockdown cells.",
    "original_text": "To further our understanding of how  fisetin  negatively regulates  mTORC1  signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in fisetin-treated TSC2-knockdown cells.",
    "entity1": "fisetin",
    "entity2": "mTORC1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of <protein> fisetin </protein> on <chemical> mTOR </chemical>.",
    "original_text": "Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of  fisetin  on  mTOR .",
    "entity1": "fisetin",
    "entity2": "mTOR"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Saturated <protein> palmitic and stearic acids </protein> increased ceramides, up-regulated <chemical> PTP1B </chemical>, and had AKt and PTP1B phosphorylation at Ser 50 impaired.",
    "original_text": "Saturated  palmitic and stearic acids  increased ceramides, up-regulated  PTP1B , and had AKt and PTP1B phosphorylation at Ser 50 impaired.",
    "entity1": "palmitic and stearic acids",
    "entity2": "PTP1B"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Indoleamine 2,3-dioxygenase (<protein> IDO </protein>), a <chemical> tryptophan </chemical> catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders.",
    "original_text": "Indoleamine 2,3-dioxygenase ( IDO ), a  tryptophan  catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders.",
    "entity1": "IDO",
    "entity2": "tryptophan"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Indoleamine 2,3-dioxygenase </protein> (IDO), a <chemical> tryptophan </chemical> catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders.",
    "original_text": " Indoleamine 2,3-dioxygenase  (IDO), a  tryptophan  catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders.",
    "entity1": "Indoleamine 2,3-dioxygenase",
    "entity2": "tryptophan"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced <protein> NADPH oxidase </protein> activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by <chemical> resveratrol </chemical>.",
    "original_text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced  NADPH oxidase  activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by  resveratrol .",
    "entity1": "NADPH oxidase",
    "entity2": "resveratrol"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits <protein> p22(phox) </protein> and NOX4, which were prevented by <chemical> resveratrol </chemical>.",
    "original_text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits  p22(phox)  and NOX4, which were prevented by  resveratrol .",
    "entity1": "p22(phox)",
    "entity2": "resveratrol"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and <protein> NOX4 </protein>, which were prevented by <chemical> resveratrol </chemical>.",
    "original_text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and  NOX4 , which were prevented by  resveratrol .",
    "entity1": "NOX4",
    "entity2": "resveratrol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Estrogens are biosynthesised from <protein> androgens </protein> by the CYP450 enzyme complex called <chemical> aromatase </chemical>.",
    "original_text": "Estrogens are biosynthesised from  androgens  by the CYP450 enzyme complex called  aromatase .",
    "entity1": "androgens",
    "entity2": "aromatase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Fumarate reductase (<protein> FRD </protein>) is the key enzyme in <chemical> fumarate </chemical> respiration induced by anaerobic growth of bacteria.",
    "original_text": "Fumarate reductase ( FRD ) is the key enzyme in  fumarate  respiration induced by anaerobic growth of bacteria.",
    "entity1": "FRD",
    "entity2": "fumarate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Fumarate reductase </protein> (FRD) is the key enzyme in <chemical> fumarate </chemical> respiration induced by anaerobic growth of bacteria.",
    "original_text": " Fumarate reductase  (FRD) is the key enzyme in  fumarate  respiration induced by anaerobic growth of bacteria.",
    "entity1": "Fumarate reductase",
    "entity2": "fumarate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The frdA gene coding for subunit A of FRD, and two control genes, <protein> copA </protein> and copP associated with the export of <chemical> copper </chemical> out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.",
    "original_text": "The frdA gene coding for subunit A of FRD, and two control genes,  copA  and copP associated with the export of  copper  out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.",
    "entity1": "copA",
    "entity2": "copper"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The frdA gene coding for subunit A of FRD, and two control genes, copA and <protein> copP </protein> associated with the export of <chemical> copper </chemical> out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.",
    "original_text": "The frdA gene coding for subunit A of FRD, and two control genes, copA and  copP  associated with the export of  copper  out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.",
    "entity1": "copP",
    "entity2": "copper"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In relation to zinc bioavailability, <protein> \u03b1-CPPs </protein>, \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased <chemical> zinc </chemical> uptake.",
    "original_text": "In relation to zinc bioavailability,  \u03b1-CPPs , \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased  zinc  uptake.",
    "entity1": "\u03b1-CPPs",
    "entity2": "zinc"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In relation to zinc bioavailability, \u03b1-CPPs, <protein> \u03b2-CPPs </protein>, \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased <chemical> zinc </chemical> uptake.",
    "original_text": "In relation to zinc bioavailability, \u03b1-CPPs,  \u03b2-CPPs , \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased  zinc  uptake.",
    "entity1": "\u03b2-CPPs",
    "entity2": "zinc"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs, <protein> \u03b1(s1)-CN </protein>(64-74)4P and \u03b2-CN(1-25)4P increased <chemical> zinc </chemical> uptake.",
    "original_text": "In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs,  \u03b1(s1)-CN (64-74)4P and \u03b2-CN(1-25)4P increased  zinc  uptake.",
    "entity1": "\u03b1(s1)-CN",
    "entity2": "zinc"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and <protein> \u03b2-CN </protein>(1-25)4P increased <chemical> zinc </chemical> uptake.",
    "original_text": "In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and  \u03b2-CN (1-25)4P increased  zinc  uptake.",
    "entity1": "\u03b2-CN",
    "entity2": "zinc"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Next to <protein> Glut-4 </protein>, the predominant protein influencing <chemical> glucose </chemical> metabolism is PPAR\u03b1 and \u03b3 whose expressions were also positively modulated.",
    "original_text": "Next to  Glut-4 , the predominant protein influencing  glucose  metabolism is PPAR\u03b1 and \u03b3 whose expressions were also positively modulated.",
    "entity1": "Glut-4",
    "entity2": "glucose"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Both the 5 alpha-reductase inhibitor finasteride and <protein> alpha 1-adrenoceptor </protein> antagonists (e.g. <chemical> alfuzosin </chemical>, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
    "original_text": "Both the 5 alpha-reductase inhibitor finasteride and  alpha 1-adrenoceptor  antagonists (e.g.  alfuzosin , doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "alfuzosin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Both the 5 alpha-reductase inhibitor finasteride and <protein> alpha 1-adrenoceptor </protein> antagonists (e.g. alfuzosin, <chemical> doxazosin </chemical>, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
    "original_text": "Both the 5 alpha-reductase inhibitor finasteride and  alpha 1-adrenoceptor  antagonists (e.g. alfuzosin,  doxazosin , prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "doxazosin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Both the 5 alpha-reductase inhibitor finasteride and <protein> alpha 1-adrenoceptor </protein> antagonists (e.g. alfuzosin, doxazosin, <chemical> prazosin </chemical>, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
    "original_text": "Both the 5 alpha-reductase inhibitor finasteride and  alpha 1-adrenoceptor  antagonists (e.g. alfuzosin, doxazosin,  prazosin , tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "prazosin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Both the 5 alpha-reductase inhibitor finasteride and <protein> alpha 1-adrenoceptor </protein> antagonists (e.g. alfuzosin, doxazosin, prazosin, <chemical> tamsulosin </chemical> and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
    "original_text": "Both the 5 alpha-reductase inhibitor finasteride and  alpha 1-adrenoceptor  antagonists (e.g. alfuzosin, doxazosin, prazosin,  tamsulosin  and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "tamsulosin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Both the 5 alpha-reductase inhibitor finasteride and <protein> alpha 1-adrenoceptor </protein> antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and <chemical> terazosin </chemical>) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
    "original_text": "Both the 5 alpha-reductase inhibitor finasteride and  alpha 1-adrenoceptor  antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and  terazosin ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "terazosin"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Injections of <protein> m-CPBG </protein>, a selective <chemical> 5-HT3 </chemical> receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states.",
    "original_text": "Injections of  m-CPBG , a selective  5-HT3  receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states.",
    "entity1": "m-CPBG",
    "entity2": "5-HT3"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The hyperglycemic effect of <protein> m-CPBG </protein> central administration was blocked by pretreatment with ondansetron, a specific <chemical> 5-HT3 </chemical> receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors.",
    "original_text": "The hyperglycemic effect of  m-CPBG  central administration was blocked by pretreatment with ondansetron, a specific  5-HT3  receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors.",
    "entity1": "m-CPBG",
    "entity2": "5-HT3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Introduction: 5-Lipoxygenase (<protein> 5-LO </protein>) is a crucial enzyme of the <chemical> arachidonic acid </chemical> (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.",
    "original_text": "Introduction: 5-Lipoxygenase ( 5-LO ) is a crucial enzyme of the  arachidonic acid  (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.",
    "entity1": "5-LO",
    "entity2": "arachidonic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Introduction: <protein> 5-Lipoxygenase </protein> (5-LO) is a crucial enzyme of the <chemical> arachidonic acid </chemical> (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.",
    "original_text": "Introduction:  5-Lipoxygenase  (5-LO) is a crucial enzyme of the  arachidonic acid  (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.",
    "entity1": "5-Lipoxygenase",
    "entity2": "arachidonic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Using a transient heterologous cell expression system, we find that the transport activities of the <protein> short OATP2B1 </protein> variant towards substrates <chemical> estrone sulfate </chemical> and rosuvastatin are similar to the well-characterized full length variant.",
    "original_text": "Using a transient heterologous cell expression system, we find that the transport activities of the  short OATP2B1  variant towards substrates  estrone sulfate  and rosuvastatin are similar to the well-characterized full length variant.",
    "entity1": "short OATP2B1",
    "entity2": "estrone sulfate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Using a transient heterologous cell expression system, we find that the transport activities of the <protein> short OATP2B1 </protein> variant towards substrates estrone sulfate and <chemical> rosuvastatin </chemical> are similar to the well-characterized full length variant.",
    "original_text": "Using a transient heterologous cell expression system, we find that the transport activities of the  short OATP2B1  variant towards substrates estrone sulfate and  rosuvastatin  are similar to the well-characterized full length variant.",
    "entity1": "short OATP2B1",
    "entity2": "rosuvastatin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Memantine </protein> is an uncompetitive (channel blocking) <chemical> NMDA receptor </chemical> antagonist.",
    "original_text": " Memantine  is an uncompetitive (channel blocking)  NMDA receptor  antagonist.",
    "entity1": "Memantine",
    "entity2": "NMDA receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Like other <protein> NMDA receptor </protein> antagonists, <chemical> memantine </chemical> at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory.",
    "original_text": "Like other  NMDA receptor  antagonists,  memantine  at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory.",
    "entity1": "NMDA receptor",
    "entity2": "memantine"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Moreover, recent in vitro studies suggest that <protein> memantine </protein> abrogates <chemical> beta-amyloid </chemical> (Abeta) toxicity and possibly inhibits Abeta production.",
    "original_text": "Moreover, recent in vitro studies suggest that  memantine  abrogates  beta-amyloid  (Abeta) toxicity and possibly inhibits Abeta production.",
    "entity1": "memantine",
    "entity2": "beta-amyloid"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Moreover, recent in vitro studies suggest that <protein> memantine </protein> abrogates beta-amyloid (<chemical> Abeta </chemical>) toxicity and possibly inhibits Abeta production.",
    "original_text": "Moreover, recent in vitro studies suggest that  memantine  abrogates beta-amyloid ( Abeta ) toxicity and possibly inhibits Abeta production.",
    "entity1": "memantine",
    "entity2": "Abeta"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Considerable attention has focused on the investigation of theories to explain the better tolerability of <protein> memantine </protein> over other <chemical> NMDA receptor </chemical> antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801).",
    "original_text": "Considerable attention has focused on the investigation of theories to explain the better tolerability of  memantine  over other  NMDA receptor  antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801).",
    "entity1": "memantine",
    "entity2": "NMDA receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The concomitantly administered effects of <protein> rifampicin </protein> on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by <chemical> p-glycoprotein </chemical> in the gastrointestinal tract and liver.",
    "original_text": "The concomitantly administered effects of  rifampicin  on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by  p-glycoprotein  in the gastrointestinal tract and liver.",
    "entity1": "rifampicin",
    "entity2": "p-glycoprotein"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The concomitantly administered effects of <protein> rifampicin </protein> on other drugs can result in their altered metabolism or transportation that are metabolised by <chemical> cytochromes P450 </chemical> or transported by p-glycoprotein in the gastrointestinal tract and liver.",
    "original_text": "The concomitantly administered effects of  rifampicin  on other drugs can result in their altered metabolism or transportation that are metabolised by  cytochromes P450  or transported by p-glycoprotein in the gastrointestinal tract and liver.",
    "entity1": "rifampicin",
    "entity2": "cytochromes P450"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Previous studies demonstrated that the <protein> Group III mGlu receptor </protein>-selective orthosteric agonist, <chemical> LSP1-2111 </chemical> produced anxiolytic- but not antidepressant-like effects upon peripheral administration.",
    "original_text": "Previous studies demonstrated that the  Group III mGlu receptor -selective orthosteric agonist,  LSP1-2111  produced anxiolytic- but not antidepressant-like effects upon peripheral administration.",
    "entity1": "Group III mGlu receptor",
    "entity2": "LSP1-2111"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the <protein> benzodiazepine receptor </protein> antagonist <chemical> flumazenil </chemical> (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin.",
    "original_text": "The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the  benzodiazepine receptor  antagonist  flumazenil  (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin.",
    "entity1": "benzodiazepine receptor",
    "entity2": "flumazenil"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, <protein> tadalafil </protein>, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for <chemical> Q817A </chemical>; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
    "original_text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil,  tadalafil , or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for  Q817A ; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
    "entity1": "tadalafil",
    "entity2": "Q817A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Role of <protein> organic cation/carnitine transporter 1 </protein> in uptake of <chemical> phenformin </chemical> and inhibitory effect on complex I respiration in mitochondria.",
    "original_text": "Role of  organic cation/carnitine transporter 1  in uptake of  phenformin  and inhibitory effect on complex I respiration in mitochondria.",
    "entity1": "organic cation/carnitine transporter 1",
    "entity2": "phenformin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These observations suggest that uptake of <protein> phenformin </protein> into liver mitochondria is at least partly mediated by <chemical> OCTN1 </chemical> and functionally relevant to its inhibition potential of complex I respiration.",
    "original_text": "These observations suggest that uptake of  phenformin  into liver mitochondria is at least partly mediated by  OCTN1  and functionally relevant to its inhibition potential of complex I respiration.",
    "entity1": "phenformin",
    "entity2": "OCTN1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists <protein> SB224289 </protein> (300 microg/kg; <chemical> 5-HT1B </chemical>), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).",
    "original_text": "The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists  SB224289  (300 microg/kg;  5-HT1B ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).",
    "entity1": "SB224289",
    "entity2": "5-HT1B"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), <protein> BRL15572 </protein> (300 microg/kg; <chemical> 5-HT1D </chemical>), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).",
    "original_text": "The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B),  BRL15572  (300 microg/kg;  5-HT1D ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).",
    "entity1": "BRL15572",
    "entity2": "5-HT1D"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the <protein> dopamine D2 </protein> agonist <chemical> apomorphine </chemical>; however, it is not clear whether both findings share the same biological basis.",
    "original_text": "In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the  dopamine D2  agonist  apomorphine ; however, it is not clear whether both findings share the same biological basis.",
    "entity1": "dopamine D2",
    "entity2": "apomorphine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Mouse brain serine racemase </protein> catalyzes specific elimination of <chemical> L-serine </chemical> to pyruvate.",
    "original_text": " Mouse brain serine racemase  catalyzes specific elimination of  L-serine  to pyruvate.",
    "entity1": "Mouse brain serine racemase",
    "entity2": "L-serine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> D-Serine </protein> was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the <chemical> N-methyl-D-aspartate (NMDA)-type receptors </chemical>.",
    "original_text": " D-Serine  was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the  N-methyl-D-aspartate (NMDA)-type receptors .",
    "entity1": "D-Serine",
    "entity2": "N-methyl-D-aspartate (NMDA)-type receptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Racemization of <protein> serine </protein> is catalyzed by <chemical> serine racemase </chemical>, a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver.",
    "original_text": "Racemization of  serine  is catalyzed by  serine racemase , a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver.",
    "entity1": "serine",
    "entity2": "serine racemase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Pharmacogenetic analysis of two genes, the <protein> warfarin </protein> metabolic enzyme <chemical> CYP2C9 </chemical> and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.",
    "original_text": "Pharmacogenetic analysis of two genes, the  warfarin  metabolic enzyme  CYP2C9  and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.",
    "entity1": "warfarin",
    "entity2": "CYP2C9"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Possession of <protein> CYP2C9 </protein>*2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean <chemical> warfarin </chemical> dose.",
    "original_text": "Possession of  CYP2C9 *2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean  warfarin  dose.",
    "entity1": "CYP2C9",
    "entity2": "warfarin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Possession of CYP2C9*2 or <protein> CYP2C9 </protein>*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean <chemical> warfarin </chemical> dose.",
    "original_text": "Possession of CYP2C9*2 or  CYP2C9 *3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean  warfarin  dose.",
    "entity1": "CYP2C9",
    "entity2": "warfarin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Monocarboxylate transporters </protein> (MCTs) are proton-linked membrane carriers involved in the transport of <chemical> monocarboxylates </chemical> such as lactate, pyruvate, as well as ketone bodies.",
    "original_text": " Monocarboxylate transporters  (MCTs) are proton-linked membrane carriers involved in the transport of  monocarboxylates  such as lactate, pyruvate, as well as ketone bodies.",
    "entity1": "Monocarboxylate transporters",
    "entity2": "monocarboxylates"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Monocarboxylate transporters (<protein> MCTs </protein>) are proton-linked membrane carriers involved in the transport of <chemical> monocarboxylates </chemical> such as lactate, pyruvate, as well as ketone bodies.",
    "original_text": "Monocarboxylate transporters ( MCTs ) are proton-linked membrane carriers involved in the transport of  monocarboxylates  such as lactate, pyruvate, as well as ketone bodies.",
    "entity1": "MCTs",
    "entity2": "monocarboxylates"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Monocarboxylate transporters </protein> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as <chemical> lactate </chemical>, pyruvate, as well as ketone bodies.",
    "original_text": " Monocarboxylate transporters  (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as  lactate , pyruvate, as well as ketone bodies.",
    "entity1": "Monocarboxylate transporters",
    "entity2": "lactate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Monocarboxylate transporters (<protein> MCTs </protein>) are proton-linked membrane carriers involved in the transport of monocarboxylates such as <chemical> lactate </chemical>, pyruvate, as well as ketone bodies.",
    "original_text": "Monocarboxylate transporters ( MCTs ) are proton-linked membrane carriers involved in the transport of monocarboxylates such as  lactate , pyruvate, as well as ketone bodies.",
    "entity1": "MCTs",
    "entity2": "lactate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Monocarboxylate transporters </protein> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, <chemical> pyruvate </chemical>, as well as ketone bodies.",
    "original_text": " Monocarboxylate transporters  (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate,  pyruvate , as well as ketone bodies.",
    "entity1": "Monocarboxylate transporters",
    "entity2": "pyruvate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Monocarboxylate transporters (<protein> MCTs </protein>) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, <chemical> pyruvate </chemical>, as well as ketone bodies.",
    "original_text": "Monocarboxylate transporters ( MCTs ) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate,  pyruvate , as well as ketone bodies.",
    "entity1": "MCTs",
    "entity2": "pyruvate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Monocarboxylate transporters </protein> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as <chemical> ketone </chemical> bodies.",
    "original_text": " Monocarboxylate transporters  (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as  ketone  bodies.",
    "entity1": "Monocarboxylate transporters",
    "entity2": "ketone"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Monocarboxylate transporters (<protein> MCTs </protein>) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as <chemical> ketone </chemical> bodies.",
    "original_text": "Monocarboxylate transporters ( MCTs ) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as  ketone  bodies.",
    "entity1": "MCTs",
    "entity2": "ketone"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Interestingly, part of <protein> MCT2 </protein> immunoreactivity is located at postsynaptic sites, suggesting a particular role of <chemical> monocarboxylates </chemical> and their transporters in synaptic transmission.",
    "original_text": "Interestingly, part of  MCT2  immunoreactivity is located at postsynaptic sites, suggesting a particular role of  monocarboxylates  and their transporters in synaptic transmission.",
    "entity1": "MCT2",
    "entity2": "monocarboxylates"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Differentiating the roles of mGlu2 and mGlu3 receptors using <protein> LY541850 </protein>, an <chemical> mGlu2 </chemical> agonist/mGlu3 antagonist.",
    "original_text": "Differentiating the roles of mGlu2 and mGlu3 receptors using  LY541850 , an  mGlu2  agonist/mGlu3 antagonist.",
    "entity1": "LY541850",
    "entity2": "mGlu2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Differentiating the roles of mGlu2 and mGlu3 receptors using <protein> LY541850 </protein>, an mGlu2 agonist/<chemical> mGlu3 </chemical> antagonist.",
    "original_text": "Differentiating the roles of mGlu2 and mGlu3 receptors using  LY541850 , an mGlu2 agonist/ mGlu3  antagonist.",
    "entity1": "LY541850",
    "entity2": "mGlu3"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> LY541850 </protein> was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric <chemical> mGlu2 </chemical> agonist and mGlu3 antagonist.",
    "original_text": " LY541850  was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric  mGlu2  agonist and mGlu3 antagonist.",
    "entity1": "LY541850",
    "entity2": "mGlu2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> LY541850 </protein> was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and <chemical> mGlu3 </chemical> antagonist.",
    "original_text": " LY541850  was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and  mGlu3  antagonist.",
    "entity1": "LY541850",
    "entity2": "mGlu3"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These results confirm the selective <protein> mGlu2 </protein> agonist and mGlu3 antagonist actions of <chemical> LY541850 </chemical>.",
    "original_text": "These results confirm the selective  mGlu2  agonist and mGlu3 antagonist actions of  LY541850 .",
    "entity1": "mGlu2",
    "entity2": "LY541850"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "These results confirm the selective mGlu2 agonist and <protein> mGlu3 </protein> antagonist actions of <chemical> LY541850 </chemical>.",
    "original_text": "These results confirm the selective mGlu2 agonist and  mGlu3  antagonist actions of  LY541850 .",
    "entity1": "mGlu3",
    "entity2": "LY541850"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Second, C427A mutant human TOP2alpha, which exhibits reduced <protein> ATPase </protein> activity, was shown to exhibit cross-resistance to all ATP-sensitive but not <chemical> ATP </chemical>-insensitive TOP2 poisons.",
    "original_text": "Second, C427A mutant human TOP2alpha, which exhibits reduced  ATPase  activity, was shown to exhibit cross-resistance to all ATP-sensitive but not  ATP -insensitive TOP2 poisons.",
    "entity1": "ATPase",
    "entity2": "ATP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> QR2 </protein> catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or <chemical> N-ribosylated nicotinamides </chemical>.",
    "original_text": " QR2  catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or  N-ribosylated nicotinamides .",
    "entity1": "QR2",
    "entity2": "N-ribosylated nicotinamides"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> QR2 </protein> catalyzes the two-electron reduction of <chemical> menadione </chemical> via the oxidation of N-alkylated or N-ribosylated nicotinamides.",
    "original_text": " QR2  catalyzes the two-electron reduction of  menadione  via the oxidation of N-alkylated or N-ribosylated nicotinamides.",
    "entity1": "QR2",
    "entity2": "menadione"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> QR2 </protein> catalyzes the two-electron reduction of menadione via the oxidation of <chemical> N-alkylated </chemical> or N-ribosylated nicotinamides.",
    "original_text": " QR2  catalyzes the two-electron reduction of menadione via the oxidation of  N-alkylated  or N-ribosylated nicotinamides.",
    "entity1": "QR2",
    "entity2": "N-alkylated"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The in vivo inhibitory effect of <protein> harmaline </protein> on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified <chemical> CYP2D6 </chemical>.",
    "original_text": "The in vivo inhibitory effect of  harmaline  on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified  CYP2D6 .",
    "entity1": "harmaline",
    "entity2": "CYP2D6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The in vivo inhibitory effect of harmaline on <protein> CYP2D6 </protein>-catalyzed <chemical> bufotenine </chemical> formation was confirmed by in vitro study using purified CYP2D6.",
    "original_text": "The in vivo inhibitory effect of harmaline on  CYP2D6 -catalyzed  bufotenine  formation was confirmed by in vitro study using purified CYP2D6.",
    "entity1": "CYP2D6",
    "entity2": "bufotenine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Given these findings, a unified PK model including the inhibition of <protein> MAO-A </protein>- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, <chemical> 5-MeO-DMT </chemical>, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
    "original_text": "Given these findings, a unified PK model including the inhibition of  MAO-A - and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline,  5-MeO-DMT , and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
    "entity1": "MAO-A",
    "entity2": "5-MeO-DMT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and <protein> CYP2D6 </protein>-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, <chemical> 5-MeO-DMT </chemical>, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
    "original_text": "Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6 -catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline,  5-MeO-DMT , and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
    "entity1": "CYP2D6",
    "entity2": "5-MeO-DMT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, <protein> 5-MeO-DMT </protein>, and bufotenine PK profiles in both wild-type and Tg-<chemical> CYP2D6 </chemical> mouse models.",
    "original_text": "Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline,  5-MeO-DMT , and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models.",
    "entity1": "5-MeO-DMT",
    "entity2": "CYP2D6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Given these findings, a unified PK model including the inhibition of <protein> MAO-A </protein>- and CYP2D6-catalyzed <chemical> 5-MeO-DMT </chemical> metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
    "original_text": "Given these findings, a unified PK model including the inhibition of  MAO-A - and CYP2D6-catalyzed  5-MeO-DMT  metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
    "entity1": "MAO-A",
    "entity2": "5-MeO-DMT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and <protein> CYP2D6 </protein>-catalyzed <chemical> 5-MeO-DMT </chemical> metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
    "original_text": "Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6 -catalyzed  5-MeO-DMT  metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
    "entity1": "CYP2D6",
    "entity2": "5-MeO-DMT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed <protein> 5-MeO-DMT </protein> metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-<chemical> CYP2D6 </chemical> mouse models.",
    "original_text": "Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed  5-MeO-DMT  metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models.",
    "entity1": "5-MeO-DMT",
    "entity2": "CYP2D6"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Compared pharmacological characteristics in humans of racemic <protein> cetirizine </protein> and levocetirizine, two <chemical> histamine H1-receptor </chemical> antagonists.",
    "original_text": "Compared pharmacological characteristics in humans of racemic  cetirizine  and levocetirizine, two  histamine H1-receptor  antagonists.",
    "entity1": "cetirizine",
    "entity2": "histamine H1-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Compared pharmacological characteristics in humans of racemic cetirizine and <protein> levocetirizine </protein>, two <chemical> histamine H1-receptor </chemical> antagonists.",
    "original_text": "Compared pharmacological characteristics in humans of racemic cetirizine and  levocetirizine , two  histamine H1-receptor  antagonists.",
    "entity1": "levocetirizine",
    "entity2": "histamine H1-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potent <protein> histamine H(1)-receptor </protein> antagonist <chemical> cetirizine </chemical> (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.",
    "original_text": "The potent  histamine H(1)-receptor  antagonist  cetirizine  (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.",
    "entity1": "histamine H(1)-receptor",
    "entity2": "cetirizine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potent <protein> histamine H(1)-receptor </protein> antagonist cetirizine (<chemical> Zyrtec </chemical>) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.",
    "original_text": "The potent  histamine H(1)-receptor  antagonist cetirizine ( Zyrtec ) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.",
    "entity1": "histamine H(1)-receptor",
    "entity2": "Zyrtec"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potent <protein> histamine H(1)-receptor </protein> antagonist cetirizine (Zyrtec) is a racemic mixture of <chemical> levocetirizine </chemical> (now available under the trademark Xyzal and dextrocetirizine.",
    "original_text": "The potent  histamine H(1)-receptor  antagonist cetirizine (Zyrtec) is a racemic mixture of  levocetirizine  (now available under the trademark Xyzal and dextrocetirizine.",
    "entity1": "histamine H(1)-receptor",
    "entity2": "levocetirizine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potent <protein> histamine H(1)-receptor </protein> antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark <chemical> Xyzal </chemical> and dextrocetirizine.",
    "original_text": "The potent  histamine H(1)-receptor  antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark  Xyzal  and dextrocetirizine.",
    "entity1": "histamine H(1)-receptor",
    "entity2": "Xyzal"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potent <protein> histamine H(1)-receptor </protein> antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and <chemical> dextrocetirizine </chemical>.",
    "original_text": "The potent  histamine H(1)-receptor  antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and  dextrocetirizine .",
    "entity1": "histamine H(1)-receptor",
    "entity2": "dextrocetirizine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Therefore, comparative histochemical and biochemical studies of <protein> u-PA </protein> and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate <chemical> Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin </chemical>.",
    "original_text": "Therefore, comparative histochemical and biochemical studies of  u-PA  and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate  Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin .",
    "entity1": "u-PA",
    "entity2": "Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Prednisolone </protein> also inhibited ACTH and cortisol secretion in response to exogenous <chemical> CRH </chemical> stimulation, inferring rapid feedback inhibition at the anterior pituitary.",
    "original_text": " Prednisolone  also inhibited ACTH and cortisol secretion in response to exogenous  CRH  stimulation, inferring rapid feedback inhibition at the anterior pituitary.",
    "entity1": "Prednisolone",
    "entity2": "CRH"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Levodopa </protein> is absorbed in the small bowel and is rapidly catabolized by <chemical> aromatic-L-amino-acid decarboxylase </chemical> (AADC) and catechol-O-methyltransferase (COMT).",
    "original_text": " Levodopa  is absorbed in the small bowel and is rapidly catabolized by  aromatic-L-amino-acid decarboxylase  (AADC) and catechol-O-methyltransferase (COMT).",
    "entity1": "Levodopa",
    "entity2": "aromatic-L-amino-acid decarboxylase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Levodopa </protein> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (<chemical> AADC </chemical>) and catechol-O-methyltransferase (COMT).",
    "original_text": " Levodopa  is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase ( AADC ) and catechol-O-methyltransferase (COMT).",
    "entity1": "Levodopa",
    "entity2": "AADC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Levodopa </protein> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and <chemical> catechol-O-methyltransferase </chemical> (COMT).",
    "original_text": " Levodopa  is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and  catechol-O-methyltransferase  (COMT).",
    "entity1": "Levodopa",
    "entity2": "catechol-O-methyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Levodopa </protein> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (<chemical> COMT </chemical>).",
    "original_text": " Levodopa  is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase ( COMT ).",
    "entity1": "Levodopa",
    "entity2": "COMT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Because gastric <protein> AADC </protein> and COMT degrade <chemical> levodopa </chemical>, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.",
    "original_text": "Because gastric  AADC  and COMT degrade  levodopa , the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.",
    "entity1": "AADC",
    "entity2": "levodopa"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Because gastric AADC and <protein> COMT </protein> degrade <chemical> levodopa </chemical>, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.",
    "original_text": "Because gastric AADC and  COMT  degrade  levodopa , the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.",
    "entity1": "COMT",
    "entity2": "levodopa"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of <protein> L-arginine </protein> for <chemical> aminopeptidase B </chemical>.",
    "original_text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of  L-arginine  for  aminopeptidase B .",
    "entity1": "L-arginine",
    "entity2": "aminopeptidase B"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: <protein> 4-methoxy-2-naphthylamide </protein> of L-alanine for <chemical> aminopeptidase N </chemical>, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "original_text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity:  4-methoxy-2-naphthylamide  of L-alanine for  aminopeptidase N , 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "entity1": "4-methoxy-2-naphthylamide",
    "entity2": "aminopeptidase N"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of <protein> L-alanine </protein> for <chemical> aminopeptidase N </chemical>, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "original_text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of  L-alanine  for  aminopeptidase N , 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "entity1": "L-alanine",
    "entity2": "aminopeptidase N"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, <protein> 4-methoxy-2-naphthylamide </protein> of L-leucine for <chemical> leucine aminopeptidase </chemical>, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "original_text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N,  4-methoxy-2-naphthylamide  of L-leucine for  leucine aminopeptidase , 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "entity1": "4-methoxy-2-naphthylamide",
    "entity2": "leucine aminopeptidase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of <protein> L-leucine </protein> for <chemical> leucine aminopeptidase </chemical>, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "original_text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of  L-leucine  for  leucine aminopeptidase , 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "entity1": "L-leucine",
    "entity2": "leucine aminopeptidase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, <protein> 4-methoxy-2-naphthylamide </protein> of L-glutamic acid for <chemical> aminopeptidase A </chemical> and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "original_text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase,  4-methoxy-2-naphthylamide  of L-glutamic acid for  aminopeptidase A  and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "entity1": "4-methoxy-2-naphthylamide",
    "entity2": "aminopeptidase A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of <protein> L-glutamic acid </protein> for <chemical> aminopeptidase A </chemical> and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "original_text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of  L-glutamic acid  for  aminopeptidase A  and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
    "entity1": "L-glutamic acid",
    "entity2": "aminopeptidase A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and <protein> 4-methoxy-2-naphthylamide </protein> of L-arginine for <chemical> aminopeptidase B </chemical>.",
    "original_text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and  4-methoxy-2-naphthylamide  of L-arginine for  aminopeptidase B .",
    "entity1": "4-methoxy-2-naphthylamide",
    "entity2": "aminopeptidase B"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here, we demonstrate that <protein> peptidyl-prolyl cis/trans-isomerase A1 </protein> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of <chemical> pSer </chemical>/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "original_text": "Here, we demonstrate that  peptidyl-prolyl cis/trans-isomerase A1  (Pin1), an enzyme that catalyzes the conversion of the peptide bond of  pSer /pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "entity1": "peptidyl-prolyl cis/trans-isomerase A1",
    "entity2": "pSer"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<protein> Pin1 </protein>), an enzyme that catalyzes the conversion of the peptide bond of <chemical> pSer </chemical>/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "original_text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 ( Pin1 ), an enzyme that catalyzes the conversion of the peptide bond of  pSer /pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "entity1": "Pin1",
    "entity2": "pSer"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here, we demonstrate that <protein> peptidyl-prolyl cis/trans-isomerase A1 </protein> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/<chemical> pThr </chemical>-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "original_text": "Here, we demonstrate that  peptidyl-prolyl cis/trans-isomerase A1  (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/ pThr -Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "entity1": "peptidyl-prolyl cis/trans-isomerase A1",
    "entity2": "pThr"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<protein> Pin1 </protein>), an enzyme that catalyzes the conversion of the peptide bond of pSer/<chemical> pThr </chemical>-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "original_text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 ( Pin1 ), an enzyme that catalyzes the conversion of the peptide bond of pSer/ pThr -Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "entity1": "Pin1",
    "entity2": "pThr"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here, we demonstrate that <protein> peptidyl-prolyl cis/trans-isomerase A1 </protein> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-<chemical> Pro </chemical> moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "original_text": "Here, we demonstrate that  peptidyl-prolyl cis/trans-isomerase A1  (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr- Pro  moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "entity1": "peptidyl-prolyl cis/trans-isomerase A1",
    "entity2": "Pro"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<protein> Pin1 </protein>), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-<chemical> Pro </chemical> moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "original_text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 ( Pin1 ), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr- Pro  moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
    "entity1": "Pin1",
    "entity2": "Pro"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Withdrawal from free-choice <protein> ethanol </protein> consumption results in increased packing density of <chemical> glutamine synthetase </chemical>-immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats.",
    "original_text": "Withdrawal from free-choice  ethanol  consumption results in increased packing density of  glutamine synthetase -immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats.",
    "entity1": "ethanol",
    "entity2": "glutamine synthetase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released <protein> glutamate </protein> and its conversion to glutamine through the enzyme <chemical> glutamine synthetase </chemical> (GS).",
    "original_text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released  glutamate  and its conversion to glutamine through the enzyme  glutamine synthetase  (GS).",
    "entity1": "glutamate",
    "entity2": "glutamine synthetase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released <protein> glutamate </protein> and its conversion to glutamine through the enzyme glutamine synthetase (<chemical> GS </chemical>).",
    "original_text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released  glutamate  and its conversion to glutamine through the enzyme glutamine synthetase ( GS ).",
    "entity1": "glutamate",
    "entity2": "GS"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> All-trans retinoic acid </protein> protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating <chemical> collagen 8A2 </chemical>.",
    "original_text": " All-trans retinoic acid  protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating  collagen 8A2 .",
    "entity1": "All-trans retinoic acid",
    "entity2": "collagen 8A2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The protein exhibited modest H(2)O(2)-dependent <protein> peroxidase </protein> activities with <chemical> guaiacol </chemical>, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).",
    "original_text": "The protein exhibited modest H(2)O(2)-dependent  peroxidase  activities with  guaiacol , potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).",
    "entity1": "peroxidase",
    "entity2": "guaiacol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The protein exhibited modest H(2)O(2)-dependent <protein> peroxidase </protein> activities with guaiacol, <chemical> potassium iodide </chemical>, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).",
    "original_text": "The protein exhibited modest H(2)O(2)-dependent  peroxidase  activities with guaiacol,  potassium iodide , and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).",
    "entity1": "peroxidase",
    "entity2": "potassium iodide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The protein exhibited modest H(2)O(2)-dependent <protein> peroxidase </protein> activities with guaiacol, potassium iodide, and <chemical> 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid </chemical> (ABTS).",
    "original_text": "The protein exhibited modest H(2)O(2)-dependent  peroxidase  activities with guaiacol, potassium iodide, and  2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid  (ABTS).",
    "entity1": "peroxidase",
    "entity2": "2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The protein exhibited modest H(2)O(2)-dependent <protein> peroxidase </protein> activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (<chemical> ABTS </chemical>).",
    "original_text": "The protein exhibited modest H(2)O(2)-dependent  peroxidase  activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid ( ABTS ).",
    "entity1": "peroxidase",
    "entity2": "ABTS"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Butein </protein> also increased heme oxygenase-1 (HO-1) protein expression and <chemical> HO </chemical> activity.",
    "original_text": " Butein  also increased heme oxygenase-1 (HO-1) protein expression and  HO  activity.",
    "entity1": "Butein",
    "entity2": "HO"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> 2-(2-Aminoethyl)-quinoline </protein> (D-1997): a novel agonist at <chemical> 5-hydroxytryptamine1-like receptors </chemical> in the canine basilar artery.",
    "original_text": " 2-(2-Aminoethyl)-quinoline  (D-1997): a novel agonist at  5-hydroxytryptamine1-like receptors  in the canine basilar artery.",
    "entity1": "2-(2-Aminoethyl)-quinoline",
    "entity2": "5-hydroxytryptamine1-like receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "2-(2-Aminoethyl)-quinoline (<protein> D-1997 </protein>): a novel agonist at <chemical> 5-hydroxytryptamine1-like receptors </chemical> in the canine basilar artery.",
    "original_text": "2-(2-Aminoethyl)-quinoline ( D-1997 ): a novel agonist at  5-hydroxytryptamine1-like receptors  in the canine basilar artery.",
    "entity1": "D-1997",
    "entity2": "5-hydroxytryptamine1-like receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the <protein> 5-HT2 receptor </protein> antagonist <chemical> ketanserin </chemical> (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
    "original_text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the  5-HT2 receptor  antagonist  ketanserin  (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
    "entity1": "5-HT2 receptor",
    "entity2": "ketanserin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the <protein> 5-HT3 </protein> and 5-HT4 receptor antagonist ICS205930 (<chemical> tropisetron </chemical>; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
    "original_text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the  5-HT3  and 5-HT4 receptor antagonist ICS205930 ( tropisetron ; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
    "entity1": "5-HT3",
    "entity2": "tropisetron"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and <protein> 5-HT4 </protein> receptor antagonist ICS205930 (<chemical> tropisetron </chemical>; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
    "original_text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and  5-HT4  receptor antagonist ICS205930 ( tropisetron ; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
    "entity1": "5-HT4",
    "entity2": "tropisetron"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the <protein> 5-HT1A </protein> receptor antagonist <chemical> spiroxatrine </chemical> (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
    "original_text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the  5-HT1A  receptor antagonist  spiroxatrine  (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
    "entity1": "5-HT1A",
    "entity2": "spiroxatrine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the <protein> alpha 1-adrenoceptor </protein> antagonist <chemical> prazosin </chemical> (0.01-1 microM).",
    "original_text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the  alpha 1-adrenoceptor  antagonist  prazosin  (0.01-1 microM).",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "prazosin"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In contrast, the <protein> D-1997 </protein>-induced responses were potently and concentration-dependently antagonized by the mixed <chemical> 5-HT1-like </chemical> and 5-HT2 receptor antagonist methiothepin (0.01-1 microM).",
    "original_text": "In contrast, the  D-1997 -induced responses were potently and concentration-dependently antagonized by the mixed  5-HT1-like  and 5-HT2 receptor antagonist methiothepin (0.01-1 microM).",
    "entity1": "D-1997",
    "entity2": "5-HT1-like"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In contrast, the <protein> D-1997 </protein>-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and <chemical> 5-HT2 receptor </chemical> antagonist methiothepin (0.01-1 microM).",
    "original_text": "In contrast, the  D-1997 -induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and  5-HT2 receptor  antagonist methiothepin (0.01-1 microM).",
    "entity1": "D-1997",
    "entity2": "5-HT2 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed <protein> 5-HT1-like </protein> and 5-HT2 receptor antagonist <chemical> methiothepin </chemical> (0.01-1 microM).",
    "original_text": "In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed  5-HT1-like  and 5-HT2 receptor antagonist  methiothepin  (0.01-1 microM).",
    "entity1": "5-HT1-like",
    "entity2": "methiothepin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and <protein> 5-HT2 receptor </protein> antagonist <chemical> methiothepin </chemical> (0.01-1 microM).",
    "original_text": "In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and  5-HT2 receptor  antagonist  methiothepin  (0.01-1 microM).",
    "entity1": "5-HT2 receptor",
    "entity2": "methiothepin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In addition, <protein> tolvaptan </protein> is metabolized by the <chemical> CYP3A4 </chemical> system; thus physicians should be aware of the potential for increased interactions with other medications.",
    "original_text": "In addition,  tolvaptan  is metabolized by the  CYP3A4  system; thus physicians should be aware of the potential for increased interactions with other medications.",
    "entity1": "tolvaptan",
    "entity2": "CYP3A4"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <protein> PhIP </protein> (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased <chemical> catalase </chemical> (CAT) activity compared with the control.",
    "original_text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased  catalase  (CAT) activity compared with the control.",
    "entity1": "PhIP",
    "entity2": "catalase"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <protein> PhIP </protein> (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (<chemical> CAT </chemical>) activity compared with the control.",
    "original_text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase ( CAT ) activity compared with the control.",
    "entity1": "PhIP",
    "entity2": "CAT"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <protein> PhIP </protein> (10 and/or 15mg/kg) significantly decreased <chemical> superoxide dismutase </chemical> (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.",
    "original_text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased  superoxide dismutase  (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.",
    "entity1": "PhIP",
    "entity2": "superoxide dismutase"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <protein> PhIP </protein> (10 and/or 15mg/kg) significantly decreased superoxide dismutase (<chemical> SOD </chemical>) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.",
    "original_text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased superoxide dismutase ( SOD ) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.",
    "entity1": "PhIP",
    "entity2": "SOD"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <protein> PhIP </protein> (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and <chemical> glutathioneperoxidase </chemical> (GPx) activities, while increased catalase (CAT) activity compared with the control.",
    "original_text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and  glutathioneperoxidase  (GPx) activities, while increased catalase (CAT) activity compared with the control.",
    "entity1": "PhIP",
    "entity2": "glutathioneperoxidase"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <protein> PhIP </protein> (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (<chemical> GPx </chemical>) activities, while increased catalase (CAT) activity compared with the control.",
    "original_text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase ( GPx ) activities, while increased catalase (CAT) activity compared with the control.",
    "entity1": "PhIP",
    "entity2": "GPx"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "These results suggest that prostacyclin may play a role in downregulating <protein> tissue factor </protein> expression in monocytes, at least in part via elevation of intracellular levels of <chemical> cyclic AMP </chemical>.",
    "original_text": "These results suggest that prostacyclin may play a role in downregulating  tissue factor  expression in monocytes, at least in part via elevation of intracellular levels of  cyclic AMP .",
    "entity1": "tissue factor",
    "entity2": "cyclic AMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PURPOSE: The <protein> fluoropyrimidine carbamate </protein> (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (<chemical> TP </chemical>) inside target tissues.",
    "original_text": "PURPOSE: The  fluoropyrimidine carbamate  (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase ( TP ) inside target tissues.",
    "entity1": "fluoropyrimidine carbamate",
    "entity2": "TP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PURPOSE: The <protein> fluoropyrimidine carbamate </protein> (capecitabine) is converted to 5-fluorouracil (5-FU) by <chemical> thymidine phosphorylase </chemical> (TP) inside target tissues.",
    "original_text": "PURPOSE: The  fluoropyrimidine carbamate  (capecitabine) is converted to 5-fluorouracil (5-FU) by  thymidine phosphorylase  (TP) inside target tissues.",
    "entity1": "fluoropyrimidine carbamate",
    "entity2": "thymidine phosphorylase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PURPOSE: The fluoropyrimidine carbamate (<protein> capecitabine </protein>) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (<chemical> TP </chemical>) inside target tissues.",
    "original_text": "PURPOSE: The fluoropyrimidine carbamate ( capecitabine ) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase ( TP ) inside target tissues.",
    "entity1": "capecitabine",
    "entity2": "TP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PURPOSE: The fluoropyrimidine carbamate (<protein> capecitabine </protein>) is converted to 5-fluorouracil (5-FU) by <chemical> thymidine phosphorylase </chemical> (TP) inside target tissues.",
    "original_text": "PURPOSE: The fluoropyrimidine carbamate ( capecitabine ) is converted to 5-fluorouracil (5-FU) by  thymidine phosphorylase  (TP) inside target tissues.",
    "entity1": "capecitabine",
    "entity2": "thymidine phosphorylase"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Histamine and <protein> Ca </protein> added to NSAIDs amplified the activating effect of the latter on <chemical> CA II </chemical>.",
    "original_text": "Histamine and  Ca  added to NSAIDs amplified the activating effect of the latter on  CA II .",
    "entity1": "Ca",
    "entity2": "CA II"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Association of PGE2 or <protein> acetazolamide </protein> to NSAIDs reduced NSAID-induced activation of <chemical> CA I </chemical> and CA II.",
    "original_text": "Association of PGE2 or  acetazolamide  to NSAIDs reduced NSAID-induced activation of  CA I  and CA II.",
    "entity1": "acetazolamide",
    "entity2": "CA I"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Association of PGE2 or <protein> acetazolamide </protein> to NSAIDs reduced NSAID-induced activation of CA I and <chemical> CA II </chemical>.",
    "original_text": "Association of PGE2 or  acetazolamide  to NSAIDs reduced NSAID-induced activation of CA I and  CA II .",
    "entity1": "acetazolamide",
    "entity2": "CA II"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "CONCLUSIONS: In the maximum registered dosage, <protein> nabumetone </protein> inhibits thromboxane production much more than meloxicam, signifying less <chemical> COX-2 </chemical> selectivity of the former.",
    "original_text": "CONCLUSIONS: In the maximum registered dosage,  nabumetone  inhibits thromboxane production much more than meloxicam, signifying less  COX-2  selectivity of the former.",
    "entity1": "nabumetone",
    "entity2": "COX-2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Correlation between activation of PPAR\u03b3 and <protein> resistin </protein> downregulation in a mouse adipocyte cell line by a series of <chemical> thiazolidinediones </chemical>.",
    "original_text": "Correlation between activation of PPAR\u03b3 and  resistin  downregulation in a mouse adipocyte cell line by a series of  thiazolidinediones .",
    "entity1": "resistin",
    "entity2": "thiazolidinediones"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In addition to this pronounced loss of function, <protein> M1766L </protein> also showed a 10-fold increase in the persistent late <chemical> sodium </chemical> current.",
    "original_text": "In addition to this pronounced loss of function,  M1766L  also showed a 10-fold increase in the persistent late  sodium  current.",
    "entity1": "M1766L",
    "entity2": "sodium"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> OMT </protein> showed partial protection in the cortical neurons via down-regulation of NR2B containing <chemical> NMDA receptors </chemical> and up-regulation of Bcl-2 family.",
    "original_text": " OMT  showed partial protection in the cortical neurons via down-regulation of NR2B containing  NMDA receptors  and up-regulation of Bcl-2 family.",
    "entity1": "OMT",
    "entity2": "NMDA receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Pharmacology of <protein> ramelteon </protein>, a selective <chemical> MT1 </chemical>/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.",
    "original_text": "Pharmacology of  ramelteon , a selective  MT1 /MT2 receptor agonist: a novel therapeutic drug for sleep disorders.",
    "entity1": "ramelteon",
    "entity2": "MT1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Pharmacology of <protein> ramelteon </protein>, a selective MT1/<chemical> MT2 </chemical> receptor agonist: a novel therapeutic drug for sleep disorders.",
    "original_text": "Pharmacology of  ramelteon , a selective MT1/ MT2  receptor agonist: a novel therapeutic drug for sleep disorders.",
    "entity1": "ramelteon",
    "entity2": "MT2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Ramelteon </protein> (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin <chemical> MT(1) </chemical>/MT(2) receptor agonist.",
    "original_text": " Ramelteon  (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin  MT(1) /MT(2) receptor agonist.",
    "entity1": "Ramelteon",
    "entity2": "MT(1)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Ramelteon </protein> (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)/<chemical> MT(2) </chemical> receptor agonist.",
    "original_text": " Ramelteon  (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)/ MT(2)  receptor agonist.",
    "entity1": "Ramelteon",
    "entity2": "MT(2)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Unlike the sedative hypnotics that target GABA(A) receptor complexes, <protein> ramelteon </protein> is a chronohypnotic that acts on the melatonin <chemical> MT(1) </chemical> and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades.",
    "original_text": "Unlike the sedative hypnotics that target GABA(A) receptor complexes,  ramelteon  is a chronohypnotic that acts on the melatonin  MT(1)  and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades.",
    "entity1": "ramelteon",
    "entity2": "MT(1)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Unlike the sedative hypnotics that target GABA(A) receptor complexes, <protein> ramelteon </protein> is a chronohypnotic that acts on the melatonin MT(1) and <chemical> MT(2) </chemical> receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades.",
    "original_text": "Unlike the sedative hypnotics that target GABA(A) receptor complexes,  ramelteon  is a chronohypnotic that acts on the melatonin MT(1) and  MT(2)  receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades.",
    "entity1": "ramelteon",
    "entity2": "MT(2)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the <protein> beta(2)-adrenoceptor </protein> agonist <chemical> formoterol </chemical> [eformoterol].",
    "original_text": "Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the  beta(2)-adrenoceptor  agonist  formoterol  [eformoterol].",
    "entity1": "beta(2)-adrenoceptor",
    "entity2": "formoterol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the <protein> beta(2)-adrenoceptor </protein> agonist formoterol <chemical>[ eformoterol </chemical>].",
    "original_text": "Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the  beta(2)-adrenoceptor  agonist formoterol [ eformoterol ].",
    "entity1": "beta(2)-adrenoceptor",
    "entity2": "[ eformoterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> tyrosine kinase </protein><chemical> tyrosine </chemical> kinase inhibitor ZD1839 (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",
    "original_text": "The  tyrosine kinase  tyrosine  kinase inhibitor ZD1839 (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",
    "entity1": "tyrosine kinase",
    "entity2": "tyrosine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "ZD1839 (\"Iressa\"), a <protein> quinazoline tyrosine </protein><chemical> tyrosine kinase </chemical> inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.",
    "original_text": "ZD1839 (\"Iressa\"), a  quinazoline tyrosine  tyrosine kinase  inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.",
    "entity1": "quinazoline tyrosine",
    "entity2": "tyrosine kinase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with <protein> phosphatidylinositol 3-kinase </protein><chemical> phosphatidylinositol </chemical> 3-kinase, and down-regulation of Akt activity.",
    "original_text": "Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with  phosphatidylinositol 3-kinase  phosphatidylinositol  3-kinase, and down-regulation of Akt activity.",
    "entity1": "phosphatidylinositol 3-kinase",
    "entity2": "phosphatidylinositol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family <protein> tyrosine kinase </protein><chemical> tyrosine </chemical> kinase signaling and suggest novel strategies to treat these particularly aggressive tumors.",
    "original_text": "These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family  tyrosine kinase  tyrosine  kinase signaling and suggest novel strategies to treat these particularly aggressive tumors.",
    "entity1": "tyrosine kinase",
    "entity2": "tyrosine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "[Pharmacological effects of a <protein> mu-opioid receptor </protein> antagonist <chemical> naltrexone </chemical> on alcohol dependence].",
    "original_text": "[Pharmacological effects of a  mu-opioid receptor  antagonist  naltrexone  on alcohol dependence].",
    "entity1": "mu-opioid receptor",
    "entity2": "naltrexone"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In many countries, a <protein> mu-opioid receptor </protein> antagonist <chemical> naltrexone </chemical> has been used in the treatment of alcohol dependence.",
    "original_text": "In many countries, a  mu-opioid receptor  antagonist  naltrexone  has been used in the treatment of alcohol dependence.",
    "entity1": "mu-opioid receptor",
    "entity2": "naltrexone"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "RESULTS: In drug discrimination studies, <protein> lisuride </protein> fully mimicked the <chemical> 5-HT(1A) </chemical> agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.",
    "original_text": "RESULTS: In drug discrimination studies,  lisuride  fully mimicked the  5-HT(1A)  agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.",
    "entity1": "lisuride",
    "entity2": "5-HT(1A)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "RESULTS: In drug discrimination studies, lisuride fully mimicked the <protein> 5-HT(1A) </protein> agonist <chemical> LY 293284 </chemical>, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.",
    "original_text": "RESULTS: In drug discrimination studies, lisuride fully mimicked the  5-HT(1A)  agonist  LY 293284 , only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.",
    "entity1": "5-HT(1A)",
    "entity2": "LY 293284"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Only pMPPI [<protein> 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride </protein>], a selective <chemical> 5-HT(1A) </chemical> antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD.",
    "original_text": "Only pMPPI [ 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride ], a selective  5-HT(1A)  antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD.",
    "entity1": "4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride",
    "entity2": "5-HT(1A)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective <protein> 5-HT(1A) </protein> agonist <chemical> LY 293284 </chemical>.",
    "original_text": "Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective  5-HT(1A)  agonist  LY 293284 .",
    "entity1": "5-HT(1A)",
    "entity2": "LY 293284"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "RGM-1 cells were treated with <protein> CDCA </protein> or GW4064, an <chemical> FXR </chemical> agonist, in the presence or absence of guggulsterone, an FXR antagonist.",
    "original_text": "RGM-1 cells were treated with  CDCA  or GW4064, an  FXR  agonist, in the presence or absence of guggulsterone, an FXR antagonist.",
    "entity1": "CDCA",
    "entity2": "FXR"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "RGM-1 cells were treated with CDCA or <protein> GW4064 </protein>, an <chemical> FXR </chemical> agonist, in the presence or absence of guggulsterone, an FXR antagonist.",
    "original_text": "RGM-1 cells were treated with CDCA or  GW4064 , an  FXR  agonist, in the presence or absence of guggulsterone, an FXR antagonist.",
    "entity1": "GW4064",
    "entity2": "FXR"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of <protein> guggulsterone </protein>, an <chemical> FXR </chemical> antagonist.",
    "original_text": "RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of  guggulsterone , an  FXR  antagonist.",
    "entity1": "guggulsterone",
    "entity2": "FXR"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Mazindol analogues as potential inhibitors of the cocaine binding site at the <protein> dopamine transporter </protein><chemical> dopamine </chemical> transporter.",
    "original_text": "Mazindol analogues as potential inhibitors of the cocaine binding site at the  dopamine transporter  dopamine  transporter.",
    "entity1": "dopamine transporter",
    "entity2": "dopamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Several active analogues were also evaluated for their ability to block uptake of DA, <protein> 5-HT </protein>, and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-<chemical> hSERT </chemical>, and HEK-hNET cells.",
    "original_text": "Several active analogues were also evaluated for their ability to block uptake of DA,  5-HT , and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK- hSERT , and HEK-hNET cells.",
    "entity1": "5-HT",
    "entity2": "hSERT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and <protein> NE </protein> and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK-<chemical> hNET </chemical> cells.",
    "original_text": "Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and  NE  and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK- hNET  cells.",
    "entity1": "NE",
    "entity2": "hNET"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Several active analogues were also evaluated for their ability to block uptake of <protein> DA </protein>, 5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-<chemical> hDAT </chemical>, HEK-hSERT, and HEK-hNET cells.",
    "original_text": "Several active analogues were also evaluated for their ability to block uptake of  DA , 5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK- hDAT , HEK-hSERT, and HEK-hNET cells.",
    "entity1": "DA",
    "entity2": "hDAT"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Upon co-exposure to V(5+) and <protein> TCDD </protein>, V(5+) significantly potentiated the TCDD-mediated induction of the <chemical> Cyp1a1 </chemical>, Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h.",
    "original_text": "Upon co-exposure to V(5+) and  TCDD , V(5+) significantly potentiated the TCDD-mediated induction of the  Cyp1a1 , Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h.",
    "entity1": "TCDD",
    "entity2": "Cyp1a1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Upon co-exposure to V(5+) and <protein> TCDD </protein>, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, <chemical> Cyp1a2 </chemical>, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h.",
    "original_text": "Upon co-exposure to V(5+) and  TCDD , V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1,  Cyp1a2 , and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h.",
    "entity1": "TCDD",
    "entity2": "Cyp1a2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Upon co-exposure to V(5+) and <protein> TCDD </protein>, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and <chemical> Cyp1b1 </chemical> mRNA, protein, and catalytic activity levels at 24\u00a0h.",
    "original_text": "Upon co-exposure to V(5+) and  TCDD , V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and  Cyp1b1  mRNA, protein, and catalytic activity levels at 24\u00a0h.",
    "entity1": "TCDD",
    "entity2": "Cyp1b1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> DEX </protein> enhanced the ratio <chemical> IFN-gamma </chemical>/IL-4 (mean +/- SEM: control, 28.7 +/- 17.6; with 10-7 M DEX, 55.0 +/- 27.5, P<0.005).",
    "original_text": " DEX  enhanced the ratio  IFN-gamma /IL-4 (mean +/- SEM: control, 28.7 +/- 17.6; with 10-7 M DEX, 55.0 +/- 27.5, P<0.005).",
    "entity1": "DEX",
    "entity2": "IFN-gamma"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> DEX </protein> enhanced the ratio IFN-gamma/<chemical> IL-4 </chemical> (mean +/- SEM: control, 28.7 +/- 17.6; with 10-7 M DEX, 55.0 +/- 27.5, P<0.005).",
    "original_text": " DEX  enhanced the ratio IFN-gamma/ IL-4  (mean +/- SEM: control, 28.7 +/- 17.6; with 10-7 M DEX, 55.0 +/- 27.5, P<0.005).",
    "entity1": "DEX",
    "entity2": "IL-4"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In the present study, we identified <protein> amprenavir </protein>, a widely used HIV PI, as a potent <chemical> PXR </chemical>-selective agonist.",
    "original_text": "In the present study, we identified  amprenavir , a widely used HIV PI, as a potent  PXR -selective agonist.",
    "entity1": "amprenavir",
    "entity2": "PXR"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of <protein> cAMP </protein> to AMP by ecto-<chemical> phosphodiesterase </chemical>, and metabolism of AMP to adenosine by ecto-5'-nucleotidase.",
    "original_text": "In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of  cAMP  to AMP by ecto- phosphodiesterase , and metabolism of AMP to adenosine by ecto-5'-nucleotidase.",
    "entity1": "cAMP",
    "entity2": "phosphodiesterase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of <protein> AMP </protein> to adenosine by <chemical> ecto-5'-nucleotidase </chemical>.",
    "original_text": "In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of  AMP  to adenosine by  ecto-5'-nucleotidase .",
    "entity1": "AMP",
    "entity2": "ecto-5'-nucleotidase"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Ambrisentan </protein> is an <chemical> endothelin type A (ET(A))-selective receptor </chemical> antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4.",
    "original_text": " Ambrisentan  is an  endothelin type A (ET(A))-selective receptor  antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4.",
    "entity1": "Ambrisentan",
    "entity2": "endothelin type A (ET(A))-selective receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Ambrisentan </protein> is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by <chemical> CYP3A4 </chemical>.",
    "original_text": " Ambrisentan  is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by  CYP3A4 .",
    "entity1": "Ambrisentan",
    "entity2": "CYP3A4"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Although <protein> glutathione S-transferase omega 1 </protein> (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze <chemical> DMAs(V) </chemical> reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.",
    "original_text": "Although  glutathione S-transferase omega 1  (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze  DMAs(V)  reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.",
    "entity1": "glutathione S-transferase omega 1",
    "entity2": "DMAs(V)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Although glutathione S-transferase omega 1 (GSTO1) and <protein> arsenic methyltransferase </protein> have been shown or thought to catalyze <chemical> DMAs(V) </chemical> reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.",
    "original_text": "Although glutathione S-transferase omega 1 (GSTO1) and  arsenic methyltransferase  have been shown or thought to catalyze  DMAs(V)  reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.",
    "entity1": "arsenic methyltransferase",
    "entity2": "DMAs(V)"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor <protein> chloramine T </protein> (CT), to destroy <chemical> plasmatic PAI-1 </chemical> and alpha2-antiplasmin.",
    "original_text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor  chloramine T  (CT), to destroy  plasmatic PAI-1  and alpha2-antiplasmin.",
    "entity1": "chloramine T",
    "entity2": "plasmatic PAI-1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor <protein> chloramine T </protein> (CT), to destroy plasmatic PAI-1 and alpha2-anti<chemical> plasmin </chemical>.",
    "original_text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor  chloramine T  (CT), to destroy plasmatic PAI-1 and alpha2-anti plasmin .",
    "entity1": "chloramine T",
    "entity2": "plasmin"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (<protein> CT </protein>), to destroy <chemical> plasmatic PAI-1 </chemical> and alpha2-antiplasmin.",
    "original_text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T ( CT ), to destroy  plasmatic PAI-1  and alpha2-antiplasmin.",
    "entity1": "CT",
    "entity2": "plasmatic PAI-1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (<protein> CT </protein>), to destroy plasmatic PAI-1 and alpha2-anti<chemical> plasmin </chemical>.",
    "original_text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T ( CT ), to destroy plasmatic PAI-1 and alpha2-anti plasmin .",
    "entity1": "CT",
    "entity2": "plasmin"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the <protein> singlet oxygen </protein> (1O2) donor chloramine T (CT), to destroy <chemical> plasmatic PAI-1 </chemical> and alpha2-antiplasmin.",
    "original_text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the  singlet oxygen  (1O2) donor chloramine T (CT), to destroy  plasmatic PAI-1  and alpha2-antiplasmin.",
    "entity1": "singlet oxygen",
    "entity2": "plasmatic PAI-1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (<protein> 1O2 </protein>) donor chloramine T (CT), to destroy <chemical> plasmatic PAI-1 </chemical> and alpha2-antiplasmin.",
    "original_text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen ( 1O2 ) donor chloramine T (CT), to destroy  plasmatic PAI-1  and alpha2-antiplasmin.",
    "entity1": "1O2",
    "entity2": "plasmatic PAI-1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "For determination of <protein> plasmin </protein> activity, 10 microL thereof was incubated with 150 microL 1.5 M <chemical> arginine </chemical>, pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C).",
    "original_text": "For determination of  plasmin  activity, 10 microL thereof was incubated with 150 microL 1.5 M  arginine , pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C).",
    "entity1": "plasmin",
    "entity2": "arginine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "For determination of [<protein> PA </protein>+Pli]-activity, <chemical> arginine </chemical> was added after this incubation.",
    "original_text": "For determination of [ PA +Pli]-activity,  arginine  was added after this incubation.",
    "entity1": "PA",
    "entity2": "arginine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "For determination of [PA+<protein> Pli </protein>]-activity, <chemical> arginine </chemical> was added after this incubation.",
    "original_text": "For determination of [PA+ Pli ]-activity,  arginine  was added after this incubation.",
    "entity1": "Pli",
    "entity2": "arginine"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Thus, the increase in mPFC <protein> DAT </protein> function was an SHR-specific long term consequence of <chemical> methylphenidate </chemical> treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration.",
    "original_text": "Thus, the increase in mPFC  DAT  function was an SHR-specific long term consequence of  methylphenidate  treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration.",
    "entity1": "DAT",
    "entity2": "methylphenidate"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Inhibition of angiogenesis and invasion by <protein> DMBT </protein> is mediated by downregulation of <chemical> VEGF </chemical> and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.",
    "original_text": "Inhibition of angiogenesis and invasion by  DMBT  is mediated by downregulation of  VEGF  and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.",
    "entity1": "DMBT",
    "entity2": "VEGF"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Inhibition of angiogenesis and invasion by <protein> DMBT </protein> is mediated by downregulation of VEGF and <chemical> MMP-9 </chemical> through Akt pathway in MDA-MB-231 breast cancer cells.",
    "original_text": "Inhibition of angiogenesis and invasion by  DMBT  is mediated by downregulation of VEGF and  MMP-9  through Akt pathway in MDA-MB-231 breast cancer cells.",
    "entity1": "DMBT",
    "entity2": "MMP-9"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "These results suggested that <protein> DMBT </protein> could inhibit invasion and angiogenesis by downregulation of <chemical> VEGF </chemical>and MMP-9, resulting from the inhibition of Akt pathway.",
    "original_text": "These results suggested that  DMBT  could inhibit invasion and angiogenesis by downregulation of  VEGF and MMP-9, resulting from the inhibition of Akt pathway.",
    "entity1": "DMBT",
    "entity2": "VEGF"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "These results suggested that <protein> DMBT </protein> could inhibit invasion and angiogenesis by downregulation of VEGFand <chemical> MMP-9 </chemical>, resulting from the inhibition of Akt pathway.",
    "original_text": "These results suggested that  DMBT  could inhibit invasion and angiogenesis by downregulation of VEGFand  MMP-9 , resulting from the inhibition of Akt pathway.",
    "entity1": "DMBT",
    "entity2": "MMP-9"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The anticonvulsant <protein> felbamate </protein> blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other <chemical> NMDA receptor </chemical> antagonists.",
    "original_text": "The anticonvulsant  felbamate  blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other  NMDA receptor  antagonists.",
    "entity1": "felbamate",
    "entity2": "NMDA receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "This selectivity could, in part, account for the more favorable clinical profile of <protein> felbamate </protein> in comparison with <chemical> NMDA receptor </chemical> antagonists that do not show subunit selectivity.",
    "original_text": "This selectivity could, in part, account for the more favorable clinical profile of  felbamate  in comparison with  NMDA receptor  antagonists that do not show subunit selectivity.",
    "entity1": "felbamate",
    "entity2": "NMDA receptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Previously, we showed that the <protein> human kappa-opioid receptor </protein> (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <chemical> U50,488H </chemical> treatment.",
    "original_text": "Previously, we showed that the  human kappa-opioid receptor  (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged  U50,488H  treatment.",
    "entity1": "human kappa-opioid receptor",
    "entity2": "U50,488H"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Previously, we showed that the human kappa-opioid receptor (<protein> hkor </protein>) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <chemical> U50,488H </chemical> treatment.",
    "original_text": "Previously, we showed that the human kappa-opioid receptor ( hkor ) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged  U50,488H  treatment.",
    "entity1": "hkor",
    "entity2": "U50,488H"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> U50, 488H </protein> caused a significant down-regulation of the <chemical> hkor </chemical>, although etorphine did not.",
    "original_text": " U50, 488H  caused a significant down-regulation of the  hkor , although etorphine did not.",
    "entity1": "U50, 488H",
    "entity2": "hkor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced <protein> U50,488H </protein>-induced down-regulation of the <chemical> hkor </chemical>.",
    "original_text": "Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced  U50,488H -induced down-regulation of the  hkor .",
    "entity1": "U50,488H",
    "entity2": "hkor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Coexpression of GRK2 or GRK2 and arrestin-2 permitted <protein> etorphine </protein> to induce down-regulation of the <chemical> hkor </chemical>, although expression of arrestin-2 or dynamin I alone did not.",
    "original_text": "Coexpression of GRK2 or GRK2 and arrestin-2 permitted  etorphine  to induce down-regulation of the  hkor , although expression of arrestin-2 or dynamin I alone did not.",
    "entity1": "etorphine",
    "entity2": "hkor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Expression of the dominant negative mutants <protein> rab5A </protein>-N133I or rab7-N125I blunted <chemical> U50,488H </chemical>-induced down-regulation.",
    "original_text": "Expression of the dominant negative mutants  rab5A -N133I or rab7-N125I blunted  U50,488H -induced down-regulation.",
    "entity1": "rab5A",
    "entity2": "U50,488H"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Expression of the dominant negative mutants rab5A-<protein> N133I </protein> or rab7-N125I blunted <chemical> U50,488H </chemical>-induced down-regulation.",
    "original_text": "Expression of the dominant negative mutants rab5A- N133I  or rab7-N125I blunted  U50,488H -induced down-regulation.",
    "entity1": "N133I",
    "entity2": "U50,488H"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Expression of the dominant negative mutants rab5A-N133I or <protein> rab7 </protein>-N125I blunted <chemical> U50,488H </chemical>-induced down-regulation.",
    "original_text": "Expression of the dominant negative mutants rab5A-N133I or  rab7 -N125I blunted  U50,488H -induced down-regulation.",
    "entity1": "rab7",
    "entity2": "U50,488H"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Expression of the dominant negative mutants rab5A-N133I or rab7-<protein> N125I </protein> blunted <chemical> U50,488H </chemical>-induced down-regulation.",
    "original_text": "Expression of the dominant negative mutants rab5A-N133I or rab7- N125I  blunted  U50,488H -induced down-regulation.",
    "entity1": "N125I",
    "entity2": "U50,488H"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "These results indicate that <protein> U50,488H </protein>-induced down-regulation of the <chemical> hkor </chemical> involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation.",
    "original_text": "These results indicate that  U50,488H -induced down-regulation of the  hkor  involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation.",
    "entity1": "U50,488H",
    "entity2": "hkor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Thus, <protein> U50,488H </protein>-induced internalization and down-regulation of the <chemical> hkor </chemical> share initial common mechanisms.",
    "original_text": "Thus,  U50,488H -induced internalization and down-regulation of the  hkor  share initial common mechanisms.",
    "entity1": "U50,488H",
    "entity2": "hkor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of <protein> [(3)H]estradiol glucuronide </protein> (E217\u03b2G) (a prototypical <chemical> MRP </chemical> substrate) into MRP-enriched inside-out membrane vesicles.",
    "original_text": "Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of  [(3)H]estradiol glucuronide  (E217\u03b2G) (a prototypical  MRP  substrate) into MRP-enriched inside-out membrane vesicles.",
    "entity1": "[(3)H]estradiol glucuronide",
    "entity2": "MRP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (<protein> E217\u03b2G </protein>) (a prototypical <chemical> MRP </chemical> substrate) into MRP-enriched inside-out membrane vesicles.",
    "original_text": "Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide ( E217\u03b2G ) (a prototypical  MRP  substrate) into MRP-enriched inside-out membrane vesicles.",
    "entity1": "E217\u03b2G",
    "entity2": "MRP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Sixteen of 34 CGPs inhibited <protein> MRP1 </protein>-mediated <chemical> E217\u03b2G </chemical> uptake by >50% (IC50's 0.7-7.6 \u03bcM).",
    "original_text": "Sixteen of 34 CGPs inhibited  MRP1 -mediated  E217\u03b2G  uptake by >50% (IC50's 0.7-7.6 \u03bcM).",
    "entity1": "MRP1",
    "entity2": "E217\u03b2G"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "When tested in the intact cells, only 4 of 16 CGPs (at 10 \u03bcM) inhibited <protein> MRP1 </protein>-mediated <chemical> calcein </chemical> efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.",
    "original_text": "When tested in the intact cells, only 4 of 16 CGPs (at 10 \u03bcM) inhibited  MRP1 -mediated  calcein  efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.",
    "entity1": "MRP1",
    "entity2": "calcein"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These five CGPs also inhibited <protein> [(3)H]E217\u03b2G </protein> uptake by <chemical> MRP4 </chemical>.",
    "original_text": "These five CGPs also inhibited  [(3)H]E217\u03b2G  uptake by  MRP4 .",
    "entity1": "[(3)H]E217\u03b2G",
    "entity2": "MRP4"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting <protein> alpha2 adrenergic receptor </protein> (AR) agonist (<chemical> dexmedetomidine </chemical>).",
    "original_text": "OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting  alpha2 adrenergic receptor  (AR) agonist ( dexmedetomidine ).",
    "entity1": "alpha2 adrenergic receptor",
    "entity2": "dexmedetomidine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor (<protein> AR </protein>) agonist (<chemical> dexmedetomidine </chemical>).",
    "original_text": "OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor ( AR ) agonist ( dexmedetomidine ).",
    "entity1": "AR",
    "entity2": "dexmedetomidine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Astemizole </protein>, a potent <chemical> histamine H1-receptor </chemical> antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.",
    "original_text": " Astemizole , a potent  histamine H1-receptor  antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.",
    "entity1": "Astemizole",
    "entity2": "histamine H1-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The efficacy of <protein> astemizole </protein>, a new, long acting, oral <chemical> histamine H1-receptor </chemical> antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982.",
    "original_text": "The efficacy of  astemizole , a new, long acting, oral  histamine H1-receptor  antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982.",
    "entity1": "astemizole",
    "entity2": "histamine H1-receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that <protein> dabrafenib </protein> is an avid substrate for both <chemical> P-gp </chemical> and BCRP.",
    "original_text": "In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that  dabrafenib  is an avid substrate for both  P-gp  and BCRP.",
    "entity1": "dabrafenib",
    "entity2": "P-gp"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that <protein> dabrafenib </protein> is an avid substrate for both P-gp and <chemical> BCRP </chemical>.",
    "original_text": "In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that  dabrafenib  is an avid substrate for both P-gp and  BCRP .",
    "entity1": "dabrafenib",
    "entity2": "BCRP"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Since the original discovery of <protein> azoles </protein> analogs as <chemical> PXR </chemical> antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.",
    "original_text": "Since the original discovery of  azoles  analogs as  PXR  antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.",
    "entity1": "azoles",
    "entity2": "PXR"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Since the original discovery of <protein> azoles </protein> analogs as PXR antagonists, we have preliminarily defined an important <chemical> PXR </chemical> antagonist pharmacophore and developed less-toxic PXR antagonists.",
    "original_text": "Since the original discovery of  azoles  analogs as PXR antagonists, we have preliminarily defined an important  PXR  antagonist pharmacophore and developed less-toxic PXR antagonists.",
    "entity1": "azoles",
    "entity2": "PXR"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Since the original discovery of <protein> azoles </protein> analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic <chemical> PXR </chemical> antagonists.",
    "original_text": "Since the original discovery of  azoles  analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic  PXR  antagonists.",
    "entity1": "azoles",
    "entity2": "PXR"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), <protein> 17-phenyl-trinor-PGE2 </protein> (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <chemical> HVA Ca2+ channels </chemical> was sulprostone>PGE2, PGE1>STA2</protein>17-phenyl-trinor-PGE2.",
    "original_text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2),  17-phenyl-trinor-PGE2  (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  HVA Ca2+ channels  was sulprostone>PGE2, PGE1>STA217-phenyl-trinor-PGE2.",
    "entity1": "17-phenyl-trinor-PGE2",
    "entity2": "HVA Ca2+ channels"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), <protein> 17-phenyl-trinor-PGE2 </protein> (an <chemical> EP1 </chemical>-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2</protein>17-phenyl-trinor-PGE2.",
    "original_text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2),  17-phenyl-trinor-PGE2  (an  EP1 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA217-phenyl-trinor-PGE2.",
    "entity1": "17-phenyl-trinor-PGE2",
    "entity2": "EP1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and <protein> sulprostone </protein> (an <chemical> EP3 </chemical>-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2</protein>17-phenyl-trinor-PGE2.",
    "original_text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and  sulprostone  (an  EP3 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA217-phenyl-trinor-PGE2.",
    "entity1": "sulprostone",
    "entity2": "EP3"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> SC-51089 </protein> (10(-5) M), a selective <chemical> EP1-receptor </chemical> antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor.",
    "original_text": " SC-51089  (10(-5) M), a selective  EP1-receptor  antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor.",
    "entity1": "SC-51089",
    "entity2": "EP1-receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The influence of sex, ethnicity, and <protein> CYP2B6 </protein> genotype on <chemical> bupropion </chemical> metabolism as an index of hepatic CYP2B6 activity in humans.",
    "original_text": "The influence of sex, ethnicity, and  CYP2B6  genotype on  bupropion  metabolism as an index of hepatic CYP2B6 activity in humans.",
    "entity1": "CYP2B6",
    "entity2": "bupropion"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using <protein> bupropion </protein> (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a <chemical> CYP2B6 </chemical> probe substrate.",
    "original_text": "To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using  bupropion  (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a  CYP2B6  probe substrate.",
    "entity1": "bupropion",
    "entity2": "CYP2B6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using bupropion (<protein> Wellbutrin SR </protein> GlaxoSmithKline, Research Triangle Park, NC) as a <chemical> CYP2B6 </chemical> probe substrate.",
    "original_text": "To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using bupropion ( Wellbutrin SR  GlaxoSmithKline, Research Triangle Park, NC) as a  CYP2B6  probe substrate.",
    "entity1": "Wellbutrin SR",
    "entity2": "CYP2B6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results suggest that <protein> CYP2B6 </protein> genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of <chemical> bupropion </chemical>.",
    "original_text": "These results suggest that  CYP2B6  genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of  bupropion .",
    "entity1": "CYP2B6",
    "entity2": "bupropion"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of <protein> CYP2B6 </protein> activity in women, when measured by the metabolism of <chemical> bupropion </chemical>.",
    "original_text": "These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of  CYP2B6  activity in women, when measured by the metabolism of  bupropion .",
    "entity1": "CYP2B6",
    "entity2": "bupropion"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> bupropion </protein> metabolic ratio appears to detect known differences in <chemical> CYP2B6 </chemical> activity associated with genetic polymorphism, across different ethnic groups.",
    "original_text": "The  bupropion  metabolic ratio appears to detect known differences in  CYP2B6  activity associated with genetic polymorphism, across different ethnic groups.",
    "entity1": "bupropion",
    "entity2": "CYP2B6"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The identification of the <protein> succinate receptor </protein> SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of <chemical> succinate </chemical> were shown to potentiate the effect of low doses of a variety of platelet agonists.",
    "original_text": "The identification of the  succinate receptor  SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of  succinate  were shown to potentiate the effect of low doses of a variety of platelet agonists.",
    "entity1": "succinate receptor",
    "entity2": "succinate"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The identification of the succinate receptor <protein> SUCNR1 </protein> in platelets is of particular interest, because physiologically relevant concentrations of <chemical> succinate </chemical> were shown to potentiate the effect of low doses of a variety of platelet agonists.",
    "original_text": "The identification of the succinate receptor  SUCNR1  in platelets is of particular interest, because physiologically relevant concentrations of  succinate  were shown to potentiate the effect of low doses of a variety of platelet agonists.",
    "entity1": "SUCNR1",
    "entity2": "succinate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Reductive detoxification of <protein> arylhydroxylamine </protein> carcinogens by human NADH cytochrome b5 reductase and <chemical> cytochrome b5 </chemical>.",
    "original_text": "Reductive detoxification of  arylhydroxylamine  carcinogens by human NADH cytochrome b5 reductase and  cytochrome b5 .",
    "entity1": "arylhydroxylamine",
    "entity2": "cytochrome b5"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Reductive detoxification of <protein> arylhydroxylamine </protein> carcinogens by <chemical> human NADH cytochrome b5 reductase </chemical> and cytochrome b5.",
    "original_text": "Reductive detoxification of  arylhydroxylamine  carcinogens by  human NADH cytochrome b5 reductase  and cytochrome b5.",
    "entity1": "arylhydroxylamine",
    "entity2": "human NADH cytochrome b5 reductase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <protein> arylhydroxylamine </protein> carcinogens was catalyzed by <chemical> NADH cytochrome b5 reductase </chemical> (b5R) and cytochrome b5 (cyt b5).",
    "original_text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of  arylhydroxylamine  carcinogens was catalyzed by  NADH cytochrome b5 reductase  (b5R) and cytochrome b5 (cyt b5).",
    "entity1": "arylhydroxylamine",
    "entity2": "NADH cytochrome b5 reductase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <protein> arylhydroxylamine </protein> carcinogens was catalyzed by NADH cytochrome b5 reductase (<chemical> b5R </chemical>) and cytochrome b5 (cyt b5).",
    "original_text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of  arylhydroxylamine  carcinogens was catalyzed by NADH cytochrome b5 reductase ( b5R ) and cytochrome b5 (cyt b5).",
    "entity1": "arylhydroxylamine",
    "entity2": "b5R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <protein> arylhydroxylamine </protein> carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and <chemical> cytochrome b5 </chemical> (cyt b5).",
    "original_text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of  arylhydroxylamine  carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and  cytochrome b5  (cyt b5).",
    "entity1": "arylhydroxylamine",
    "entity2": "cytochrome b5"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <protein> arylhydroxylamine </protein> carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 (<chemical> cyt b5 </chemical>).",
    "original_text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of  arylhydroxylamine  carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 ( cyt b5 ).",
    "entity1": "arylhydroxylamine",
    "entity2": "cyt b5"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic <protein> hydroxylamines </protein> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <chemical> human b5R </chemical> and cyt b5.",
    "original_text": "We found that reduction of the carcinogenic  hydroxylamines  of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5.",
    "entity1": "hydroxylamines",
    "entity2": "human b5R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic <protein> hydroxylamines </protein> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <chemical> cyt b5 </chemical>.",
    "original_text": "We found that reduction of the carcinogenic  hydroxylamines  of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5 .",
    "entity1": "hydroxylamines",
    "entity2": "cyt b5"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the <protein> aromatic amine </protein> 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <chemical> human b5R </chemical> and cyt b5.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the  aromatic amine  4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5.",
    "entity1": "aromatic amine",
    "entity2": "human b5R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the <protein> aromatic amine </protein> 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <chemical> cyt b5 </chemical>.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the  aromatic amine  4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5 .",
    "entity1": "aromatic amine",
    "entity2": "cyt b5"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine <protein> 4-aminobiphenyl </protein> (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <chemical> human b5R </chemical> and cyt b5.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine  4-aminobiphenyl  (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5.",
    "entity1": "4-aminobiphenyl",
    "entity2": "human b5R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine <protein> 4-aminobiphenyl </protein> (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <chemical> cyt b5 </chemical>.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine  4-aminobiphenyl  (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5 .",
    "entity1": "4-aminobiphenyl",
    "entity2": "cyt b5"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (<protein> 4-ABP </protein>; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <chemical> human b5R </chemical> and cyt b5.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl ( 4-ABP ; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5.",
    "entity1": "4-ABP",
    "entity2": "human b5R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (<protein> 4-ABP </protein>; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <chemical> cyt b5 </chemical>.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl ( 4-ABP ; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5 .",
    "entity1": "4-ABP",
    "entity2": "cyt b5"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the <protein> heterocyclic amine </protein> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <chemical> human b5R </chemical> and cyt b5.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the  heterocyclic amine  2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5.",
    "entity1": "heterocyclic amine",
    "entity2": "human b5R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the <protein> heterocyclic amine </protein> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <chemical> cyt b5 </chemical>.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the  heterocyclic amine  2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5 .",
    "entity1": "heterocyclic amine",
    "entity2": "cyt b5"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine <protein> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine </protein> (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <chemical> human b5R </chemical> and cyt b5.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine  2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine  (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5.",
    "entity1": "2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine",
    "entity2": "human b5R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine <protein> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine </protein> (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <chemical> cyt b5 </chemical>.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine  2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine  (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5 .",
    "entity1": "2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine",
    "entity2": "cyt b5"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (<protein> PhIP </protein>; found in grilled meats) was indeed catalyzed by a purified system containing only <chemical> human b5R </chemical> and cyt b5.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine ( PhIP ; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5.",
    "entity1": "PhIP",
    "entity2": "human b5R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (<protein> PhIP </protein>; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <chemical> cyt b5 </chemical>.",
    "original_text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine ( PhIP ; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5 .",
    "entity1": "PhIP",
    "entity2": "cyt b5"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Polyclonal antisera to either <protein> b5R </protein> or cyt b5 significantly inhibited <chemical> N-hydroxy-4-aminobiphenyl </chemical> (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
    "original_text": "Polyclonal antisera to either  b5R  or cyt b5 significantly inhibited  N-hydroxy-4-aminobiphenyl  (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
    "entity1": "b5R",
    "entity2": "N-hydroxy-4-aminobiphenyl"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Polyclonal antisera to either b5R or <protein> cyt b5 </protein> significantly inhibited <chemical> N-hydroxy-4-aminobiphenyl </chemical> (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
    "original_text": "Polyclonal antisera to either b5R or  cyt b5  significantly inhibited  N-hydroxy-4-aminobiphenyl  (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
    "entity1": "cyt b5",
    "entity2": "N-hydroxy-4-aminobiphenyl"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Polyclonal antisera to either <protein> b5R </protein> or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (<chemical> NHOH-4-ABP </chemical>) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
    "original_text": "Polyclonal antisera to either  b5R  or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl ( NHOH-4-ABP ) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
    "entity1": "b5R",
    "entity2": "NHOH-4-ABP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Polyclonal antisera to either b5R or <protein> cyt b5 </protein> significantly inhibited N-hydroxy-4-aminobiphenyl (<chemical> NHOH-4-ABP </chemical>) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
    "original_text": "Polyclonal antisera to either b5R or  cyt b5  significantly inhibited N-hydroxy-4-aminobiphenyl ( NHOH-4-ABP ) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
    "entity1": "cyt b5",
    "entity2": "NHOH-4-ABP"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Clinical effects of <protein> pranlukast </protein>, an oral <chemical> leukotriene receptor </chemical> antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.",
    "original_text": "Clinical effects of  pranlukast , an oral  leukotriene receptor  antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.",
    "entity1": "pranlukast",
    "entity2": "leukotriene receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The purified <protein> phosphodiester alpha-GlcNAcase </protein> has a specific activity of 498 micromol of <chemical> [3H]GlcNAc-alpha-phosphomannose-alpha-methyl </chemical> cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate.",
    "original_text": "The purified  phosphodiester alpha-GlcNAcase  has a specific activity of 498 micromol of  [3H]GlcNAc-alpha-phosphomannose-alpha-methyl  cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate.",
    "entity1": "phosphodiester alpha-GlcNAcase",
    "entity2": "[3H]GlcNAc-alpha-phosphomannose-alpha-methyl"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The purified <protein> phosphodiester alpha-GlcNAcase </protein> has a specific activity of 498 micromol of [3H]GlcNAc-alpha-phosphomannose-alpha-methyl cleaved per h per mg of protein using 0.5 mM <chemical> [3H]GlcNAc-alpha-phosphomannose-alpha-methyl </chemical> as substrate.",
    "original_text": "The purified  phosphodiester alpha-GlcNAcase  has a specific activity of 498 micromol of [3H]GlcNAc-alpha-phosphomannose-alpha-methyl cleaved per h per mg of protein using 0.5 mM  [3H]GlcNAc-alpha-phosphomannose-alpha-methyl  as substrate.",
    "entity1": "phosphodiester alpha-GlcNAcase",
    "entity2": "[3H]GlcNAc-alpha-phosphomannose-alpha-methyl"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Conivaptan </protein>: a dual <chemical> vasopressin receptor v1a/v2 </chemical> antagonist [corrected].",
    "original_text": " Conivaptan : a dual  vasopressin receptor v1a/v2  antagonist [corrected].",
    "entity1": "Conivaptan",
    "entity2": "vasopressin receptor v1a/v2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Conivaptan </protein> is a nonpeptide dual <chemical> V1a/V2 AVP receptor </chemical> antagonist.",
    "original_text": " Conivaptan  is a nonpeptide dual  V1a/V2 AVP receptor  antagonist.",
    "entity1": "Conivaptan",
    "entity2": "V1a/V2 AVP receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> H1-receptor </protein> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which histamine is considered to be of pathogenic importance and conversely to help elucidate the role of <chemical> histamine </chemical> in disease, through an evaluation of their influence on disease expression.",
    "original_text": " H1-receptor  antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which histamine is considered to be of pathogenic importance and conversely to help elucidate the role of  histamine  in disease, through an evaluation of their influence on disease expression.",
    "entity1": "H1-receptor",
    "entity2": "histamine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> H1-receptor </protein> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which <chemical> histamine </chemical> is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression.",
    "original_text": " H1-receptor  antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which  histamine  is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression.",
    "entity1": "H1-receptor",
    "entity2": "histamine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "While there is considerable indirect evidence to implicate <protein> histamine </protein> in the pathogenesis of asthma, a critical evaluation of <chemical> H1-receptor </chemical> antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity.",
    "original_text": "While there is considerable indirect evidence to implicate  histamine  in the pathogenesis of asthma, a critical evaluation of  H1-receptor  antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity.",
    "entity1": "histamine",
    "entity2": "H1-receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "While there is considerable indirect evidence to implicate <protein> histamine </protein> in the pathogenesis of asthma, a critical evaluation of H1-receptor antagonism in this condition has, until recently, proved difficult, as many of the early <chemical> H1-receptor </chemical> antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity.",
    "original_text": "While there is considerable indirect evidence to implicate  histamine  in the pathogenesis of asthma, a critical evaluation of H1-receptor antagonism in this condition has, until recently, proved difficult, as many of the early  H1-receptor  antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity.",
    "entity1": "histamine",
    "entity2": "H1-receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The recent development of <protein> H1-receptor </protein> antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of <chemical> histamine </chemical> in this condition.",
    "original_text": "The recent development of  H1-receptor  antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of  histamine  in this condition.",
    "entity1": "H1-receptor",
    "entity2": "histamine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The recent development of H1-receptor antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of <protein> H1-receptor </protein> blockade within the airways, thus permitting a better appraisal of the role of <chemical> histamine </chemical> in this condition.",
    "original_text": "The recent development of H1-receptor antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of  H1-receptor  blockade within the airways, thus permitting a better appraisal of the role of  histamine  in this condition.",
    "entity1": "H1-receptor",
    "entity2": "histamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Cholesterol esterase </protein> (CE) induced surface erosion of poly(ethylene carbonate) (<chemical> PEC </chemical>) and drug release from PEC under mild physiological environment was investigated.",
    "original_text": " Cholesterol esterase  (CE) induced surface erosion of poly(ethylene carbonate) ( PEC ) and drug release from PEC under mild physiological environment was investigated.",
    "entity1": "Cholesterol esterase",
    "entity2": "PEC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cholesterol esterase (<protein> CE </protein>) induced surface erosion of poly(ethylene carbonate) (<chemical> PEC </chemical>) and drug release from PEC under mild physiological environment was investigated.",
    "original_text": "Cholesterol esterase ( CE ) induced surface erosion of poly(ethylene carbonate) ( PEC ) and drug release from PEC under mild physiological environment was investigated.",
    "entity1": "CE",
    "entity2": "PEC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Cholesterol esterase </protein> (CE) induced surface erosion of <chemical> poly(ethylene carbonate) </chemical> (PEC) and drug release from PEC under mild physiological environment was investigated.",
    "original_text": " Cholesterol esterase  (CE) induced surface erosion of  poly(ethylene carbonate)  (PEC) and drug release from PEC under mild physiological environment was investigated.",
    "entity1": "Cholesterol esterase",
    "entity2": "poly(ethylene carbonate)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cholesterol esterase (<protein> CE </protein>) induced surface erosion of <chemical> poly(ethylene carbonate) </chemical> (PEC) and drug release from PEC under mild physiological environment was investigated.",
    "original_text": "Cholesterol esterase ( CE ) induced surface erosion of  poly(ethylene carbonate)  (PEC) and drug release from PEC under mild physiological environment was investigated.",
    "entity1": "CE",
    "entity2": "poly(ethylene carbonate)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> PIP5K1B </protein> encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates <chemical> phosphatidylinositol 4-phosphate </chemical> [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "original_text": " PIP5K1B  encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates  phosphatidylinositol 4-phosphate  [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "entity1": "PIP5K1B",
    "entity2": "phosphatidylinositol 4-phosphate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PIP5K1B encodes <protein> phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I </protein> (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates <chemical> phosphatidylinositol 4-phosphate </chemical> [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "original_text": "PIP5K1B encodes  phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I  (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates  phosphatidylinositol 4-phosphate  [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "entity1": "phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I",
    "entity2": "phosphatidylinositol 4-phosphate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (<protein> pip5k1\u03b2 </protein>), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates <chemical> phosphatidylinositol 4-phosphate </chemical> [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "original_text": "PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I ( pip5k1\u03b2 ), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates  phosphatidylinositol 4-phosphate  [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "entity1": "pip5k1\u03b2",
    "entity2": "phosphatidylinositol 4-phosphate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> PIP5K1B </protein> encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate <chemical>[ PI(4)P </chemical>] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "original_text": " PIP5K1B  encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [ PI(4)P ] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "entity1": "PIP5K1B",
    "entity2": "[ PI(4)P"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PIP5K1B encodes <protein> phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I </protein> (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate <chemical>[ PI(4)P </chemical>] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "original_text": "PIP5K1B encodes  phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I  (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [ PI(4)P ] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "entity1": "phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I",
    "entity2": "[ PI(4)P"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (<protein> pip5k1\u03b2 </protein>), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate <chemical>[ PI(4)P </chemical>] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "original_text": "PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I ( pip5k1\u03b2 ), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [ PI(4)P ] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].",
    "entity1": "pip5k1\u03b2",
    "entity2": "[ PI(4)P"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Carboxylesterases </protein> hydrolyze <chemical> esters </chemical>, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.",
    "original_text": " Carboxylesterases  hydrolyze  esters , amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.",
    "entity1": "Carboxylesterases",
    "entity2": "esters"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Carboxylesterases </protein> hydrolyze esters, <chemical> amides </chemical>, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.",
    "original_text": " Carboxylesterases  hydrolyze esters,  amides , and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.",
    "entity1": "Carboxylesterases",
    "entity2": "amides"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Carboxylesterases </protein> hydrolyze esters, amides, and <chemical> thioesters </chemical> to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.",
    "original_text": " Carboxylesterases  hydrolyze esters, amides, and  thioesters  to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.",
    "entity1": "Carboxylesterases",
    "entity2": "thioesters"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Uridine 5'-diphosphate- glucuronosyltransferases </protein> are colocalized with carboxylesterases and have the potential to further metabolize <chemical> carboxylic acids </chemical> to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.",
    "original_text": " Uridine 5'-diphosphate- glucuronosyltransferases  are colocalized with carboxylesterases and have the potential to further metabolize  carboxylic acids  to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.",
    "entity1": "Uridine 5'-diphosphate- glucuronosyltransferases",
    "entity2": "carboxylic acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with <protein> carboxylesterases </protein> and have the potential to further metabolize <chemical> carboxylic acids </chemical> to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.",
    "original_text": "Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with  carboxylesterases  and have the potential to further metabolize  carboxylic acids  to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.",
    "entity1": "carboxylesterases",
    "entity2": "carboxylic acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Objective: This study explores the ability of <protein> acyl glucuronides </protein> to act as substrates or inhibitors of <chemical> human carboxylesterases 1 </chemical> (hCES1) and 2 (hCES2).",
    "original_text": "Objective: This study explores the ability of  acyl glucuronides  to act as substrates or inhibitors of  human carboxylesterases 1  (hCES1) and 2 (hCES2).",
    "entity1": "acyl glucuronides",
    "entity2": "human carboxylesterases 1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Objective: This study explores the ability of <protein> acyl glucuronides </protein> to act as substrates or inhibitors of human carboxylesterases 1 (<chemical> hCES1 </chemical>) and 2 (hCES2).",
    "original_text": "Objective: This study explores the ability of  acyl glucuronides  to act as substrates or inhibitors of human carboxylesterases 1 ( hCES1 ) and 2 (hCES2).",
    "entity1": "acyl glucuronides",
    "entity2": "hCES1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Objective: This study explores the ability of <protein> acyl glucuronides </protein> to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (<chemical> hCES2 </chemical>).",
    "original_text": "Objective: This study explores the ability of  acyl glucuronides  to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 ( hCES2 ).",
    "entity1": "acyl glucuronides",
    "entity2": "hCES2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Methods: The stability of six <protein> acyl glucuronides </protein> in the presence of <chemical> hCES1 </chemical>, hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated.",
    "original_text": "Methods: The stability of six  acyl glucuronides  in the presence of  hCES1 , hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated.",
    "entity1": "acyl glucuronides",
    "entity2": "hCES1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Methods: The stability of six <protein> acyl glucuronides </protein> in the presence of hCES1, <chemical> hCES2 </chemical>, and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated.",
    "original_text": "Methods: The stability of six  acyl glucuronides  in the presence of hCES1,  hCES2 , and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated.",
    "entity1": "acyl glucuronides",
    "entity2": "hCES2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of <protein> Bax </protein>/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by <chemical> DZN </chemical>.",
    "original_text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of  Bax /Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by  DZN .",
    "entity1": "Bax",
    "entity2": "DZN"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Crocin </protein> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of <chemical> cytochrome c </chemical> to the cytosol induced by DZN.",
    "original_text": " Crocin  (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of  cytochrome c  to the cytosol induced by DZN.",
    "entity1": "Crocin",
    "entity2": "cytochrome c"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/<protein> Bcl2 </protein> ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by <chemical> DZN </chemical>.",
    "original_text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/ Bcl2  ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by  DZN .",
    "entity1": "Bcl2",
    "entity2": "DZN"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial <protein> muscarinic receptor </protein> agonist <chemical> 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium </chemical> (McN-A-343) and histamine.",
    "original_text": "After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial  muscarinic receptor  agonist  4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium  (McN-A-343) and histamine.",
    "entity1": "muscarinic receptor",
    "entity2": "4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial <protein> muscarinic receptor </protein> agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and <chemical> histamine </chemical>.",
    "original_text": "After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial  muscarinic receptor  agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and  histamine .",
    "entity1": "muscarinic receptor",
    "entity2": "histamine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full <protein> muscarinic receptor </protein> agonist <chemical> methacholine </chemical>, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine.",
    "original_text": "After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full  muscarinic receptor  agonist  methacholine , the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine.",
    "entity1": "muscarinic receptor",
    "entity2": "methacholine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Aldose reductase </protein> (AR) catalyzes the reduction of toxic lipid <chemical> aldehydes </chemical> to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).",
    "original_text": " Aldose reductase  (AR) catalyzes the reduction of toxic lipid  aldehydes  to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).",
    "entity1": "Aldose reductase",
    "entity2": "aldehydes"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Aldose reductase (<protein> AR </protein>) catalyzes the reduction of toxic lipid <chemical> aldehydes </chemical> to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).",
    "original_text": "Aldose reductase ( AR ) catalyzes the reduction of toxic lipid  aldehydes  to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).",
    "entity1": "AR",
    "entity2": "aldehydes"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Effect of <protein> ramelteon </protein> (TAK-375), a selective <chemical> MT1/MT2 receptor </chemical> agonist, on motor performance in mice.",
    "original_text": "Effect of  ramelteon  (TAK-375), a selective  MT1/MT2 receptor  agonist, on motor performance in mice.",
    "entity1": "ramelteon",
    "entity2": "MT1/MT2 receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Effect of ramelteon (<protein> TAK-375 </protein>), a selective <chemical> MT1/MT2 receptor </chemical> agonist, on motor performance in mice.",
    "original_text": "Effect of ramelteon ( TAK-375 ), a selective  MT1/MT2 receptor  agonist, on motor performance in mice.",
    "entity1": "TAK-375",
    "entity2": "MT1/MT2 receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (<protein> ramelteon </protein>, TAK-375), a selective <chemical> MT1/MT2 receptor </chemical> agonist, on motor coordination was studied using rota-rod performance in mice.",
    "original_text": "Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide ( ramelteon , TAK-375), a selective  MT1/MT2 receptor  agonist, on motor coordination was studied using rota-rod performance in mice.",
    "entity1": "ramelteon",
    "entity2": "MT1/MT2 receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon, <protein> TAK-375 </protein>), a selective <chemical> MT1/MT2 receptor </chemical> agonist, on motor coordination was studied using rota-rod performance in mice.",
    "original_text": "Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon,  TAK-375 ), a selective  MT1/MT2 receptor  agonist, on motor coordination was studied using rota-rod performance in mice.",
    "entity1": "TAK-375",
    "entity2": "MT1/MT2 receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Effect of <protein> (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide </protein> (ramelteon, TAK-375), a selective <chemical> MT1/MT2 receptor </chemical> agonist, on motor coordination was studied using rota-rod performance in mice.",
    "original_text": "Effect of  (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide  (ramelteon, TAK-375), a selective  MT1/MT2 receptor  agonist, on motor coordination was studied using rota-rod performance in mice.",
    "entity1": "(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide",
    "entity2": "MT1/MT2 receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Firstly, the V(max) of <protein> GAD </protein> was increased when ApoCaM was present whereas the affinity for the substrate, <chemical> glutamate </chemical>, was not affected.",
    "original_text": "Firstly, the V(max) of  GAD  was increased when ApoCaM was present whereas the affinity for the substrate,  glutamate , was not affected.",
    "entity1": "GAD",
    "entity2": "glutamate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulphide (H(2)S) is synthesized from <protein> L-cysteine </protein> via the action of cystathionine-gamma-lyase (<chemical> CSE </chemical>) and cystathionine-beta-synthase (CBS).",
    "original_text": "Hydrogen sulphide (H(2)S) is synthesized from  L-cysteine  via the action of cystathionine-gamma-lyase ( CSE ) and cystathionine-beta-synthase (CBS).",
    "entity1": "L-cysteine",
    "entity2": "CSE"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulphide (H(2)S) is synthesized from <protein> L-cysteine </protein> via the action of cystathionine-gamma-lyase (CSE) and <chemical> cystathionine-beta-synthase </chemical> (CBS).",
    "original_text": "Hydrogen sulphide (H(2)S) is synthesized from  L-cysteine  via the action of cystathionine-gamma-lyase (CSE) and  cystathionine-beta-synthase  (CBS).",
    "entity1": "L-cysteine",
    "entity2": "cystathionine-beta-synthase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulphide (H(2)S) is synthesized from <protein> L-cysteine </protein> via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<chemical> CBS </chemical>).",
    "original_text": "Hydrogen sulphide (H(2)S) is synthesized from  L-cysteine  via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ( CBS ).",
    "entity1": "L-cysteine",
    "entity2": "CBS"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulphide (H(2)S) is synthesized from <protein> L-cysteine </protein> via the action of <chemical> cystathionine-gamma-lyase </chemical> (CSE) and cystathionine-beta-synthase (CBS).",
    "original_text": "Hydrogen sulphide (H(2)S) is synthesized from  L-cysteine  via the action of  cystathionine-gamma-lyase  (CSE) and cystathionine-beta-synthase (CBS).",
    "entity1": "L-cysteine",
    "entity2": "cystathionine-gamma-lyase"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "The results showed that administration of <protein> AlCl3 </protein> resulted in a significant elevation in the levels of <chemical> AchE </chemical> activity, CRP, NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level.",
    "original_text": "The results showed that administration of  AlCl3  resulted in a significant elevation in the levels of  AchE  activity, CRP, NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level.",
    "entity1": "AlCl3",
    "entity2": "AchE"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> 6-DHSG </protein> was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of <chemical> glutathione-S-transferase </chemical> (GST).",
    "original_text": " 6-DHSG  was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  glutathione-S-transferase  (GST).",
    "entity1": "6-DHSG",
    "entity2": "glutathione-S-transferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> 6-DHSG </protein> was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (<chemical> GST </chemical>).",
    "original_text": " 6-DHSG  was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( GST ).",
    "entity1": "6-DHSG",
    "entity2": "GST"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Mechanisms of <protein> cefadroxil </protein> uptake in the choroid plexus: studies in wild-type and <chemical> PEPT2 </chemical> knockout mice.",
    "original_text": "Mechanisms of  cefadroxil  uptake in the choroid plexus: studies in wild-type and  PEPT2  knockout mice.",
    "entity1": "cefadroxil",
    "entity2": "PEPT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The choroid plexus uptake of <protein> [(3)H]cefadroxil </protein> was studied in <chemical> peptide transporter 2 </chemical> (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.",
    "original_text": "The choroid plexus uptake of  [(3)H]cefadroxil  was studied in  peptide transporter 2  (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.",
    "entity1": "[(3)H]cefadroxil",
    "entity2": "peptide transporter 2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The choroid plexus uptake of <protein> [(3)H]cefadroxil </protein> was studied in peptide transporter 2 (<chemical> PEPT2 </chemical>) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.",
    "original_text": "The choroid plexus uptake of  [(3)H]cefadroxil  was studied in peptide transporter 2 ( PEPT2 ) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.",
    "entity1": "[(3)H]cefadroxil",
    "entity2": "PEPT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM <protein> cefadroxil </protein> was reduced by 83% in <chemical> PEPT2 </chemical>(-/-) mice as compared with PEPT2(+/+) mice (p < 0.001).",
    "original_text": "At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM  cefadroxil  was reduced by 83% in  PEPT2 (-/-) mice as compared with PEPT2(+/+) mice (p < 0.001).",
    "entity1": "cefadroxil",
    "entity2": "PEPT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM <protein> cefadroxil </protein> was reduced by 83% in PEPT2(-/-) mice as compared with <chemical> PEPT2 </chemical>(+/+) mice (p < 0.001).",
    "original_text": "At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM  cefadroxil  was reduced by 83% in PEPT2(-/-) mice as compared with  PEPT2 (+/+) mice (p < 0.001).",
    "entity1": "cefadroxil",
    "entity2": "PEPT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Glycylsarcosine coadministration could inhibit the uptake of <protein> cefadroxil </protein> in <chemical> PEPT2 </chemical>(+/+) mice (p < 0.01) but not PEPT2(-/-) mice.",
    "original_text": "Glycylsarcosine coadministration could inhibit the uptake of  cefadroxil  in  PEPT2 (+/+) mice (p < 0.01) but not PEPT2(-/-) mice.",
    "entity1": "cefadroxil",
    "entity2": "PEPT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Glycylsarcosine coadministration could inhibit the uptake of <protein> cefadroxil </protein> in PEPT2(+/+) mice (p < 0.01) but not <chemical> PEPT2 </chemical>(-/-) mice.",
    "original_text": "Glycylsarcosine coadministration could inhibit the uptake of  cefadroxil  in PEPT2(+/+) mice (p < 0.01) but not  PEPT2 (-/-) mice.",
    "entity1": "cefadroxil",
    "entity2": "PEPT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Although a proton-stimulated uptake of <protein> cefadroxil </protein> was demonstrated in <chemical> PEPT2 </chemical>(+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2(-/-) mice.",
    "original_text": "Although a proton-stimulated uptake of  cefadroxil  was demonstrated in  PEPT2 (+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2(-/-) mice.",
    "entity1": "cefadroxil",
    "entity2": "PEPT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Although a proton-stimulated uptake of <protein> cefadroxil </protein> was demonstrated in PEPT2(+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in <chemical> PEPT2 </chemical>(-/-) mice.",
    "original_text": "Although a proton-stimulated uptake of  cefadroxil  was demonstrated in PEPT2(+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in  PEPT2 (-/-) mice.",
    "entity1": "cefadroxil",
    "entity2": "PEPT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These findings demonstrate that <protein> PEPT2 </protein> is the primary transporter responsible for <chemical> cefadroxil </chemical> uptake in the choroid plexus.",
    "original_text": "These findings demonstrate that  PEPT2  is the primary transporter responsible for  cefadroxil  uptake in the choroid plexus.",
    "entity1": "PEPT2",
    "entity2": "cefadroxil"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The effects of the <protein> adenosine A3 receptor </protein> agonist <chemical> IB-MECA </chemical> on sodium taurocholate-induced experimental acute pancreatitis.",
    "original_text": "The effects of the  adenosine A3 receptor  agonist  IB-MECA  on sodium taurocholate-induced experimental acute pancreatitis.",
    "entity1": "adenosine A3 receptor",
    "entity2": "IB-MECA"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the <protein> adenosine A3 receptor </protein> agonist <chemical> IB-MECA </chemical> (1-deoxy-1-6<chemical>(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75\u00a0mg/kg b.w.",
    "original_text": "The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the  adenosine A3 receptor  agonist  IB-MECA  (1-deoxy-1-6(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75\u00a0mg/kg b.w.",
    "entity1": "adenosine A3 receptor",
    "entity2": "IB-MECA"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the <protein> adenosine A3 receptor </protein> agonist IB-MECA <chemical> (1-deoxy-1-6<chemical>(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide </chemical> at a dose of 0.75\u00a0mg/kg b.w.",
    "original_text": "The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the  adenosine A3 receptor  agonist IB-MECA  (1-deoxy-1-6(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide  at a dose of 0.75\u00a0mg/kg b.w.",
    "entity1": "adenosine A3 receptor",
    "entity2": "(1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The use of <protein> A3 receptor </protein> agonist <chemical> IB-MECA </chemical> attenuates EAP.",
    "original_text": "The use of  A3 receptor  agonist  IB-MECA  attenuates EAP.",
    "entity1": "A3 receptor",
    "entity2": "IB-MECA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "BACKGROUND AND AIMS: <protein> Glutamic acid decarboxylase </protein> (GAD, EC 4.1.1.15) catalyses the conversion of <chemical> glutamate </chemical> to gamma-aminobutyric acid (GABA).",
    "original_text": "BACKGROUND AND AIMS:  Glutamic acid decarboxylase  (GAD, EC 4.1.1.15) catalyses the conversion of  glutamate  to gamma-aminobutyric acid (GABA).",
    "entity1": "Glutamic acid decarboxylase",
    "entity2": "glutamate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase (<protein> GAD </protein>, EC 4.1.1.15) catalyses the conversion of <chemical> glutamate </chemical> to gamma-aminobutyric acid (GABA).",
    "original_text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase ( GAD , EC 4.1.1.15) catalyses the conversion of  glutamate  to gamma-aminobutyric acid (GABA).",
    "entity1": "GAD",
    "entity2": "glutamate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, <protein> EC 4.1.1.15 </protein>) catalyses the conversion of <chemical> glutamate </chemical> to gamma-aminobutyric acid (GABA).",
    "original_text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD,  EC 4.1.1.15 ) catalyses the conversion of  glutamate  to gamma-aminobutyric acid (GABA).",
    "entity1": "EC 4.1.1.15",
    "entity2": "glutamate"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than <protein> estrogen receptor \u03b1 </protein> antagonist <chemical> ICI 82,780 </chemical>.",
    "original_text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than  estrogen receptor \u03b1  antagonist  ICI 82,780 .",
    "entity1": "estrogen receptor \u03b1",
    "entity2": "ICI 82,780"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "These protective effects were abolished by <protein> glucocorticoid receptor </protein> (GR) antagonist <chemical> RU486 </chemical> or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780.",
    "original_text": "These protective effects were abolished by  glucocorticoid receptor  (GR) antagonist  RU486  or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780.",
    "entity1": "glucocorticoid receptor",
    "entity2": "RU486"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "These protective effects were abolished by glucocorticoid receptor (<protein> GR </protein>) antagonist <chemical> RU486 </chemical> or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780.",
    "original_text": "These protective effects were abolished by glucocorticoid receptor ( GR ) antagonist  RU486  or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780.",
    "entity1": "GR",
    "entity2": "RU486"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The <protein> alpha(1)-adrenoceptor </protein> antagonist, <chemical> tamsulosin </chemical>, is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors.",
    "original_text": "The  alpha(1)-adrenoceptor  antagonist,  tamsulosin , is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors.",
    "entity1": "alpha(1)-adrenoceptor",
    "entity2": "tamsulosin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The alpha(1)-adrenoceptor antagonist, <protein> tamsulosin </protein>, is selective for <chemical> alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors </chemical>.",
    "original_text": "The alpha(1)-adrenoceptor antagonist,  tamsulosin , is selective for  alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors .",
    "entity1": "tamsulosin",
    "entity2": "alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Synthesis and antagonistic activity at <protein> muscarinic receptor </protein> subtypes of some 2-carbonyl derivatives of <chemical> diphenidol </chemical>.",
    "original_text": "Synthesis and antagonistic activity at  muscarinic receptor  subtypes of some 2-carbonyl derivatives of  diphenidol .",
    "entity1": "muscarinic receptor",
    "entity2": "diphenidol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Synthesis and antagonistic activity at <protein> muscarinic receptor </protein> subtypes of some <chemical> 2-carbonyl </chemical> derivatives of diphenidol.",
    "original_text": "Synthesis and antagonistic activity at  muscarinic receptor  subtypes of some  2-carbonyl  derivatives of diphenidol.",
    "entity1": "muscarinic receptor",
    "entity2": "2-carbonyl"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A series of 2-carbonyl analogues of the muscarinic antagonist <protein> diphenidol </protein> bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the <chemical> M2 and M3 muscarinic receptor </chemical> subtypes was evaluated by functional tests.",
    "original_text": "A series of 2-carbonyl analogues of the muscarinic antagonist  diphenidol  bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the  M2 and M3 muscarinic receptor  subtypes was evaluated by functional tests.",
    "entity1": "diphenidol",
    "entity2": "M2 and M3 muscarinic receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "This work showed that appropriate structural modification of <protein> diphenidol </protein> can lead to <chemical> M2 </chemical>-selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.",
    "original_text": "This work showed that appropriate structural modification of  diphenidol  can lead to  M2 -selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.",
    "entity1": "diphenidol",
    "entity2": "M2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of <protein> CRH </protein>-induced ACTH secretion was significantly lower after <chemical> loperamide </chemical>.",
    "original_text": "CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of  CRH -induced ACTH secretion was significantly lower after  loperamide .",
    "entity1": "CRH",
    "entity2": "loperamide"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Pre-clinical pharmacology of <protein> zolmitriptan </protein> (Zomig; formerly 311C90), a centrally and peripherally acting <chemical> 5HT1B/1D </chemical> agonist for migraine.",
    "original_text": "Pre-clinical pharmacology of  zolmitriptan  (Zomig; formerly 311C90), a centrally and peripherally acting  5HT1B/1D  agonist for migraine.",
    "entity1": "zolmitriptan",
    "entity2": "5HT1B/1D"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Pre-clinical pharmacology of zolmitriptan (<protein> Zomig </protein>; formerly 311C90), a centrally and peripherally acting <chemical> 5HT1B/1D </chemical> agonist for migraine.",
    "original_text": "Pre-clinical pharmacology of zolmitriptan ( Zomig ; formerly 311C90), a centrally and peripherally acting  5HT1B/1D  agonist for migraine.",
    "entity1": "Zomig",
    "entity2": "5HT1B/1D"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Pre-clinical pharmacology of zolmitriptan (Zomig; formerly <protein> 311C90 </protein>), a centrally and peripherally acting <chemical> 5HT1B/1D </chemical> agonist for migraine.",
    "original_text": "Pre-clinical pharmacology of zolmitriptan (Zomig; formerly  311C90 ), a centrally and peripherally acting  5HT1B/1D  agonist for migraine.",
    "entity1": "311C90",
    "entity2": "5HT1B/1D"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Zolmitriptan (Zomig; formerly <protein> 311C90 </protein>) is a novel <chemical> 5-hydroxytryptamine (5HT)1B/1D </chemical> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.",
    "original_text": "Zolmitriptan (Zomig; formerly  311C90 ) is a novel  5-hydroxytryptamine (5HT)1B/1D  receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.",
    "entity1": "311C90",
    "entity2": "5-hydroxytryptamine (5HT)1B/1D"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Zolmitriptan </protein> (Zomig; formerly 311C90) is a novel <chemical> 5-hydroxytryptamine (5HT)1B/1D </chemical> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.",
    "original_text": " Zolmitriptan  (Zomig; formerly 311C90) is a novel  5-hydroxytryptamine (5HT)1B/1D  receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.",
    "entity1": "Zolmitriptan",
    "entity2": "5-hydroxytryptamine (5HT)1B/1D"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Zolmitriptan (<protein> Zomig </protein>; formerly 311C90) is a novel <chemical> 5-hydroxytryptamine (5HT)1B/1D </chemical> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.",
    "original_text": "Zolmitriptan ( Zomig ; formerly 311C90) is a novel  5-hydroxytryptamine (5HT)1B/1D  receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.",
    "entity1": "Zomig",
    "entity2": "5-hydroxytryptamine (5HT)1B/1D"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "It has been reported that oligomeric <protein> procyanidins </protein> of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and <chemical> insulin </chemical>-potentiating activities.",
    "original_text": "It has been reported that oligomeric  procyanidins  of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and  insulin -potentiating activities.",
    "entity1": "procyanidins",
    "entity2": "insulin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "They all expressed ASS, but not <protein> ornithine transcarbamylase </protein> (OTC), the enzyme that converts <chemical> ornithine </chemical>, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS.",
    "original_text": "They all expressed ASS, but not  ornithine transcarbamylase  (OTC), the enzyme that converts  ornithine , the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS.",
    "entity1": "ornithine transcarbamylase",
    "entity2": "ornithine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "They all expressed ASS, but not ornithine transcarbamylase (<protein> OTC </protein>), the enzyme that converts <chemical> ornithine </chemical>, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS.",
    "original_text": "They all expressed ASS, but not ornithine transcarbamylase ( OTC ), the enzyme that converts  ornithine , the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS.",
    "entity1": "OTC",
    "entity2": "ornithine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of <protein> arginine </protein> with <chemical> rhArg </chemical>, to citrulline, which is converted back to arginine via ASS.",
    "original_text": "They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of  arginine  with  rhArg , to citrulline, which is converted back to arginine via ASS.",
    "entity1": "arginine",
    "entity2": "rhArg"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to <protein> arginine </protein> via <chemical> ASS </chemical>.",
    "original_text": "They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to  arginine  via  ASS .",
    "entity1": "arginine",
    "entity2": "ASS"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to <protein> rhArg </protein>-mediated <chemical> arginine </chemical> depletion.",
    "original_text": "This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to  rhArg -mediated  arginine  depletion.",
    "entity1": "rhArg",
    "entity2": "arginine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to <protein> arginine </protein> depletion with <chemical> arginine-depleting enzymes </chemical>.",
    "original_text": "Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to  arginine  depletion with  arginine-depleting enzymes .",
    "entity1": "arginine",
    "entity2": "arginine-depleting enzymes"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective <protein> 5-HT1F </protein> receptor agonist (<chemical> LY 344864 </chemical>) on c-fos protein expression in the trigeminal nucleus caudalis.",
    "original_text": "To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective  5-HT1F  receptor agonist ( LY 344864 ) on c-fos protein expression in the trigeminal nucleus caudalis.",
    "entity1": "5-HT1F",
    "entity2": "LY 344864"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist <protein> SDZ 21-009 </protein>, which displays high affinity for <chemical> rat 5-HT1B </chemical> receptors.",
    "original_text": "The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist  SDZ 21-009 , which displays high affinity for  rat 5-HT1B  receptors.",
    "entity1": "SDZ 21-009",
    "entity2": "rat 5-HT1B"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of <protein> EP1 </protein> and EP2 receptors is indicated by studies with the EP1 selective agonist <chemical> 17-phenyl trinor PGE2 </chemical>, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "original_text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the EP1 selective agonist  17-phenyl trinor PGE2 , and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "entity1": "EP1",
    "entity2": "17-phenyl trinor PGE2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the <protein> EP1 </protein> selective agonist <chemical> 17-phenyl trinor PGE2 </chemical>, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "original_text": "The involvement of EP1 and EP2 receptors is indicated by studies with the  EP1  selective agonist  17-phenyl trinor PGE2 , and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "entity1": "EP1",
    "entity2": "17-phenyl trinor PGE2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of EP1 and <protein> EP2 receptors </protein> is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist <chemical> butaprost </chemical> (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "original_text": "The involvement of EP1 and  EP2 receptors  is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist  butaprost  (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "entity1": "EP2 receptors",
    "entity2": "butaprost"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the <protein> EP2 </protein> selective agonist <chemical> butaprost </chemical> (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "original_text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the  EP2  selective agonist  butaprost  (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "entity1": "EP2",
    "entity2": "butaprost"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of <protein> EP1 </protein> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <chemical> SC-51089 </chemical> (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "original_text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists  SC-51089  (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "entity1": "EP1",
    "entity2": "SC-51089"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the <protein> EP1 </protein> selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <chemical> SC-51089 </chemical> (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "original_text": "The involvement of EP1 and EP2 receptors is indicated by studies with the  EP1  selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists  SC-51089  (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
    "entity1": "EP1",
    "entity2": "SC-51089"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <protein> SC-51089 </protein> (EP1 specific) and AH 6809 (<chemical> EP1 </chemical> and EP2 specific).",
    "original_text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists  SC-51089  (EP1 specific) and AH 6809 ( EP1  and EP2 specific).",
    "entity1": "SC-51089",
    "entity2": "EP1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of <protein> EP1 </protein> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <chemical> AH 6809 </chemical> (EP1 and EP2 specific).",
    "original_text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and  AH 6809  (EP1 and EP2 specific).",
    "entity1": "EP1",
    "entity2": "AH 6809"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of EP1 and <protein> EP2 receptors </protein> is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <chemical> AH 6809 </chemical> (EP1 and EP2 specific).",
    "original_text": "The involvement of EP1 and  EP2 receptors  is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and  AH 6809  (EP1 and EP2 specific).",
    "entity1": "EP2 receptors",
    "entity2": "AH 6809"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the <protein> EP1 </protein> selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <chemical> AH 6809 </chemical> (EP1 and EP2 specific).",
    "original_text": "The involvement of EP1 and EP2 receptors is indicated by studies with the  EP1  selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and  AH 6809  (EP1 and EP2 specific).",
    "entity1": "EP1",
    "entity2": "AH 6809"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the <protein> EP2 </protein> selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <chemical> AH 6809 </chemical> (EP1 and EP2 specific).",
    "original_text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the  EP2  selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and  AH 6809  (EP1 and EP2 specific).",
    "entity1": "EP2",
    "entity2": "AH 6809"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <protein> AH 6809 </protein> (<chemical> EP1 </chemical> and EP2 specific).",
    "original_text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and  AH 6809  ( EP1  and EP2 specific).",
    "entity1": "AH 6809",
    "entity2": "EP1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <protein> AH 6809 </protein> (EP1 and <chemical> EP2 </chemical> specific).",
    "original_text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and  AH 6809  (EP1 and  EP2  specific).",
    "entity1": "AH 6809",
    "entity2": "EP2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the <protein> calmodulin </protein> antagonists <chemical> W7 </chemical> and W13.",
    "original_text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the  calmodulin  antagonists  W7  and W13.",
    "entity1": "calmodulin",
    "entity2": "W7"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the <protein> calmodulin </protein> antagonists W7 and <chemical> W13 </chemical>.",
    "original_text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the  calmodulin  antagonists W7 and  W13 .",
    "entity1": "calmodulin",
    "entity2": "W13"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of <protein> inducible nitric-oxide synthase </protein> by <chemical> 15-deoxy-Delta12,14-prostaglandin J2 </chemical>.",
    "original_text": "Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of  inducible nitric-oxide synthase  by  15-deoxy-Delta12,14-prostaglandin J2 .",
    "entity1": "inducible nitric-oxide synthase",
    "entity2": "15-deoxy-Delta12,14-prostaglandin J2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> (+)-Tamsulosin </protein>, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <chemical> human alpha 1D adrenoceptors </chemical>.",
    "original_text": " (+)-Tamsulosin , (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors .",
    "entity1": "(+)-Tamsulosin",
    "entity2": "human alpha 1D adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "(+)-Tamsulosin, <protein> (-)-tamsulosin </protein>, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <chemical> human alpha 1D adrenoceptors </chemical>.",
    "original_text": "(+)-Tamsulosin,  (-)-tamsulosin , SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors .",
    "entity1": "(-)-tamsulosin",
    "entity2": "human alpha 1D adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "(+)-Tamsulosin, (-)-tamsulosin, <protein> SL 89,0591 </protein>, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <chemical> human alpha 1D adrenoceptors </chemical>.",
    "original_text": "(+)-Tamsulosin, (-)-tamsulosin,  SL 89,0591 , Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors .",
    "entity1": "SL 89,0591",
    "entity2": "human alpha 1D adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, <protein> Rec 15/2739 </protein>, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <chemical> human alpha 1D adrenoceptors </chemical>.",
    "original_text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591,  Rec 15/2739 , SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors .",
    "entity1": "Rec 15/2739",
    "entity2": "human alpha 1D adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, <protein> SNAP 1069 </protein> and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <chemical> human alpha 1D adrenoceptors </chemical>.",
    "original_text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739,  SNAP 1069  and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors .",
    "entity1": "SNAP 1069",
    "entity2": "human alpha 1D adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and <protein> RS 17053 </protein> appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <chemical> human alpha 1D adrenoceptors </chemical>.",
    "original_text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and  RS 17053  appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors .",
    "entity1": "RS 17053",
    "entity2": "human alpha 1D adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potency of the antipsychotic drug, <protein> risperidone </protein>, to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and <chemical> alpha 1B-adrenoceptor </chemical>-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.",
    "original_text": "The potency of the antipsychotic drug,  risperidone , to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and  alpha 1B-adrenoceptor -mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.",
    "entity1": "risperidone",
    "entity2": "alpha 1B-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potency of the antipsychotic drug, <protein> risperidone </protein>, to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of <chemical> alpha 1-adrenoceptor </chemical> subtype-discriminating antagonists.",
    "original_text": "The potency of the antipsychotic drug,  risperidone , to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of  alpha 1-adrenoceptor  subtype-discriminating antagonists.",
    "entity1": "risperidone",
    "entity2": "alpha 1-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potency of the antipsychotic drug, <protein> risperidone </protein>, to antagonize <chemical> alpha 1A-adrenoceptor </chemical>-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.",
    "original_text": "The potency of the antipsychotic drug,  risperidone , to antagonize  alpha 1A-adrenoceptor -mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.",
    "entity1": "risperidone",
    "entity2": "alpha 1A-adrenoceptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "From these data, it is inferred that both the <protein> SERT </protein> and NET contribute to the active clearance of exogenously applied <chemical> 5-HT </chemical> in the dentate gyrus.",
    "original_text": "From these data, it is inferred that both the  SERT  and NET contribute to the active clearance of exogenously applied  5-HT  in the dentate gyrus.",
    "entity1": "SERT",
    "entity2": "5-HT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "From these data, it is inferred that both the SERT and <protein> NET </protein> contribute to the active clearance of exogenously applied <chemical> 5-HT </chemical> in the dentate gyrus.",
    "original_text": "From these data, it is inferred that both the SERT and  NET  contribute to the active clearance of exogenously applied  5-HT  in the dentate gyrus.",
    "entity1": "NET",
    "entity2": "5-HT"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In another experiment, <protein> cyanopindolol </protein>, an antagonist of the <chemical> serotonin terminal autoreceptor </chemical>, also prolonged the clearance of 5-HT from the CA3 region.",
    "original_text": "In another experiment,  cyanopindolol , an antagonist of the  serotonin terminal autoreceptor , also prolonged the clearance of 5-HT from the CA3 region.",
    "entity1": "cyanopindolol",
    "entity2": "serotonin terminal autoreceptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of <protein> 5-HT </protein> uptake through an effect on the <chemical> serotonin transporter </chemical>.",
    "original_text": "These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of  5-HT  uptake through an effect on the  serotonin transporter .",
    "entity1": "5-HT",
    "entity2": "serotonin transporter"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These and other data have generated a working hypothesis that activation of the terminal <protein> serotonin autoreceptor </protein> enhances the kinetics of <chemical> 5-HT </chemical> uptake through an effect on the serotonin transporter.",
    "original_text": "These and other data have generated a working hypothesis that activation of the terminal  serotonin autoreceptor  enhances the kinetics of  5-HT  uptake through an effect on the serotonin transporter.",
    "entity1": "serotonin autoreceptor",
    "entity2": "5-HT"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a <protein> 5-HT1A </protein>-selective agonist, <chemical> 8-hydroxy-2-(di-n-propylamino)tetralin </chemical>, was inactive.",
    "original_text": "The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a  5-HT1A -selective agonist,  8-hydroxy-2-(di-n-propylamino)tetralin , was inactive.",
    "entity1": "5-HT1A",
    "entity2": "8-hydroxy-2-(di-n-propylamino)tetralin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective <protein> 5-HT2 </protein> antagonist, <chemical> ritanserin </chemical>.",
    "original_text": "The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective  5-HT2  antagonist,  ritanserin .",
    "entity1": "5-HT2",
    "entity2": "ritanserin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Even though the activities of <protein> MAT </protein> and GNMT were elevated, the concentration of liver <chemical> S-adenosylmethionine </chemical> was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice.",
    "original_text": "Even though the activities of  MAT  and GNMT were elevated, the concentration of liver  S-adenosylmethionine  was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice.",
    "entity1": "MAT",
    "entity2": "S-adenosylmethionine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Even though the activities of MAT and <protein> GNMT </protein> were elevated, the concentration of liver <chemical> S-adenosylmethionine </chemical> was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice.",
    "original_text": "Even though the activities of MAT and  GNMT  were elevated, the concentration of liver  S-adenosylmethionine  was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice.",
    "entity1": "GNMT",
    "entity2": "S-adenosylmethionine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific <protein> alpha2-adrenoceptor </protein> agonists of the type such as <chemical> dexmedetomidine </chemical>.",
    "original_text": "BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific  alpha2-adrenoceptor  agonists of the type such as  dexmedetomidine .",
    "entity1": "alpha2-adrenoceptor",
    "entity2": "dexmedetomidine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist, <protein> dexmedetomidine </protein>, were determined in mice deficient in <chemical> alpha2-receptor </chemical> subtypes.",
    "original_text": "METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist,  dexmedetomidine , were determined in mice deficient in  alpha2-receptor  subtypes.",
    "entity1": "dexmedetomidine",
    "entity2": "alpha2-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Inhibition of binding of the <protein> alpha2-receptor </protein> antagonist <chemical> [3H]RX821002 </chemical> to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.",
    "original_text": "Inhibition of binding of the  alpha2-receptor  antagonist  [3H]RX821002  to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.",
    "entity1": "alpha2-receptor",
    "entity2": "[3H]RX821002"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Inhibition of binding of the alpha2-receptor antagonist <protein> [3H]RX821002 </protein> to recombinant <chemical> alpha2-receptors </chemical> by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.",
    "original_text": "Inhibition of binding of the alpha2-receptor antagonist  [3H]RX821002  to recombinant  alpha2-receptors  by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.",
    "entity1": "[3H]RX821002",
    "entity2": "alpha2-receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In membranes from HEK293 cells transfected with <protein> alpha2-receptors </protein>, etomidate inhibited binding of the alpha2-antagonist, <chemical> [3H]RX821002 </chemical>, with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",
    "original_text": "In membranes from HEK293 cells transfected with  alpha2-receptors , etomidate inhibited binding of the alpha2-antagonist,  [3H]RX821002 , with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",
    "entity1": "alpha2-receptors",
    "entity2": "[3H]RX821002"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In membranes from HEK293 cells transfected with alpha2-receptors, etomidate inhibited binding of the alpha2-antagonist, <protein> [3H]RX821002 </protein>, with higher potency from alpha2B- and alpha2C-receptors than from <chemical> alpha2A-receptors </chemical> (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",
    "original_text": "In membranes from HEK293 cells transfected with alpha2-receptors, etomidate inhibited binding of the alpha2-antagonist,  [3H]RX821002 , with higher potency from alpha2B- and alpha2C-receptors than from  alpha2A-receptors  (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",
    "entity1": "[3H]RX821002",
    "entity2": "alpha2A-receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "CONCLUSIONS: These results indicate that <protein> etomidate </protein> acts as an agonist at <chemical> alpha2-adrenoceptors </chemical>, which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure.",
    "original_text": "CONCLUSIONS: These results indicate that  etomidate  acts as an agonist at  alpha2-adrenoceptors , which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure.",
    "entity1": "etomidate",
    "entity2": "alpha2-adrenoceptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> CYP2B6*6 </protein> Allele Significantly Alters the N-demethylation of <chemical> Ketamine </chemical> Enantiomers In Vitro.",
    "original_text": "The  CYP2B6*6  Allele Significantly Alters the N-demethylation of  Ketamine  Enantiomers In Vitro.",
    "entity1": "CYP2B6*6",
    "entity2": "Ketamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Ketamine </protein> is primarily metabolized to norketamine by hepatic <chemical> cytochrome P450 (CYP) 2B6 </chemical> and CYP3A4-mediated N-demethylation.",
    "original_text": " Ketamine  is primarily metabolized to norketamine by hepatic  cytochrome P450 (CYP) 2B6  and CYP3A4-mediated N-demethylation.",
    "entity1": "Ketamine",
    "entity2": "cytochrome P450 (CYP) 2B6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Ketamine </protein> is primarily metabolized to norketamine by hepatic cytochrome P450 (CYP) 2B6 and <chemical> CYP3A4 </chemical>-mediated N-demethylation.",
    "original_text": " Ketamine  is primarily metabolized to norketamine by hepatic cytochrome P450 (CYP) 2B6 and  CYP3A4 -mediated N-demethylation.",
    "entity1": "Ketamine",
    "entity2": "CYP3A4"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> CYP2B6*6 </protein> allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in <chemical> ketamine </chemical> metabolism.",
    "original_text": "The  CYP2B6*6  allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in  ketamine  metabolism.",
    "entity1": "CYP2B6*6",
    "entity2": "ketamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We examined the N-demethylation of individual <protein> ketamine </protein> enantiomers using human liver microsomes (HLMs) genotyped for the <chemical> CYP2B6*6 </chemical> allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant.",
    "original_text": "We examined the N-demethylation of individual  ketamine  enantiomers using human liver microsomes (HLMs) genotyped for the  CYP2B6*6  allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant.",
    "entity1": "ketamine",
    "entity2": "CYP2B6*6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The intrinsic clearance for both <protein> ketamine </protein> enantiomers by the high affinity enzyme in HLMs with <chemical> CYP2B6*1 </chemical>/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype.",
    "original_text": "The intrinsic clearance for both  ketamine  enantiomers by the high affinity enzyme in HLMs with  CYP2B6*1 /*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype.",
    "entity1": "ketamine",
    "entity2": "CYP2B6*1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results indicate a major role of <protein> CYP2B6 </protein> in <chemical> ketamine </chemical> N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.",
    "original_text": "These results indicate a major role of  CYP2B6  in  ketamine  N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.",
    "entity1": "CYP2B6",
    "entity2": "ketamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the <protein> CYP2B6*6 </protein> allele on enzyme-<chemical> ketamine </chemical> binding and catalytic activity.",
    "original_text": "These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the  CYP2B6*6  allele on enzyme- ketamine  binding and catalytic activity.",
    "entity1": "CYP2B6*6",
    "entity2": "ketamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The results show that CYP2E1 inhibits <protein> CYP2B4 </protein>-mediated metabolism of <chemical> benzphetamine </chemical> (BNZ) with a K(i) of 0.04 \u00b5M.",
    "original_text": "The results show that CYP2E1 inhibits  CYP2B4 -mediated metabolism of  benzphetamine  (BNZ) with a K(i) of 0.04 \u00b5M.",
    "entity1": "CYP2B4",
    "entity2": "benzphetamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The results show that CYP2E1 inhibits <protein> CYP2B4 </protein>-mediated metabolism of benzphetamine (<chemical> BNZ </chemical>) with a K(i) of 0.04 \u00b5M.",
    "original_text": "The results show that CYP2E1 inhibits  CYP2B4 -mediated metabolism of benzphetamine ( BNZ ) with a K(i) of 0.04 \u00b5M.",
    "entity1": "CYP2B4",
    "entity2": "BNZ"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, CYP2B4 is not an inhibitor of <protein> CYP2E1 </protein>-mediated <chemical> p-nitrophenol </chemical> hydroxylation.",
    "original_text": "However, CYP2B4 is not an inhibitor of  CYP2E1 -mediated  p-nitrophenol  hydroxylation.",
    "entity1": "CYP2E1",
    "entity2": "p-nitrophenol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Synthesis and in Vitro Characterisation of <protein> Ifenprodil </protein>-Based Fluorescein Conjugates as <chemical> GluN1 </chemical>/GluN2B N-Methyl-D-aspartate Receptor Antagonists.",
    "original_text": "Synthesis and in Vitro Characterisation of  Ifenprodil -Based Fluorescein Conjugates as  GluN1 /GluN2B N-Methyl-D-aspartate Receptor Antagonists.",
    "entity1": "Ifenprodil",
    "entity2": "GluN1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Synthesis and in Vitro Characterisation of <protein> Ifenprodil </protein>-Based Fluorescein Conjugates as GluN1/<chemical> GluN2B </chemical> N-Methyl-D-aspartate Receptor Antagonists.",
    "original_text": "Synthesis and in Vitro Characterisation of  Ifenprodil -Based Fluorescein Conjugates as GluN1/ GluN2B  N-Methyl-D-aspartate Receptor Antagonists.",
    "entity1": "Ifenprodil",
    "entity2": "GluN2B"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Synthesis and in Vitro Characterisation of <protein> Ifenprodil </protein>-Based Fluorescein Conjugates as GluN1/GluN2B <chemical> N-Methyl-D-aspartate Receptor </chemical> Antagonists.",
    "original_text": "Synthesis and in Vitro Characterisation of  Ifenprodil -Based Fluorescein Conjugates as GluN1/GluN2B  N-Methyl-D-aspartate Receptor  Antagonists.",
    "entity1": "Ifenprodil",
    "entity2": "N-Methyl-D-aspartate Receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based <protein> Fluorescein </protein> Conjugates as <chemical> GluN1 </chemical>/GluN2B N-Methyl-D-aspartate Receptor Antagonists.",
    "original_text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based  Fluorescein  Conjugates as  GluN1 /GluN2B N-Methyl-D-aspartate Receptor Antagonists.",
    "entity1": "Fluorescein",
    "entity2": "GluN1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based <protein> Fluorescein </protein> Conjugates as GluN1/<chemical> GluN2B </chemical> N-Methyl-D-aspartate Receptor Antagonists.",
    "original_text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based  Fluorescein  Conjugates as GluN1/ GluN2B  N-Methyl-D-aspartate Receptor Antagonists.",
    "entity1": "Fluorescein",
    "entity2": "GluN2B"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based <protein> Fluorescein </protein> Conjugates as GluN1/GluN2B <chemical> N-Methyl-D-aspartate Receptor </chemical> Antagonists.",
    "original_text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based  Fluorescein  Conjugates as GluN1/GluN2B  N-Methyl-D-aspartate Receptor  Antagonists.",
    "entity1": "Fluorescein",
    "entity2": "N-Methyl-D-aspartate Receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Ifenprodil </protein>, known as the <chemical> GluNR2B </chemical> antagonist of reference, was chosen as the template for the elaboration of probes.",
    "original_text": " Ifenprodil , known as the  GluNR2B  antagonist of reference, was chosen as the template for the elaboration of probes.",
    "entity1": "Ifenprodil",
    "entity2": "GluNR2B"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on <protein> VMAT2 </protein> activity by measuring adenosine triphosphate-dependent <chemical> [(3)H]dopamine </chemical> uptake into synaptic vesicles prepared from rat striatum.",
    "original_text": "The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on  VMAT2  activity by measuring adenosine triphosphate-dependent  [(3)H]dopamine  uptake into synaptic vesicles prepared from rat striatum.",
    "entity1": "VMAT2",
    "entity2": "[(3)H]dopamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Moreover, kinetic analysis revealed that inhibition by reserpine, a typical <protein> VMAT2 </protein> inhibitor, was uncompetitive, decreasing maximum velocity and affinity for <chemical> dopamine </chemical>.",
    "original_text": "Moreover, kinetic analysis revealed that inhibition by reserpine, a typical  VMAT2  inhibitor, was uncompetitive, decreasing maximum velocity and affinity for  dopamine .",
    "entity1": "VMAT2",
    "entity2": "dopamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Betaxolol </protein>, a <chemical> beta(1)-adrenoceptor </chemical> antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.",
    "original_text": " Betaxolol , a  beta(1)-adrenoceptor  antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.",
    "entity1": "Betaxolol",
    "entity2": "beta(1)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Betaxolol </protein>, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other <chemical> beta-adrenoceptor </chemical> antagonists.",
    "original_text": " Betaxolol , a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other  beta-adrenoceptor  antagonists.",
    "entity1": "Betaxolol",
    "entity2": "beta-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Betaxolol </protein>, a <chemical> beta(1)-adrenoceptor </chemical> antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia/excitotoxicity.",
    "original_text": " Betaxolol , a  beta(1)-adrenoceptor  antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia/excitotoxicity.",
    "entity1": "Betaxolol",
    "entity2": "beta(1)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In this study, we examined whether <protein> betaxolol </protein> and other <chemical> beta-adrenoceptor </chemical> antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes.",
    "original_text": "In this study, we examined whether  betaxolol  and other  beta-adrenoceptor  antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes.",
    "entity1": "betaxolol",
    "entity2": "beta-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Comparison of all the <protein> beta-adrenoceptor </protein> antagonists tested revealed a potency order of <chemical> propranolol </chemical>>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.",
    "original_text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of  propranolol >betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.",
    "entity1": "beta-adrenoceptor",
    "entity2": "propranolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Comparison of all the <protein> beta-adrenoceptor </protein> antagonists tested revealed a potency order of propranolol><chemical> betaxolol </chemical> approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.",
    "original_text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol> betaxolol  approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.",
    "entity1": "beta-adrenoceptor",
    "entity2": "betaxolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Comparison of all the <protein> beta-adrenoceptor </protein> antagonists tested revealed a potency order of propranolol>betaxolol approximately <chemical> levobetaxolol </chemical>>levobunolol approximately carteolol>/=timolol>atenolol.",
    "original_text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol>betaxolol approximately  levobetaxolol >levobunolol approximately carteolol>/=timolol>atenolol.",
    "entity1": "beta-adrenoceptor",
    "entity2": "levobetaxolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Comparison of all the <protein> beta-adrenoceptor </protein> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol><chemical> levobunolol </chemical> approximately carteolol>/=timolol>atenolol.",
    "original_text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol> levobunolol  approximately carteolol>/=timolol>atenolol.",
    "entity1": "beta-adrenoceptor",
    "entity2": "levobunolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Comparison of all the <protein> beta-adrenoceptor </protein> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately <chemical> carteolol </chemical>>/=timolol>atenolol.",
    "original_text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately  carteolol >/=timolol>atenolol.",
    "entity1": "beta-adrenoceptor",
    "entity2": "carteolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Comparison of all the <protein> beta-adrenoceptor </protein> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=<chemical> timolol </chemical>>atenolol.",
    "original_text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/= timolol >atenolol.",
    "entity1": "beta-adrenoceptor",
    "entity2": "timolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Comparison of all the <protein> beta-adrenoceptor </protein> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol><chemical> atenolol </chemical>.",
    "original_text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol> atenolol .",
    "entity1": "beta-adrenoceptor",
    "entity2": "atenolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment with <protein> pranlukast </protein> (1.5 ng/mouse, intracerebroventricularly), a <chemical> CysLT(1)R </chemical> antagonist, blocked LTD4-induced amyloidogenesis, memory deficits.",
    "original_text": "Pretreatment with  pranlukast  (1.5 ng/mouse, intracerebroventricularly), a  CysLT(1)R  antagonist, blocked LTD4-induced amyloidogenesis, memory deficits.",
    "entity1": "pranlukast",
    "entity2": "CysLT(1)R"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Statins </protein> increase p21 through inhibition of histone deacetylase activity and release of promoter-associated <chemical> HDAC1/2 </chemical>.",
    "original_text": " Statins  increase p21 through inhibition of histone deacetylase activity and release of promoter-associated  HDAC1/2 .",
    "entity1": "Statins",
    "entity2": "HDAC1/2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using <protein> dexamethasone 21-phosphate </protein> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to <chemical> CYP3A </chemical>, respectively.",
    "original_text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using  dexamethasone 21-phosphate  (DEX-P) and midazolam (MDZ) as an inducer and a substrate to  CYP3A , respectively.",
    "entity1": "dexamethasone 21-phosphate",
    "entity2": "CYP3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (<protein> DEX-P </protein>) and midazolam (MDZ) as an inducer and a substrate to <chemical> CYP3A </chemical>, respectively.",
    "original_text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate ( DEX-P ) and midazolam (MDZ) as an inducer and a substrate to  CYP3A , respectively.",
    "entity1": "DEX-P",
    "entity2": "CYP3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal <protein> cytochrome P450 3A </protein> (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and <chemical> midazolam </chemical> (MDZ) as an inducer and a substrate to CYP3A, respectively.",
    "original_text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal  cytochrome P450 3A  (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and  midazolam  (MDZ) as an inducer and a substrate to CYP3A, respectively.",
    "entity1": "cytochrome P450 3A",
    "entity2": "midazolam"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<protein> CYP3A </protein>) in rats using dexamethasone 21-phosphate (DEX-P) and <chemical> midazolam </chemical> (MDZ) as an inducer and a substrate to CYP3A, respectively.",
    "original_text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A ) in rats using dexamethasone 21-phosphate (DEX-P) and  midazolam  (MDZ) as an inducer and a substrate to CYP3A, respectively.",
    "entity1": "CYP3A",
    "entity2": "midazolam"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and <protein> midazolam </protein> (MDZ) as an inducer and a substrate to <chemical> CYP3A </chemical>, respectively.",
    "original_text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and  midazolam  (MDZ) as an inducer and a substrate to  CYP3A , respectively.",
    "entity1": "midazolam",
    "entity2": "CYP3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<protein> CYP3A </protein>) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<chemical> MDZ </chemical>) as an inducer and a substrate to CYP3A, respectively.",
    "original_text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A ) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ( MDZ ) as an inducer and a substrate to CYP3A, respectively.",
    "entity1": "CYP3A",
    "entity2": "MDZ"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<protein> MDZ </protein>) as an inducer and a substrate to <chemical> CYP3A </chemical>, respectively.",
    "original_text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ( MDZ ) as an inducer and a substrate to  CYP3A , respectively.",
    "entity1": "MDZ",
    "entity2": "CYP3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> LDH </protein> is responsible for <chemical> pyruvate </chemical> conversion to lactate through glycolysis.",
    "original_text": " LDH  is responsible for  pyruvate  conversion to lactate through glycolysis.",
    "entity1": "LDH",
    "entity2": "pyruvate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both <protein> cAMP </protein> and cGMP (<chemical> PDE10A </chemical>).",
    "original_text": "Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both  cAMP  and cGMP ( PDE10A ).",
    "entity1": "cAMP",
    "entity2": "PDE10A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cloning and characterization of a novel <protein> human phosphodiesterase </protein> that hydrolyzes both <chemical> cAMP </chemical> and cGMP (PDE10A).",
    "original_text": "Cloning and characterization of a novel  human phosphodiesterase  that hydrolyzes both  cAMP  and cGMP (PDE10A).",
    "entity1": "human phosphodiesterase",
    "entity2": "cAMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and <protein> cGMP </protein> (<chemical> PDE10A </chemical>).",
    "original_text": "Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and  cGMP  ( PDE10A ).",
    "entity1": "cGMP",
    "entity2": "PDE10A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cloning and characterization of a novel <protein> human phosphodiesterase </protein> that hydrolyzes both cAMP and <chemical> cGMP </chemical> (PDE10A).",
    "original_text": "Cloning and characterization of a novel  human phosphodiesterase  that hydrolyzes both cAMP and  cGMP  (PDE10A).",
    "entity1": "human phosphodiesterase",
    "entity2": "cGMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Recombinant <protein> PDE10A </protein> transfected and expressed in COS-7 cells hydrolyzed <chemical> cAMP </chemical> and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP.",
    "original_text": "Recombinant  PDE10A  transfected and expressed in COS-7 cells hydrolyzed  cAMP  and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP.",
    "entity1": "PDE10A",
    "entity2": "cAMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Recombinant <protein> PDE10A </protein> transfected and expressed in COS-7 cells hydrolyzed cAMP and <chemical> cGMP </chemical> with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP.",
    "original_text": "Recombinant  PDE10A  transfected and expressed in COS-7 cells hydrolyzed cAMP and  cGMP  with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP.",
    "entity1": "PDE10A",
    "entity2": "cGMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Recombinant <protein> PDE10A </protein> transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with <chemical> cGMP </chemical> was almost twice that with cAMP.",
    "original_text": "Recombinant  PDE10A  transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with  cGMP  was almost twice that with cAMP.",
    "entity1": "PDE10A",
    "entity2": "cGMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Recombinant <protein> PDE10A </protein> transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with <chemical> cAMP </chemical>.",
    "original_text": "Recombinant  PDE10A  transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with  cAMP .",
    "entity1": "PDE10A",
    "entity2": "cAMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Of the <protein> PDE </protein> inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of <chemical> cAMP </chemical> and cGMP hydrolysis, respectively.",
    "original_text": "Of the  PDE  inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of  cAMP  and cGMP hydrolysis, respectively.",
    "entity1": "PDE",
    "entity2": "cAMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Of the <protein> PDE </protein> inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and <chemical> cGMP </chemical> hydrolysis, respectively.",
    "original_text": "Of the  PDE  inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and  cGMP  hydrolysis, respectively.",
    "entity1": "PDE",
    "entity2": "cGMP"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "This effect has been attributed to the antagonist effects of <protein> pindolol </protein> at the <chemical> 5-HT(1A) </chemical> receptor.",
    "original_text": "This effect has been attributed to the antagonist effects of  pindolol  at the  5-HT(1A)  receptor.",
    "entity1": "pindolol",
    "entity2": "5-HT(1A)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the present study, we compared the pharmacology of <protein> (+/-)pindolol </protein>, WAY-100635 (a <chemical> 5-HT(1A) </chemical> antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",
    "original_text": "In the present study, we compared the pharmacology of  (+/-)pindolol , WAY-100635 (a  5-HT(1A)  antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",
    "entity1": "(+/-)pindolol",
    "entity2": "5-HT(1A)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the present study, we compared the pharmacology of (+/-)pindolol, <protein> WAY-100635 </protein> (a <chemical> 5-HT(1A) </chemical> antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",
    "original_text": "In the present study, we compared the pharmacology of (+/-)pindolol,  WAY-100635  (a  5-HT(1A)  antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",
    "entity1": "WAY-100635",
    "entity2": "5-HT(1A)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and <protein> isamoltane </protein> (a <chemical> 5-HT(1B) </chemical> antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",
    "original_text": "In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and  isamoltane  (a  5-HT(1B)  antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",
    "entity1": "isamoltane",
    "entity2": "5-HT(1B)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In addition, by comparing the combined administration of (+/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that <protein> (+/-)pindolol </protein> produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B/D) receptor in addition to any activity it has at the presynaptic <chemical> 5-HT(1A) </chemical> receptor.",
    "original_text": "In addition, by comparing the combined administration of (+/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that  (+/-)pindolol  produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B/D) receptor in addition to any activity it has at the presynaptic  5-HT(1A)  receptor.",
    "entity1": "(+/-)pindolol",
    "entity2": "5-HT(1A)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the local presence into the LC of the <protein> \u03b12-adrenoceptor </protein> antagonist <chemical> RS79948 </chemical> (1\u00a0\u03bcM), systemic citalopram increased NA in the LC (Emax\u2009=\u2009157\u2009\u00b1\u200925\u00a0%) and PFC (Emax\u2009=\u2009175\u2009\u00b1\u200924\u00a0%).",
    "original_text": "In the local presence into the LC of the  \u03b12-adrenoceptor  antagonist  RS79948  (1\u00a0\u03bcM), systemic citalopram increased NA in the LC (Emax\u2009=\u2009157\u2009\u00b1\u200925\u00a0%) and PFC (Emax\u2009=\u2009175\u2009\u00b1\u200924\u00a0%).",
    "entity1": "\u03b12-adrenoceptor",
    "entity2": "RS79948"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Local LC citalopram effect was abolished by LC presence of the <protein> 5-HT3 </protein> receptor antagonist <chemical> MDL72222 </chemical> (1\u00a0\u03bcM) but not the 5-HT1/2 receptor antagonist methiothepin (1\u00a0\u03bcM).",
    "original_text": "Local LC citalopram effect was abolished by LC presence of the  5-HT3  receptor antagonist  MDL72222  (1\u00a0\u03bcM) but not the 5-HT1/2 receptor antagonist methiothepin (1\u00a0\u03bcM).",
    "entity1": "5-HT3",
    "entity2": "MDL72222"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1\u00a0\u03bcM) but not the <protein> 5-HT1/2 </protein> receptor antagonist <chemical> methiothepin </chemical> (1\u00a0\u03bcM).",
    "original_text": "Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1\u00a0\u03bcM) but not the  5-HT1/2  receptor antagonist  methiothepin  (1\u00a0\u03bcM).",
    "entity1": "5-HT1/2",
    "entity2": "methiothepin"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "alpha(1)-Adrenoceptor antagonists were tested against the <protein> phenylephrine </protein> (<chemical> alpha(1)-adrenoceptor </chemical> agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.",
    "original_text": "alpha(1)-Adrenoceptor antagonists were tested against the  phenylephrine  ( alpha(1)-adrenoceptor  agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.",
    "entity1": "phenylephrine",
    "entity2": "alpha(1)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Noradrenaline and <protein> phenylephrine </protein> (<chemical> alpha(1)-adrenoceptor </chemical> agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.",
    "original_text": "Noradrenaline and  phenylephrine  ( alpha(1)-adrenoceptor  agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.",
    "entity1": "phenylephrine",
    "entity2": "alpha(1)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Noradrenaline </protein> and phenylephrine (<chemical> alpha(1)-adrenoceptor </chemical> agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.",
    "original_text": " Noradrenaline  and phenylephrine ( alpha(1)-adrenoceptor  agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.",
    "entity1": "Noradrenaline",
    "entity2": "alpha(1)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Prazosin (nonselective <protein> alpha(1)-adrenoceptor </protein> antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the <chemical> phenylephrine </chemical>-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "original_text": "Prazosin (nonselective  alpha(1)-adrenoceptor  antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the  phenylephrine -induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "entity1": "alpha(1)-adrenoceptor",
    "entity2": "phenylephrine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective <protein> alpha(1A)-adrenoceptor </protein> antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the <chemical> phenylephrine </chemical>-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "original_text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective  alpha(1A)-adrenoceptor  antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the  phenylephrine -induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "entity1": "alpha(1A)-adrenoceptor",
    "entity2": "phenylephrine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective <protein> alpha(1D)-adrenoceptor </protein> antagonist) competitively antagonized the <chemical> phenylephrine </chemical>-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "original_text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective  alpha(1D)-adrenoceptor  antagonist) competitively antagonized the  phenylephrine -induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "entity1": "alpha(1D)-adrenoceptor",
    "entity2": "phenylephrine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Prazosin </protein> (nonselective <chemical> alpha(1)-adrenoceptor </chemical> antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "original_text": " Prazosin  (nonselective  alpha(1)-adrenoceptor  antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "entity1": "Prazosin",
    "entity2": "alpha(1)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), <protein> silodosin </protein> (selective <chemical> alpha(1A)-adrenoceptor </chemical> antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "original_text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist),  silodosin  (selective  alpha(1A)-adrenoceptor  antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "entity1": "silodosin",
    "entity2": "alpha(1A)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and <protein> BMY-7378 </protein> (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective <chemical> alpha(1D)-adrenoceptor </chemical> antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "original_text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and  BMY-7378  (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective  alpha(1D)-adrenoceptor  antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "entity1": "BMY-7378",
    "entity2": "alpha(1D)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (<protein> 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride </protein>) (selective <chemical> alpha(1D)-adrenoceptor </chemical> antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "original_text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 ( 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride ) (selective  alpha(1D)-adrenoceptor  antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
    "entity1": "8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride",
    "entity2": "alpha(1D)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to <protein> dihydropyridine </protein> (DHP) <chemical> L-VGCC </chemical> antagonists.",
    "original_text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to  dihydropyridine  (DHP)  L-VGCC  antagonists.",
    "entity1": "dihydropyridine",
    "entity2": "L-VGCC"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (<protein> DHP </protein>) <chemical> L-VGCC </chemical> antagonists.",
    "original_text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine ( DHP )  L-VGCC  antagonists.",
    "entity1": "DHP",
    "entity2": "L-VGCC"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Further, <protein> 5HHMF </protein> increased specific DNA-binding activity of Nrf2, and transient knockdown with <chemical> Nrf2 </chemical> siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity.",
    "original_text": "Further,  5HHMF  increased specific DNA-binding activity of Nrf2, and transient knockdown with  Nrf2  siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity.",
    "entity1": "5HHMF",
    "entity2": "Nrf2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Further, 5HHMF increased specific DNA-binding activity of <protein> Nrf2 </protein>, and transient knockdown with Nrf2 siRNA subsequently reversed <chemical> 5HHMF </chemical>-induced NO inhibition, which was followed by suppression of HO-1 activity.",
    "original_text": "Further, 5HHMF increased specific DNA-binding activity of  Nrf2 , and transient knockdown with Nrf2 siRNA subsequently reversed  5HHMF -induced NO inhibition, which was followed by suppression of HO-1 activity.",
    "entity1": "Nrf2",
    "entity2": "5HHMF"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with <protein> Nrf2 </protein> siRNA subsequently reversed <chemical> 5HHMF </chemical>-induced NO inhibition, which was followed by suppression of HO-1 activity.",
    "original_text": "Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with  Nrf2  siRNA subsequently reversed  5HHMF -induced NO inhibition, which was followed by suppression of HO-1 activity.",
    "entity1": "Nrf2",
    "entity2": "5HHMF"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced <protein> NO </protein> inhibition, which was followed by suppression of <chemical> HO-1 </chemical> activity.",
    "original_text": "Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced  NO  inhibition, which was followed by suppression of  HO-1  activity.",
    "entity1": "NO",
    "entity2": "HO-1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Taken together, our findings indicate that 5HHMF suppresses <protein> NO </protein> production through modulation of iNOS, consequently suppressing <chemical> NF-\u03baB </chemical> activity and induction of Nrf2-dependent HO-1 activity.",
    "original_text": "Taken together, our findings indicate that 5HHMF suppresses  NO  production through modulation of iNOS, consequently suppressing  NF-\u03baB  activity and induction of Nrf2-dependent HO-1 activity.",
    "entity1": "NO",
    "entity2": "NF-\u03baB"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Taken together, our findings indicate that 5HHMF suppresses <protein> NO </protein> production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of <chemical> Nrf2 </chemical>-dependent HO-1 activity.",
    "original_text": "Taken together, our findings indicate that 5HHMF suppresses  NO  production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of  Nrf2 -dependent HO-1 activity.",
    "entity1": "NO",
    "entity2": "Nrf2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Taken together, our findings indicate that 5HHMF suppresses <protein> NO </protein> production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent <chemical> HO-1 </chemical> activity.",
    "original_text": "Taken together, our findings indicate that 5HHMF suppresses  NO  production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent  HO-1  activity.",
    "entity1": "NO",
    "entity2": "HO-1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of <protein> 2,4,6-trisubstituted 1,3,5-triazines </protein> as <chemical> CB2 </chemical> agonists.",
    "original_text": "Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of  2,4,6-trisubstituted 1,3,5-triazines  as  CB2  agonists.",
    "entity1": "2,4,6-trisubstituted 1,3,5-triazines",
    "entity2": "CB2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "One of the <protein> CB2 </protein> agonists, <chemical> N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine </chemical> (19, -logEC(50)=7.5, E(max)=255%) was selected for further development.",
    "original_text": "One of the  CB2  agonists,  N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine  (19, -logEC(50)=7.5, E(max)=255%) was selected for further development.",
    "entity1": "CB2",
    "entity2": "N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "As far as we are aware, the compound's <protein> 1,3,5-triazine </protein> scaffold represents a new core structure for <chemical> CB2 </chemical> agonists.",
    "original_text": "As far as we are aware, the compound's  1,3,5-triazine  scaffold represents a new core structure for  CB2  agonists.",
    "entity1": "1,3,5-triazine",
    "entity2": "CB2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The discovery of an inducible <protein> oxidase </protein> whose apparent substrate preference is <chemical> spermine </chemical> indicates that polyamine catabolism is more complex than that originally proposed.",
    "original_text": "The discovery of an inducible  oxidase  whose apparent substrate preference is  spermine  indicates that polyamine catabolism is more complex than that originally proposed.",
    "entity1": "oxidase",
    "entity2": "spermine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Purified <protein> PAOh1 </protein>/SMO oxidizes both <chemical> spermine </chemical> (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.",
    "original_text": "Purified  PAOh1 /SMO oxidizes both  spermine  (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.",
    "entity1": "PAOh1",
    "entity2": "spermine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Purified PAOh1/<protein> SMO </protein> oxidizes both <chemical> spermine </chemical> (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.",
    "original_text": "Purified PAOh1/ SMO  oxidizes both  spermine  (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.",
    "entity1": "SMO",
    "entity2": "spermine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Purified <protein> PAOh1 </protein>/SMO oxidizes both spermine (K(m)=1.6 microM) and <chemical> N(1)-acetylspermine </chemical> (K(m)=51 microM), but does not oxidize spermidine.",
    "original_text": "Purified  PAOh1 /SMO oxidizes both spermine (K(m)=1.6 microM) and  N(1)-acetylspermine  (K(m)=51 microM), but does not oxidize spermidine.",
    "entity1": "PAOh1",
    "entity2": "N(1)-acetylspermine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Purified PAOh1/<protein> SMO </protein> oxidizes both spermine (K(m)=1.6 microM) and <chemical> N(1)-acetylspermine </chemical> (K(m)=51 microM), but does not oxidize spermidine.",
    "original_text": "Purified PAOh1/ SMO  oxidizes both spermine (K(m)=1.6 microM) and  N(1)-acetylspermine  (K(m)=51 microM), but does not oxidize spermidine.",
    "entity1": "SMO",
    "entity2": "N(1)-acetylspermine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of <protein> spermine </protein> by <chemical> PAOh1 </chemical>/SMO.",
    "original_text": "The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of  spermine  by  PAOh1 /SMO.",
    "entity1": "spermine",
    "entity2": "PAOh1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of <protein> spermine </protein> by PAOh1/<chemical> SMO </chemical>.",
    "original_text": "The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of  spermine  by PAOh1/ SMO .",
    "entity1": "spermine",
    "entity2": "SMO"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> L-serine dehydratase </protein> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of <chemical> L-serine </chemical> and L-threonine to yield pyruvate or 2-oxobutyrate.",
    "original_text": " L-serine dehydratase  (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of  L-serine  and L-threonine to yield pyruvate or 2-oxobutyrate.",
    "entity1": "L-serine dehydratase",
    "entity2": "L-serine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "L-serine dehydratase (<protein> SDH </protein>), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of <chemical> L-serine </chemical> and L-threonine to yield pyruvate or 2-oxobutyrate.",
    "original_text": "L-serine dehydratase ( SDH ), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of  L-serine  and L-threonine to yield pyruvate or 2-oxobutyrate.",
    "entity1": "SDH",
    "entity2": "L-serine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> L-serine dehydratase </protein> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and <chemical> L-threonine </chemical> to yield pyruvate or 2-oxobutyrate.",
    "original_text": " L-serine dehydratase  (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and  L-threonine  to yield pyruvate or 2-oxobutyrate.",
    "entity1": "L-serine dehydratase",
    "entity2": "L-threonine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "L-serine dehydratase (<protein> SDH </protein>), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and <chemical> L-threonine </chemical> to yield pyruvate or 2-oxobutyrate.",
    "original_text": "L-serine dehydratase ( SDH ), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and  L-threonine  to yield pyruvate or 2-oxobutyrate.",
    "entity1": "SDH",
    "entity2": "L-threonine"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of <protein> CREB </protein> in the nucleus accumbens, and those changes can be reversed by <chemical> naloxone </chemical>, which may be one kind of the molecular mechanisms associated with ethanol dependence.",
    "original_text": "CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of  CREB  in the nucleus accumbens, and those changes can be reversed by  naloxone , which may be one kind of the molecular mechanisms associated with ethanol dependence.",
    "entity1": "CREB",
    "entity2": "naloxone"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "CONCLUSION: A long-term intake of <protein> ethanol </protein> solution down-regulates the phosphorylation of <chemical> CREB </chemical> in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence.",
    "original_text": "CONCLUSION: A long-term intake of  ethanol  solution down-regulates the phosphorylation of  CREB  in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence.",
    "entity1": "ethanol",
    "entity2": "CREB"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Adenosine and N(6)-cyclopentyl-adenosine (<protein> CPA </protein>, <chemical> A1R </chemical> agonist) constricted MVs but not MAs.",
    "original_text": "Adenosine and N(6)-cyclopentyl-adenosine ( CPA ,  A1R  agonist) constricted MVs but not MAs.",
    "entity1": "CPA",
    "entity2": "A1R"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Adenosine </protein> and N(6)-cyclopentyl-adenosine (CPA, <chemical> A1R </chemical> agonist) constricted MVs but not MAs.",
    "original_text": " Adenosine  and N(6)-cyclopentyl-adenosine (CPA,  A1R  agonist) constricted MVs but not MAs.",
    "entity1": "Adenosine",
    "entity2": "A1R"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Adenosine and <protein> N(6)-cyclopentyl-adenosine </protein> (CPA, <chemical> A1R </chemical> agonist) constricted MVs but not MAs.",
    "original_text": "Adenosine and  N(6)-cyclopentyl-adenosine  (CPA,  A1R  agonist) constricted MVs but not MAs.",
    "entity1": "N(6)-cyclopentyl-adenosine",
    "entity2": "A1R"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The <protein> A2A adenosine receptor </protein> agonist CGS21680 (<chemical> C23H29N7O6.HCl.xH2O </chemical>) (0.001-0.1 \u03bcM) did not alter NE oxidation currents.",
    "original_text": "The  A2A adenosine receptor  agonist CGS21680 ( C23H29N7O6.HCl.xH2O ) (0.001-0.1 \u03bcM) did not alter NE oxidation currents.",
    "entity1": "A2A adenosine receptor",
    "entity2": "C23H29N7O6.HCl.xH2O"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The <protein> A2A adenosine receptor </protein> agonist <chemical> CGS21680 </chemical> (C23H29N7O6.HCl.xH2O) (0.001-0.1 \u03bcM) did not alter NE oxidation currents.",
    "original_text": "The  A2A adenosine receptor  agonist  CGS21680  (C23H29N7O6.HCl.xH2O) (0.001-0.1 \u03bcM) did not alter NE oxidation currents.",
    "entity1": "A2A adenosine receptor",
    "entity2": "CGS21680"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Megalin, a family of <protein> endocytic receptors </protein> related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular <chemical> aminoglycoside </chemical> accumulation.",
    "original_text": "Megalin, a family of  endocytic receptors  related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular  aminoglycoside  accumulation.",
    "entity1": "endocytic receptors",
    "entity2": "aminoglycoside"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Megalin, a family of endocytic receptors related to the <protein> low-density lipoprotein (LDL) receptor </protein>, is a major pathway for proximal tubular <chemical> aminoglycoside </chemical> accumulation.",
    "original_text": "Megalin, a family of endocytic receptors related to the  low-density lipoprotein (LDL) receptor , is a major pathway for proximal tubular  aminoglycoside  accumulation.",
    "entity1": "low-density lipoprotein (LDL) receptor",
    "entity2": "aminoglycoside"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "We previously reported that <protein> aminoglycoside </protein> antibiotics reduce <chemical> SGLT1 </chemical>-dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity.",
    "original_text": "We previously reported that  aminoglycoside  antibiotics reduce  SGLT1 -dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity.",
    "entity1": "aminoglycoside",
    "entity2": "SGLT1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the <protein> SGLT1 </protein>-dependent <chemical> methyl alpha-D-glucopyranoside </chemical> (AMG) uptake and levels of SGLT1 expression were determined.",
    "original_text": "Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the  SGLT1 -dependent  methyl alpha-D-glucopyranoside  (AMG) uptake and levels of SGLT1 expression were determined.",
    "entity1": "SGLT1",
    "entity2": "methyl alpha-D-glucopyranoside"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the <protein> SGLT1 </protein>-dependent methyl alpha-D-glucopyranoside (<chemical> AMG </chemical>) uptake and levels of SGLT1 expression were determined.",
    "original_text": "Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the  SGLT1 -dependent methyl alpha-D-glucopyranoside ( AMG ) uptake and levels of SGLT1 expression were determined.",
    "entity1": "SGLT1",
    "entity2": "AMG"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Actions of <protein> nizatidine </protein>, a selective <chemical> histamine H2-receptor </chemical> antagonist, on gastric acid secretion in dogs, rats and frogs.",
    "original_text": "Actions of  nizatidine , a selective  histamine H2-receptor  antagonist, on gastric acid secretion in dogs, rats and frogs.",
    "entity1": "nizatidine",
    "entity2": "histamine H2-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Nizatidine </protein> (LY139037), a selective <chemical> histamine H2-receptor </chemical> antagonist, is a potent inhibitor of gastric acid secretion.",
    "original_text": " Nizatidine  (LY139037), a selective  histamine H2-receptor  antagonist, is a potent inhibitor of gastric acid secretion.",
    "entity1": "Nizatidine",
    "entity2": "histamine H2-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Nizatidine (<protein> LY139037 </protein>), a selective <chemical> histamine H2-receptor </chemical> antagonist, is a potent inhibitor of gastric acid secretion.",
    "original_text": "Nizatidine ( LY139037 ), a selective  histamine H2-receptor  antagonist, is a potent inhibitor of gastric acid secretion.",
    "entity1": "LY139037",
    "entity2": "histamine H2-receptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Thus prolonged activation of NMDA receptors in hippocampal neurons reduced <protein> GABAR \u03b4 subunit </protein> expression through <chemical> Ca2+ </chemical> entry and at least in part by ERK1/2 activation.",
    "original_text": "Thus prolonged activation of NMDA receptors in hippocampal neurons reduced  GABAR \u03b4 subunit  expression through  Ca2+  entry and at least in part by ERK1/2 activation.",
    "entity1": "GABAR \u03b4 subunit",
    "entity2": "Ca2+"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Amitriptyline </protein> is a <chemical> TrkA </chemical> and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.",
    "original_text": " Amitriptyline  is a  TrkA  and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.",
    "entity1": "Amitriptyline",
    "entity2": "TrkA"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Amitriptyline </protein> is a TrkA and <chemical> TrkB </chemical> receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.",
    "original_text": " Amitriptyline  is a TrkA and  TrkB  receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.",
    "entity1": "Amitriptyline",
    "entity2": "TrkB"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Thus, <protein> amitriptyline </protein> acts as a TrkA and <chemical> TrkB </chemical> agonist and possesses marked neurotrophic activity.",
    "original_text": "Thus,  amitriptyline  acts as a TrkA and  TrkB  agonist and possesses marked neurotrophic activity.",
    "entity1": "amitriptyline",
    "entity2": "TrkB"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Thus, <protein> amitriptyline </protein> acts as a <chemical> TrkA </chemical> and TrkB agonist and possesses marked neurotrophic activity.",
    "original_text": "Thus,  amitriptyline  acts as a  TrkA  and TrkB agonist and possesses marked neurotrophic activity.",
    "entity1": "amitriptyline",
    "entity2": "TrkA"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Kynurenic acid </protein> (KA) is an endogenous <chemical> glutamate receptor </chemical> antagonist at the level of the different ionotropic glutamate receptors.",
    "original_text": " Kynurenic acid  (KA) is an endogenous  glutamate receptor  antagonist at the level of the different ionotropic glutamate receptors.",
    "entity1": "Kynurenic acid",
    "entity2": "glutamate receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Kynurenic acid </protein> (KA) is an endogenous glutamate receptor antagonist at the level of the different <chemical> ionotropic glutamate receptors </chemical>.",
    "original_text": " Kynurenic acid  (KA) is an endogenous glutamate receptor antagonist at the level of the different  ionotropic glutamate receptors .",
    "entity1": "Kynurenic acid",
    "entity2": "ionotropic glutamate receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Kynurenic acid (<protein> KA </protein>) is an endogenous <chemical> glutamate receptor </chemical> antagonist at the level of the different ionotropic glutamate receptors.",
    "original_text": "Kynurenic acid ( KA ) is an endogenous  glutamate receptor  antagonist at the level of the different ionotropic glutamate receptors.",
    "entity1": "KA",
    "entity2": "glutamate receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Kynurenic acid (<protein> KA </protein>) is an endogenous glutamate receptor antagonist at the level of the different <chemical> ionotropic glutamate receptors </chemical>.",
    "original_text": "Kynurenic acid ( KA ) is an endogenous glutamate receptor antagonist at the level of the different  ionotropic glutamate receptors .",
    "entity1": "KA",
    "entity2": "ionotropic glutamate receptors"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that IR tyrosine phosphorylation (<protein> pIR </protein>) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (<chemical> MSG </chemical>, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "original_text": "The results showed that IR tyrosine phosphorylation ( pIR ) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice ( MSG , 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "entity1": "pIR",
    "entity2": "MSG"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <protein> pIR </protein> by 76\u00a0% in MSG mice without affecting control mice (<chemical> MSG </chemical>, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "original_text": "The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in MSG mice without affecting control mice ( MSG , 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "entity1": "pIR",
    "entity2": "MSG"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that IR tyrosine phosphorylation (<protein> pIR </protein>) was reduced by 42\u00a0% in <chemical> MSG </chemical>-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "original_text": "The results showed that IR tyrosine phosphorylation ( pIR ) was reduced by 42\u00a0% in  MSG -obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "entity1": "pIR",
    "entity2": "MSG"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in <protein> MSG </protein>-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <chemical> pIR </chemical> by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "original_text": "The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in  MSG -obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "entity1": "MSG",
    "entity2": "pIR"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that IR tyrosine phosphorylation (<protein> pIR </protein>) was reduced by 42\u00a0% in MSG-obese mice (<chemical> MSG </chemical>, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "original_text": "The results showed that IR tyrosine phosphorylation ( pIR ) was reduced by 42\u00a0% in MSG-obese mice ( MSG , 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "entity1": "pIR",
    "entity2": "MSG"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (<protein> MSG </protein>, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <chemical> pIR </chemical> by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "original_text": "The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice ( MSG , 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "entity1": "MSG",
    "entity2": "pIR"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that IR tyrosine phosphorylation (<protein> pIR </protein>) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in <chemical> MSG </chemical> mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "original_text": "The results showed that IR tyrosine phosphorylation ( pIR ) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in  MSG  mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "entity1": "pIR",
    "entity2": "MSG"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <protein> pIR </protein> by 76\u00a0% in <chemical> MSG </chemical> mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "original_text": "The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in  MSG  mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
    "entity1": "pIR",
    "entity2": "MSG"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Although the treatment with <protein> MSG </protein> increased IRS-1 tyrosine phosphorylation (<chemical> pIRS-1 </chemical>) by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; MSG, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.).",
    "original_text": "Although the treatment with  MSG  increased IRS-1 tyrosine phosphorylation ( pIRS-1 ) by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; MSG, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.).",
    "entity1": "MSG",
    "entity2": "pIRS-1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Although the treatment with MSG increased IRS-1 tyrosine phosphorylation (<protein> pIRS-1 </protein>) by 96\u00a0% (<chemical> MSG </chemical>, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; MSG, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.).",
    "original_text": "Although the treatment with MSG increased IRS-1 tyrosine phosphorylation ( pIRS-1 ) by 96\u00a0% ( MSG , 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; MSG, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.).",
    "entity1": "pIRS-1",
    "entity2": "MSG"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Although the treatment with MSG increased IRS-1 tyrosine phosphorylation (<protein> pIRS-1 </protein>) by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; <chemical> MSG </chemical>, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.).",
    "original_text": "Although the treatment with MSG increased IRS-1 tyrosine phosphorylation ( pIRS-1 ) by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1;  MSG , 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.).",
    "entity1": "pIRS-1",
    "entity2": "MSG"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of <protein> PDE5 </protein> that breaks down <chemical> cGMP </chemical>, the key pathway for the production of erectile function in humans.",
    "original_text": "The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of  PDE5  that breaks down  cGMP , the key pathway for the production of erectile function in humans.",
    "entity1": "PDE5",
    "entity2": "cGMP"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Combination treatment with the selective <protein> 5-HT1A </protein> antagonist <chemical> WAY100635 </chemical> produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone.",
    "original_text": "Combination treatment with the selective  5-HT1A  antagonist  WAY100635  produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone.",
    "entity1": "5-HT1A",
    "entity2": "WAY100635"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The beta-adrenergic/<protein> 5-HT1A </protein> receptor antagonist <chemical> (+/-)pindolol </chemical> and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.",
    "original_text": "The beta-adrenergic/ 5-HT1A  receptor antagonist  (+/-)pindolol  and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.",
    "entity1": "5-HT1A",
    "entity2": "(+/-)pindolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the <protein> GluR5 </protein> kainate receptor antagonist <chemical> LY293558 </chemical>.",
    "original_text": "The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the  GluR5  kainate receptor antagonist  LY293558 .",
    "entity1": "GluR5",
    "entity2": "LY293558"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 <protein> kainate receptor </protein> antagonist <chemical> LY293558 </chemical>.",
    "original_text": "The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5  kainate receptor  antagonist  LY293558 .",
    "entity1": "kainate receptor",
    "entity2": "LY293558"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Multidrug resistance-associated proteins </protein> are involved in the transport of the <chemical> glutathione </chemical> conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.",
    "original_text": " Multidrug resistance-associated proteins  are involved in the transport of the  glutathione  conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.",
    "entity1": "Multidrug resistance-associated proteins",
    "entity2": "glutathione"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Inhibition studies revealed that the <protein> multidrug resistance-associated proteins </protein> (ABCCs) are involved in the transport of <chemical> BPDE glutathione </chemical> conjugates.",
    "original_text": "Inhibition studies revealed that the  multidrug resistance-associated proteins  (ABCCs) are involved in the transport of  BPDE glutathione  conjugates.",
    "entity1": "multidrug resistance-associated proteins",
    "entity2": "BPDE glutathione"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Inhibition studies revealed that the multidrug resistance-associated proteins (<protein> ABCCs </protein>) are involved in the transport of <chemical> BPDE glutathione </chemical> conjugates.",
    "original_text": "Inhibition studies revealed that the multidrug resistance-associated proteins ( ABCCs ) are involved in the transport of  BPDE glutathione  conjugates.",
    "entity1": "ABCCs",
    "entity2": "BPDE glutathione"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Stable <protein> ABCC1 </protein>, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of <chemical> BPDE glutathione </chemical> conjugates.",
    "original_text": "Stable  ABCC1 , ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of  BPDE glutathione  conjugates.",
    "entity1": "ABCC1",
    "entity2": "BPDE glutathione"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Stable ABCC1, <protein> ABCC2 </protein> and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of <chemical> BPDE glutathione </chemical> conjugates.",
    "original_text": "Stable ABCC1,  ABCC2  and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of  BPDE glutathione  conjugates.",
    "entity1": "ABCC2",
    "entity2": "BPDE glutathione"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that <protein> ABCC1 </protein> mediates the basolateral and ABCC2 the apical excretion of <chemical> BPDE glutathione </chemical> conjugates.",
    "original_text": "Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that  ABCC1  mediates the basolateral and ABCC2 the apical excretion of  BPDE glutathione  conjugates.",
    "entity1": "ABCC1",
    "entity2": "BPDE glutathione"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and <protein> ABCC2 </protein> the apical excretion of <chemical> BPDE glutathione </chemical> conjugates.",
    "original_text": "Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and  ABCC2  the apical excretion of  BPDE glutathione  conjugates.",
    "entity1": "ABCC2",
    "entity2": "BPDE glutathione"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "RESULTS: <protein> Ketorolac </protein> was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against <chemical> COX-2 </chemical> (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).",
    "original_text": "RESULTS:  Ketorolac  was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against  COX-2  (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).",
    "entity1": "Ketorolac",
    "entity2": "COX-2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "RESULTS: <protein> Ketorolac </protein> was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than <chemical> COX-1 </chemical> (IC(50) = 0.210 microM).",
    "original_text": "RESULTS:  Ketorolac  was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than  COX-1  (IC(50) = 0.210 microM).",
    "entity1": "Ketorolac",
    "entity2": "COX-1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "RESULTS: Ketorolac was six times more active against <protein> COX-1 </protein> (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while <chemical> bromfenac </chemical> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).",
    "original_text": "RESULTS: Ketorolac was six times more active against  COX-1  (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while  bromfenac  was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).",
    "entity1": "COX-1",
    "entity2": "bromfenac"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than <protein> COX-2 </protein> (IC(50) = 0.12 microM) while <chemical> bromfenac </chemical> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).",
    "original_text": "RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than  COX-2  (IC(50) = 0.12 microM) while  bromfenac  was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).",
    "entity1": "COX-2",
    "entity2": "bromfenac"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PGE(2) is synthesized from <protein> arachidonic acid </protein> by <chemical> cyclooxygenases </chemical> (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
    "original_text": "PGE(2) is synthesized from  arachidonic acid  by  cyclooxygenases  (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
    "entity1": "arachidonic acid",
    "entity2": "cyclooxygenases"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PGE(2) is synthesized from <protein> arachidonic acid </protein> by cyclooxygenases (<chemical> COX </chemical>) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
    "original_text": "PGE(2) is synthesized from  arachidonic acid  by cyclooxygenases ( COX ) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
    "entity1": "arachidonic acid",
    "entity2": "COX"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PGE(2) is synthesized from <protein> arachidonic acid </protein> by cyclooxygenases (COX) and <chemical> prostaglandin E synthases </chemical> (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
    "original_text": "PGE(2) is synthesized from  arachidonic acid  by cyclooxygenases (COX) and  prostaglandin E synthases  (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
    "entity1": "arachidonic acid",
    "entity2": "prostaglandin E synthases"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PGE(2) is synthesized from <protein> arachidonic acid </protein> by cyclooxygenases (COX) and prostaglandin E synthases (<chemical> PGES </chemical>) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
    "original_text": "PGE(2) is synthesized from  arachidonic acid  by cyclooxygenases (COX) and prostaglandin E synthases ( PGES ) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
    "entity1": "arachidonic acid",
    "entity2": "PGES"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> EP(1) </protein> and EP(3) receptor antagonists <chemical> ONO-8713 </chemical> and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "original_text": " EP(1)  and EP(3) receptor antagonists  ONO-8713  and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "entity1": "EP(1)",
    "entity2": "ONO-8713"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "EP(1) and <protein> EP(3) receptor </protein> antagonists <chemical> ONO-8713 </chemical> and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "original_text": "EP(1) and  EP(3) receptor  antagonists  ONO-8713  and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "entity1": "EP(3) receptor",
    "entity2": "ONO-8713"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> EP(1) </protein> and EP(3) receptor antagonists ONO-8713 and <chemical> ONO-AE3-240 </chemical>, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "original_text": " EP(1)  and EP(3) receptor antagonists ONO-8713 and  ONO-AE3-240 , but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "entity1": "EP(1)",
    "entity2": "ONO-AE3-240"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "EP(1) and <protein> EP(3) receptor </protein> antagonists ONO-8713 and <chemical> ONO-AE3-240 </chemical>, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "original_text": "EP(1) and  EP(3) receptor  antagonists ONO-8713 and  ONO-AE3-240 , but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "entity1": "EP(3) receptor",
    "entity2": "ONO-AE3-240"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the <protein> EP(4) </protein> antagonists <chemical> ONO-AE3-208 </chemical> and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "original_text": "EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the  EP(4)  antagonists  ONO-AE3-208  and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "entity1": "EP(4)",
    "entity2": "ONO-AE3-208"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the <protein> EP(4) </protein> antagonists ONO-AE3-208 and <chemical> AH 23848 </chemical>, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "original_text": "EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the  EP(4)  antagonists ONO-AE3-208 and  AH 23848 , inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
    "entity1": "EP(4)",
    "entity2": "AH 23848"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> GW9662 </protein>, a <chemical> PPARgamma </chemical> antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells.",
    "original_text": " GW9662 , a  PPARgamma  antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells.",
    "entity1": "GW9662",
    "entity2": "PPARgamma"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Thus, the <protein> TCDD </protein>-induced reduction in canonical Wnt signaling is associated with a decrease in activators (<chemical> Rspo2 </chemical> and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.",
    "original_text": "Thus, the  TCDD -induced reduction in canonical Wnt signaling is associated with a decrease in activators ( Rspo2  and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.",
    "entity1": "TCDD",
    "entity2": "Rspo2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Thus, the <protein> TCDD </protein>-induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and <chemical> Rspo3 </chemical>) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.",
    "original_text": "Thus, the  TCDD -induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and  Rspo3 ) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.",
    "entity1": "TCDD",
    "entity2": "Rspo3"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Thus, the <protein> TCDD </protein>-induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (<chemical> Dkk1 </chemical> and Dkk2) of the pathway.",
    "original_text": "Thus, the  TCDD -induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors ( Dkk1  and Dkk2) of the pathway.",
    "entity1": "TCDD",
    "entity2": "Dkk1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Thus, the <protein> TCDD </protein>-induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and <chemical> Dkk2 </chemical>) of the pathway.",
    "original_text": "Thus, the  TCDD -induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and  Dkk2 ) of the pathway.",
    "entity1": "TCDD",
    "entity2": "Dkk2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Cytochrome P450 epoxygenase 2J2 </protein> (CYP2J2) metabolizes <chemical> arachidonic acids </chemical> to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system.",
    "original_text": " Cytochrome P450 epoxygenase 2J2  (CYP2J2) metabolizes  arachidonic acids  to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system.",
    "entity1": "Cytochrome P450 epoxygenase 2J2",
    "entity2": "arachidonic acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cytochrome P450 epoxygenase 2J2 (<protein> CYP2J2 </protein>) metabolizes <chemical> arachidonic acids </chemical> to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system.",
    "original_text": "Cytochrome P450 epoxygenase 2J2 ( CYP2J2 ) metabolizes  arachidonic acids  to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system.",
    "entity1": "CYP2J2",
    "entity2": "arachidonic acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The beta subunit has been cloned and shown to lower the K(m) of <protein> methionine adenosyltransferase II alpha2 </protein> (the MAT2A product) for <chemical> methionine </chemical> and to render the enzyme more susceptible to S-adenosylmethionine inhibition.",
    "original_text": "The beta subunit has been cloned and shown to lower the K(m) of  methionine adenosyltransferase II alpha2  (the MAT2A product) for  methionine  and to render the enzyme more susceptible to S-adenosylmethionine inhibition.",
    "entity1": "methionine adenosyltransferase II alpha2",
    "entity2": "methionine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the <protein> MAT2A </protein> product) for <chemical> methionine </chemical> and to render the enzyme more susceptible to S-adenosylmethionine inhibition.",
    "original_text": "The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the  MAT2A  product) for  methionine  and to render the enzyme more susceptible to S-adenosylmethionine inhibition.",
    "entity1": "MAT2A",
    "entity2": "methionine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific <protein> CB1 </protein> antagonist <chemical> SR 141716A </chemical>.",
    "original_text": "Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific  CB1  antagonist  SR 141716A .",
    "entity1": "CB1",
    "entity2": "SR 141716A"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas <protein> mifepristone </protein> and its monodemethylated metabolite manifested slight <chemical> glucocorticoid </chemical> agonist activity.",
    "original_text": "At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas  mifepristone  and its monodemethylated metabolite manifested slight  glucocorticoid  agonist activity.",
    "entity1": "mifepristone",
    "entity2": "glucocorticoid"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Antiarrhythmic effects of <protein> (-)-epicatechin-3-gallate </protein>, a novel <chemical> sodium channel </chemical> agonist in cultured neonatal rat ventricular myocytes.",
    "original_text": "Antiarrhythmic effects of  (-)-epicatechin-3-gallate , a novel  sodium channel  agonist in cultured neonatal rat ventricular myocytes.",
    "entity1": "(-)-epicatechin-3-gallate",
    "entity2": "sodium channel"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Choline dehydrogenase </protein> (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in <chemical> choline </chemical> oxidation.",
    "original_text": " Choline dehydrogenase  (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in  choline  oxidation.",
    "entity1": "Choline dehydrogenase",
    "entity2": "choline"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Choline dehydrogenase (<protein> CHDH </protein>) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in <chemical> choline </chemical> oxidation.",
    "original_text": "Choline dehydrogenase ( CHDH ) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in  choline  oxidation.",
    "entity1": "CHDH",
    "entity2": "choline"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Choline dehydrogenase (CHDH) and <protein> betaine-homocysteine methyltransferase </protein> (BHMT) are 2 enzymes involved in <chemical> choline </chemical> oxidation.",
    "original_text": "Choline dehydrogenase (CHDH) and  betaine-homocysteine methyltransferase  (BHMT) are 2 enzymes involved in  choline  oxidation.",
    "entity1": "betaine-homocysteine methyltransferase",
    "entity2": "choline"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (<protein> BHMT </protein>) are 2 enzymes involved in <chemical> choline </chemical> oxidation.",
    "original_text": "Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase ( BHMT ) are 2 enzymes involved in  choline  oxidation.",
    "entity1": "BHMT",
    "entity2": "choline"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> calcium </protein> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (<chemical> PLB </chemical>), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",
    "original_text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban ( PLB ), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",
    "entity1": "calcium",
    "entity2": "PLB"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> calcium </protein> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), <chemical> phospho-PLB </chemical>, and calsequestrin 2 are important for contraction and relaxation.",
    "original_text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB),  phospho-PLB , and calsequestrin 2 are important for contraction and relaxation.",
    "entity1": "calcium",
    "entity2": "phospho-PLB"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> calcium </protein> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and <chemical> calsequestrin 2 </chemical> are important for contraction and relaxation.",
    "original_text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and  calsequestrin 2  are important for contraction and relaxation.",
    "entity1": "calcium",
    "entity2": "calsequestrin 2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> calcium </protein> homeostasis proteins <chemical> sarcoendoplasmic reticulum ATPase 2a </chemical> (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",
    "original_text": "The  calcium  homeostasis proteins  sarcoendoplasmic reticulum ATPase 2a  (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",
    "entity1": "calcium",
    "entity2": "sarcoendoplasmic reticulum ATPase 2a"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> calcium </protein> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (<chemical> SERCA2a </chemical>), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",
    "original_text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a ( SERCA2a ), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",
    "entity1": "calcium",
    "entity2": "SERCA2a"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> calcium </protein> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), <chemical> sodium calcium exchanger-1 </chemical>, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",
    "original_text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a),  sodium calcium exchanger-1 , phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",
    "entity1": "calcium",
    "entity2": "sodium calcium exchanger-1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> calcium </protein> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, <chemical> phospholamban </chemical> (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",
    "original_text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1,  phospholamban  (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",
    "entity1": "calcium",
    "entity2": "phospholamban"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> mitochondrial respiratory chain complex IV </protein> (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular <chemical> oxygen </chemical>, yielding water.",
    "original_text": "The  mitochondrial respiratory chain complex IV  (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular  oxygen , yielding water.",
    "entity1": "mitochondrial respiratory chain complex IV",
    "entity2": "oxygen"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The mitochondrial respiratory chain complex IV (<protein> cytochrome c oxidase </protein>) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular <chemical> oxygen </chemical>, yielding water.",
    "original_text": "The mitochondrial respiratory chain complex IV ( cytochrome c oxidase ) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular  oxygen , yielding water.",
    "entity1": "cytochrome c oxidase",
    "entity2": "oxygen"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Similarly, pelargonidin induced the expression of <protein> CYP1A1 </protein> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (<chemical> TCDD </chemical>), the most potent activator of AhR.",
    "original_text": "Similarly, pelargonidin induced the expression of  CYP1A1  mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin ( TCDD ), the most potent activator of AhR.",
    "entity1": "CYP1A1",
    "entity2": "TCDD"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "CYP1A1 and CYP1A2 mRNAs were also increased by <protein> pelargonidin </protein> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in <chemical> CYP1A1 </chemical> protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
    "original_text": "CYP1A1 and CYP1A2 mRNAs were also increased by  pelargonidin  in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in  CYP1A1  protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
    "entity1": "pelargonidin",
    "entity2": "CYP1A1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "CYP1A1 and CYP1A2 mRNAs were also increased by <protein> pelargonidin </protein> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of <chemical> CYP1A1 </chemical> enzyme.",
    "original_text": "CYP1A1 and CYP1A2 mRNAs were also increased by  pelargonidin  in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of  CYP1A1  enzyme.",
    "entity1": "pelargonidin",
    "entity2": "CYP1A1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> CYP1A1 </protein> and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <chemical> TCDD </chemical> potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
    "original_text": " CYP1A1  and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of  TCDD  potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
    "entity1": "CYP1A1",
    "entity2": "TCDD"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "CYP1A1 and <protein> CYP1A2 </protein> mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <chemical> TCDD </chemical> potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
    "original_text": "CYP1A1 and  CYP1A2  mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of  TCDD  potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
    "entity1": "CYP1A2",
    "entity2": "TCDD"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <protein> TCDD </protein> potency) and the increase in <chemical> CYP1A1 </chemical> protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
    "original_text": "CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of  TCDD  potency) and the increase in  CYP1A1  protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
    "entity1": "TCDD",
    "entity2": "CYP1A1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <protein> TCDD </protein> potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of <chemical> CYP1A1 </chemical> enzyme.",
    "original_text": "CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of  TCDD  potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of  CYP1A1  enzyme.",
    "entity1": "TCDD",
    "entity2": "CYP1A1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of <protein> FADS2 </protein> affects the PUFA biosynthetic pathway and consequently modifies the effect of <chemical> alpha-linolenic acid </chemical> (ALA) on myocardial infarction (MI).",
    "original_text": "OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of  FADS2  affects the PUFA biosynthetic pathway and consequently modifies the effect of  alpha-linolenic acid  (ALA) on myocardial infarction (MI).",
    "entity1": "FADS2",
    "entity2": "alpha-linolenic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of <protein> FADS2 </protein> affects the PUFA biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (<chemical> ALA </chemical>) on myocardial infarction (MI).",
    "original_text": "OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of  FADS2  affects the PUFA biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid ( ALA ) on myocardial infarction (MI).",
    "entity1": "FADS2",
    "entity2": "ALA"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "However, after 12h <protein> CdCl2 </protein> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of <chemical> metallothionein-II </chemical> production, and an increase in p53 activation and the pro-apoptotic protein Bax.",
    "original_text": "However, after 12h  CdCl2  treatment, cell viability diminished in 50%, accompanied by a drastic decrease of  metallothionein-II  production, and an increase in p53 activation and the pro-apoptotic protein Bax.",
    "entity1": "CdCl2",
    "entity2": "metallothionein-II"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the <protein> G protein-coupled receptor </protein> agonist <chemical> acetylcholine </chemical> (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.",
    "original_text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the  G protein-coupled receptor  agonist  acetylcholine  (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.",
    "entity1": "G protein-coupled receptor",
    "entity2": "acetylcholine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the <protein> G protein-coupled receptor </protein> agonist acetylcholine (<chemical> ACh </chemical>) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.",
    "original_text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the  G protein-coupled receptor  agonist acetylcholine ( ACh ) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.",
    "entity1": "G protein-coupled receptor",
    "entity2": "ACh"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A <protein> naloxone-steroid hybrid azine </protein> with selective and long-acting opioid antagonism at <chemical> delta receptors </chemical> in vitro.",
    "original_text": "A  naloxone-steroid hybrid azine  with selective and long-acting opioid antagonism at  delta receptors  in vitro.",
    "entity1": "naloxone-steroid hybrid azine",
    "entity2": "delta receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The ARB <protein> eprosartan </protein> is a nonbiphenyl nontetrazole <chemical> angiotensin II type 1 receptor </chemical> (AT1) antagonist, which acts to decrease total peripheral resistance.",
    "original_text": "The ARB  eprosartan  is a nonbiphenyl nontetrazole  angiotensin II type 1 receptor  (AT1) antagonist, which acts to decrease total peripheral resistance.",
    "entity1": "eprosartan",
    "entity2": "angiotensin II type 1 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The ARB <protein> eprosartan </protein> is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (<chemical> AT1 </chemical>) antagonist, which acts to decrease total peripheral resistance.",
    "original_text": "The ARB  eprosartan  is a nonbiphenyl nontetrazole angiotensin II type 1 receptor ( AT1 ) antagonist, which acts to decrease total peripheral resistance.",
    "entity1": "eprosartan",
    "entity2": "AT1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The putative <protein> alpha 1L-adrenoceptor </protein> antagonist <chemical> JTH-601 </chemical>, but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA.",
    "original_text": "The putative  alpha 1L-adrenoceptor  antagonist  JTH-601 , but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA.",
    "entity1": "alpha 1L-adrenoceptor",
    "entity2": "JTH-601"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the <protein> alpha 1B-adrenoceptor </protein> antagonist <chemical> chloroethylclonidine </chemical> (10 microM) antagonized noradrenaline-induced contractions of SMA.",
    "original_text": "The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the  alpha 1B-adrenoceptor  antagonist  chloroethylclonidine  (10 microM) antagonized noradrenaline-induced contractions of SMA.",
    "entity1": "alpha 1B-adrenoceptor",
    "entity2": "chloroethylclonidine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective <protein> alpha 1A-adrenoceptor </protein> agonist <chemical> A-61603 </chemical> (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.",
    "original_text": "The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective  alpha 1A-adrenoceptor  agonist  A-61603  (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.",
    "entity1": "alpha 1A-adrenoceptor",
    "entity2": "A-61603"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potency of the selective <protein> alpha 1D-adrenoceptor </protein> antagonist <chemical> BMY 7378 </chemical> against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.",
    "original_text": "The potency of the selective  alpha 1D-adrenoceptor  antagonist  BMY 7378  against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.",
    "entity1": "alpha 1D-adrenoceptor",
    "entity2": "BMY 7378"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective <protein> alpha 1A-adrenoceptor </protein> antagonist <chemical> RS-17053 </chemical> against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.",
    "original_text": "The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective  alpha 1A-adrenoceptor  antagonist  RS-17053  against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.",
    "entity1": "alpha 1A-adrenoceptor",
    "entity2": "RS-17053"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the <protein> dopamine D1 receptor </protein> antagonist <chemical> SCH 39166 </chemical> ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).",
    "original_text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the  dopamine D1 receptor  antagonist  SCH 39166  ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).",
    "entity1": "dopamine D1 receptor",
    "entity2": "SCH 39166"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the <protein> dopamine D1 receptor </protein> antagonist SCH 39166 (<chemical> (-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine </chemical>) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).",
    "original_text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the  dopamine D1 receptor  antagonist SCH 39166 ( (-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine ) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).",
    "entity1": "dopamine D1 receptor",
    "entity2": "(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the <protein> dopamine D2 receptor </protein> antagonist <chemical> raclopride </chemical> (both at 0.003-0.03 mg/kg).",
    "original_text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the  dopamine D2 receptor  antagonist  raclopride  (both at 0.003-0.03 mg/kg).",
    "entity1": "dopamine D2 receptor",
    "entity2": "raclopride"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In combination with <protein> clofarabine </protein>, the ability of resveratrol to reduce the contents of <chemical> Sp1 </chemical> and its target gene products was also evident in a time- and dose-dependent experiment.",
    "original_text": "In combination with  clofarabine , the ability of resveratrol to reduce the contents of  Sp1  and its target gene products was also evident in a time- and dose-dependent experiment.",
    "entity1": "clofarabine",
    "entity2": "Sp1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In combination with clofarabine, the ability of <protein> resveratrol </protein> to reduce the contents of <chemical> Sp1 </chemical> and its target gene products was also evident in a time- and dose-dependent experiment.",
    "original_text": "In combination with clofarabine, the ability of  resveratrol  to reduce the contents of  Sp1  and its target gene products was also evident in a time- and dose-dependent experiment.",
    "entity1": "resveratrol",
    "entity2": "Sp1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Treatment of A549 and H1299 cells with <protein> dioscin </protein> caused a dose-dependent increase in ERK1/2 and <chemical> JNK1/2 </chemical> activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.",
    "original_text": "Treatment of A549 and H1299 cells with  dioscin  caused a dose-dependent increase in ERK1/2 and  JNK1/2  activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.",
    "entity1": "dioscin",
    "entity2": "JNK1/2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Treatment of A549 and H1299 cells with <protein> dioscin </protein> caused a dose-dependent increase in <chemical> ERK1/2 </chemical> and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.",
    "original_text": "Treatment of A549 and H1299 cells with  dioscin  caused a dose-dependent increase in  ERK1/2  and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.",
    "entity1": "dioscin",
    "entity2": "ERK1/2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Ribonucleotide reductase </protein> activity was found to be strongly increased in the <chemical> gemcitabine </chemical>-selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line.",
    "original_text": " Ribonucleotide reductase  activity was found to be strongly increased in the  gemcitabine -selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line.",
    "entity1": "Ribonucleotide reductase",
    "entity2": "gemcitabine"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine-selected line and <protein> purine nucleoside phosphorylase </protein> was increased in the <chemical> 2-chlorodeoxyadenosine </chemical>-selected line.",
    "original_text": "Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine-selected line and  purine nucleoside phosphorylase  was increased in the  2-chlorodeoxyadenosine -selected line.",
    "entity1": "purine nucleoside phosphorylase",
    "entity2": "2-chlorodeoxyadenosine"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> IRF3 </protein> activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by <chemical> auranofin </chemical>.",
    "original_text": " IRF3  activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by  auranofin .",
    "entity1": "IRF3",
    "entity2": "auranofin"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The results suggest that the suppression of <protein> TLR4 </protein> activity by auranofin may be the molecular mechanism through which <chemical> auranofin </chemical> exerts anti-rheumatic activity.",
    "original_text": "The results suggest that the suppression of  TLR4  activity by auranofin may be the molecular mechanism through which  auranofin  exerts anti-rheumatic activity.",
    "entity1": "TLR4",
    "entity2": "auranofin"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed <protein> phorbol 12-myristate 13-acetate </protein> plus ionomycin-induced <chemical> IL-2 </chemical> secretion in a concentration-dependent manner.",
    "original_text": "Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed  phorbol 12-myristate 13-acetate  plus ionomycin-induced  IL-2  secretion in a concentration-dependent manner.",
    "entity1": "phorbol 12-myristate 13-acetate",
    "entity2": "IL-2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Carnitine acetyltransferases (<protein> CrAT </protein>) catalyze the reversible conversion of <chemical> acetyl-CoA </chemical> and carnitine to acetylcarnitine and free CoA.",
    "original_text": "Carnitine acetyltransferases ( CrAT ) catalyze the reversible conversion of  acetyl-CoA  and carnitine to acetylcarnitine and free CoA.",
    "entity1": "CrAT",
    "entity2": "acetyl-CoA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Carnitine acetyltransferases (<protein> CrAT </protein>) catalyze the reversible conversion of acetyl-CoA and <chemical> carnitine </chemical> to acetylcarnitine and free CoA.",
    "original_text": "Carnitine acetyltransferases ( CrAT ) catalyze the reversible conversion of acetyl-CoA and  carnitine  to acetylcarnitine and free CoA.",
    "entity1": "CrAT",
    "entity2": "carnitine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> M564G </protein> mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, <chemical> acetyl-CoA </chemical>.",
    "original_text": "The  M564G  mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate,  acetyl-CoA .",
    "entity1": "M564G",
    "entity2": "acetyl-CoA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The M564G mutated <protein> CrAT </protein> showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, <chemical> acetyl-CoA </chemical>.",
    "original_text": "The M564G mutated  CrAT  showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate,  acetyl-CoA .",
    "entity1": "CrAT",
    "entity2": "acetyl-CoA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type <protein> CrAT </protein>, and lower activity toward its natural substrate, <chemical> acetyl-CoA </chemical>.",
    "original_text": "The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type  CrAT , and lower activity toward its natural substrate,  acetyl-CoA .",
    "entity1": "CrAT",
    "entity2": "acetyl-CoA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> M564G </protein> mutated CrAT showed higher activity toward longer chain <chemical> acyl-CoAs </chemical>: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
    "original_text": "The  M564G  mutated CrAT showed higher activity toward longer chain  acyl-CoAs : activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
    "entity1": "M564G",
    "entity2": "acyl-CoAs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The M564G mutated <protein> CrAT </protein> showed higher activity toward longer chain <chemical> acyl-CoAs </chemical>: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
    "original_text": "The M564G mutated  CrAT  showed higher activity toward longer chain  acyl-CoAs : activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
    "entity1": "CrAT",
    "entity2": "acyl-CoAs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The M564G mutated CrAT showed higher activity toward longer chain <protein> acyl-CoAs </protein>: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type <chemical> CrAT </chemical>, and lower activity toward its natural substrate, acetyl-CoA.",
    "original_text": "The M564G mutated CrAT showed higher activity toward longer chain  acyl-CoAs : activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type  CrAT , and lower activity toward its natural substrate, acetyl-CoA.",
    "entity1": "acyl-CoAs",
    "entity2": "CrAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> M564G </protein> mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward <chemical> myristoyl-CoA </chemical> was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
    "original_text": "The  M564G  mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward  myristoyl-CoA  was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
    "entity1": "M564G",
    "entity2": "myristoyl-CoA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The M564G mutated <protein> CrAT </protein> showed higher activity toward longer chain acyl-CoAs: activity toward <chemical> myristoyl-CoA </chemical> was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
    "original_text": "The M564G mutated  CrAT  showed higher activity toward longer chain acyl-CoAs: activity toward  myristoyl-CoA  was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
    "entity1": "CrAT",
    "entity2": "myristoyl-CoA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward <protein> myristoyl-CoA </protein> was 1250-fold higher than that of the wild-type <chemical> CrAT </chemical>, and lower activity toward its natural substrate, acetyl-CoA.",
    "original_text": "The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward  myristoyl-CoA  was 1250-fold higher than that of the wild-type  CrAT , and lower activity toward its natural substrate, acetyl-CoA.",
    "entity1": "myristoyl-CoA",
    "entity2": "CrAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Kinetic constants of the mutant <protein> CrAT </protein> showed modification in favor of longer <chemical> acyl-CoAs </chemical> as substrates.",
    "original_text": "Kinetic constants of the mutant  CrAT  showed modification in favor of longer  acyl-CoAs  as substrates.",
    "entity1": "CrAT",
    "entity2": "acyl-CoAs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in <protein> carnitine octanoyltransferase </protein> (COT) decreased activity toward its natural substrates, medium- and long-chain <chemical> acyl-CoAs </chemical>, and increased activity toward short-chain acyl-CoAs.",
    "original_text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in  carnitine octanoyltransferase  (COT) decreased activity toward its natural substrates, medium- and long-chain  acyl-CoAs , and increased activity toward short-chain acyl-CoAs.",
    "entity1": "carnitine octanoyltransferase",
    "entity2": "acyl-CoAs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (<protein> COT </protein>) decreased activity toward its natural substrates, medium- and long-chain <chemical> acyl-CoAs </chemical>, and increased activity toward short-chain acyl-CoAs.",
    "original_text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase ( COT ) decreased activity toward its natural substrates, medium- and long-chain  acyl-CoAs , and increased activity toward short-chain acyl-CoAs.",
    "entity1": "COT",
    "entity2": "acyl-CoAs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in <protein> carnitine octanoyltransferase </protein> (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain <chemical> acyl-CoAs </chemical>.",
    "original_text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in  carnitine octanoyltransferase  (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain  acyl-CoAs .",
    "entity1": "carnitine octanoyltransferase",
    "entity2": "acyl-CoAs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (<protein> COT </protein>) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain <chemical> acyl-CoAs </chemical>.",
    "original_text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase ( COT ) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain  acyl-CoAs .",
    "entity1": "COT",
    "entity2": "acyl-CoAs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We conclude that Met564 blocks the entry of medium- and long-chain <protein> acyl-CoAs </protein> to the catalytic site of <chemical> CrAT </chemical>.",
    "original_text": "We conclude that Met564 blocks the entry of medium- and long-chain  acyl-CoAs  to the catalytic site of  CrAT .",
    "entity1": "acyl-CoAs",
    "entity2": "CrAT"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Dexamethasone </protein> (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <chemical> human or rat GR </chemical>.",
    "original_text": " Dexamethasone  (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either  human or rat GR .",
    "entity1": "Dexamethasone",
    "entity2": "human or rat GR"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Dexamethasone (<protein> DEX </protein>), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <chemical> human or rat GR </chemical>.",
    "original_text": "Dexamethasone ( DEX ), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either  human or rat GR .",
    "entity1": "DEX",
    "entity2": "human or rat GR"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Dexamethasone (DEX), <protein> betamethasone </protein> (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <chemical> human or rat GR </chemical>.",
    "original_text": "Dexamethasone (DEX),  betamethasone  (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either  human or rat GR .",
    "entity1": "betamethasone",
    "entity2": "human or rat GR"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Dexamethasone (DEX), betamethasone (<protein> BM </protein>), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <chemical> human or rat GR </chemical>.",
    "original_text": "Dexamethasone (DEX), betamethasone ( BM ), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either  human or rat GR .",
    "entity1": "BM",
    "entity2": "human or rat GR"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The esterified-<protein> BM </protein>, however, had only partial transactivation agonistic activity in cells transfected with <chemical> rat GR </chemical>, whereas BM and esterified-DEX had full transactivation agonistic activity.",
    "original_text": "The esterified- BM , however, had only partial transactivation agonistic activity in cells transfected with  rat GR , whereas BM and esterified-DEX had full transactivation agonistic activity.",
    "entity1": "BM",
    "entity2": "rat GR"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Moreover, in rat hepatoma H4-II-E cells, the esterified-<protein> BM </protein> failed to induce tyrosine aminotransferase, which is regulated by <chemical> GR </chemical>-mediated transactivation activity.",
    "original_text": "Moreover, in rat hepatoma H4-II-E cells, the esterified- BM  failed to induce tyrosine aminotransferase, which is regulated by  GR -mediated transactivation activity.",
    "entity1": "BM",
    "entity2": "GR"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Consistent with the weak transactivation activity of esterified-<protein> BM </protein> mediated by <chemical> rat GR </chemical>, there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats.",
    "original_text": "Consistent with the weak transactivation activity of esterified- BM  mediated by  rat GR , there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats.",
    "entity1": "BM",
    "entity2": "rat GR"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Transport by <protein> OATP1B1 </protein> and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several <chemical> quercetin </chemical> derivatives.",
    "original_text": "Transport by  OATP1B1  and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several  quercetin  derivatives.",
    "entity1": "OATP1B1",
    "entity2": "quercetin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Transport by OATP1B1 and <protein> OATP1B3 </protein> enhances the cytotoxicity of epigallocatechin 3-O-gallate and several <chemical> quercetin </chemical> derivatives.",
    "original_text": "Transport by OATP1B1 and  OATP1B3  enhances the cytotoxicity of epigallocatechin 3-O-gallate and several  quercetin  derivatives.",
    "entity1": "OATP1B3",
    "entity2": "quercetin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Transport by <protein> OATP1B1 </protein> and OATP1B3 enhances the cytotoxicity of <chemical> epigallocatechin 3-O-gallate </chemical> and several quercetin derivatives.",
    "original_text": "Transport by  OATP1B1  and OATP1B3 enhances the cytotoxicity of  epigallocatechin 3-O-gallate  and several quercetin derivatives.",
    "entity1": "OATP1B1",
    "entity2": "epigallocatechin 3-O-gallate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Transport by OATP1B1 and <protein> OATP1B3 </protein> enhances the cytotoxicity of <chemical> epigallocatechin 3-O-gallate </chemical> and several quercetin derivatives.",
    "original_text": "Transport by OATP1B1 and  OATP1B3  enhances the cytotoxicity of  epigallocatechin 3-O-gallate  and several quercetin derivatives.",
    "entity1": "OATP1B3",
    "entity2": "epigallocatechin 3-O-gallate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Uptake of the radiolabeled model substrates <protein> estradiol 17\u03b2-glucuronide </protein>, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <chemical> OATP1B1 </chemical> or OATP1B3.",
    "original_text": "Uptake of the radiolabeled model substrates  estradiol 17\u03b2-glucuronide , estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either  OATP1B1  or OATP1B3.",
    "entity1": "estradiol 17\u03b2-glucuronide",
    "entity2": "OATP1B1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Uptake of the radiolabeled model substrates <protein> estradiol 17\u03b2-glucuronide </protein>, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <chemical> OATP1B3 </chemical>.",
    "original_text": "Uptake of the radiolabeled model substrates  estradiol 17\u03b2-glucuronide , estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or  OATP1B3 .",
    "entity1": "estradiol 17\u03b2-glucuronide",
    "entity2": "OATP1B3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, <protein> estrone 3-sulfate </protein>, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <chemical> OATP1B1 </chemical> or OATP1B3.",
    "original_text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide,  estrone 3-sulfate , and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either  OATP1B1  or OATP1B3.",
    "entity1": "estrone 3-sulfate",
    "entity2": "OATP1B1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, <protein> estrone 3-sulfate </protein>, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <chemical> OATP1B3 </chemical>.",
    "original_text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide,  estrone 3-sulfate , and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or  OATP1B3 .",
    "entity1": "estrone 3-sulfate",
    "entity2": "OATP1B3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and <protein> dehydroepiandrosterone sulfate </protein> (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <chemical> OATP1B1 </chemical> or OATP1B3.",
    "original_text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and  dehydroepiandrosterone sulfate  (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either  OATP1B1  or OATP1B3.",
    "entity1": "dehydroepiandrosterone sulfate",
    "entity2": "OATP1B1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and <protein> dehydroepiandrosterone sulfate </protein> (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <chemical> OATP1B3 </chemical>.",
    "original_text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and  dehydroepiandrosterone sulfate  (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or  OATP1B3 .",
    "entity1": "dehydroepiandrosterone sulfate",
    "entity2": "OATP1B3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (<protein> DHEAS </protein>) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <chemical> OATP1B1 </chemical> or OATP1B3.",
    "original_text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate ( DHEAS ) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either  OATP1B1  or OATP1B3.",
    "entity1": "DHEAS",
    "entity2": "OATP1B1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (<protein> DHEAS </protein>) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <chemical> OATP1B3 </chemical>.",
    "original_text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate ( DHEAS ) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or  OATP1B3 .",
    "entity1": "DHEAS",
    "entity2": "OATP1B3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Compound 6 stimulated OATP1B3-mediated <protein> estradiol 17\u03b2-glucuronide </protein> uptake by increasing the apparent affinity of <chemical> OATP1B3 </chemical> for its substrate.",
    "original_text": "Compound 6 stimulated OATP1B3-mediated  estradiol 17\u03b2-glucuronide  uptake by increasing the apparent affinity of  OATP1B3  for its substrate.",
    "entity1": "estradiol 17\u03b2-glucuronide",
    "entity2": "OATP1B3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Compound 6 stimulated <protein> OATP1B3 </protein>-mediated <chemical> estradiol 17\u03b2-glucuronide </chemical> uptake by increasing the apparent affinity of OATP1B3 for its substrate.",
    "original_text": "Compound 6 stimulated  OATP1B3 -mediated  estradiol 17\u03b2-glucuronide  uptake by increasing the apparent affinity of OATP1B3 for its substrate.",
    "entity1": "OATP1B3",
    "entity2": "estradiol 17\u03b2-glucuronide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cytotoxicity assays demonstrated that <protein> epigallocatechin 3-O-gallate </protein> (EGCG) and most of compounds 1-6 killed preferentially <chemical> OATP </chemical>-expressing CHO cells.",
    "original_text": "Cytotoxicity assays demonstrated that  epigallocatechin 3-O-gallate  (EGCG) and most of compounds 1-6 killed preferentially  OATP -expressing CHO cells.",
    "entity1": "epigallocatechin 3-O-gallate",
    "entity2": "OATP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate (<protein> EGCG </protein>) and most of compounds 1-6 killed preferentially <chemical> OATP </chemical>-expressing CHO cells.",
    "original_text": "Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate ( EGCG ) and most of compounds 1-6 killed preferentially  OATP -expressing CHO cells.",
    "entity1": "EGCG",
    "entity2": "OATP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "EGCG, 1, and 3 were the most potent cytotoxic compounds, with <protein> EGCG </protein> and 3 selectively killing <chemical> OATP1B3 </chemical>-expressing cells.",
    "original_text": "EGCG, 1, and 3 were the most potent cytotoxic compounds, with  EGCG  and 3 selectively killing  OATP1B3 -expressing cells.",
    "entity1": "EGCG",
    "entity2": "OATP1B3"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Sulindac </protein> metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit <chemical> ERK1/2 </chemical> phosphorylation in human colon cancer cells.",
    "original_text": " Sulindac  metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit  ERK1/2  phosphorylation in human colon cancer cells.",
    "entity1": "Sulindac",
    "entity2": "ERK1/2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "After inflammation was established mice were dosed with the <protein> H4R </protein> antagonist, <chemical> JNJ 7777120 </chemical>, or anti-IL-13 antibody for comparison.",
    "original_text": "After inflammation was established mice were dosed with the  H4R  antagonist,  JNJ 7777120 , or anti-IL-13 antibody for comparison.",
    "entity1": "H4R",
    "entity2": "JNJ 7777120"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Absorption and secretion of <protein> fluoride </protein> increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a <chemical> F(-)/OH(-) antiporter </chemical>.",
    "original_text": "Absorption and secretion of  fluoride  increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a  F(-)/OH(-) antiporter .",
    "entity1": "fluoride",
    "entity2": "F(-)/OH(-) antiporter"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Absorption and secretion of <protein> fluoride </protein> increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a <chemical> F(-)/H(+) cotransporter </chemical> or a F(-)/OH(-) antiporter.",
    "original_text": "Absorption and secretion of  fluoride  increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a  F(-)/H(+) cotransporter  or a F(-)/OH(-) antiporter.",
    "entity1": "fluoride",
    "entity2": "F(-)/H(+) cotransporter"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Low levels of <protein> serotonin </protein> may reduce the density of the <chemical> serotonin transporter </chemical> (SERT) by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\".",
    "original_text": "Low levels of  serotonin  may reduce the density of the  serotonin transporter  (SERT) by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\".",
    "entity1": "serotonin",
    "entity2": "serotonin transporter"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Low levels of <protein> serotonin </protein> may reduce the density of the serotonin transporter (<chemical> SERT </chemical>) by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\".",
    "original_text": "Low levels of  serotonin  may reduce the density of the serotonin transporter ( SERT ) by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\".",
    "entity1": "serotonin",
    "entity2": "SERT"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "To determine whether <protein> 3,4-methylenedioxymethamphetamine </protein> (MDMA)-induced reductions in <chemical> SERT </chemical> density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.",
    "original_text": "To determine whether  3,4-methylenedioxymethamphetamine  (MDMA)-induced reductions in  SERT  density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.",
    "entity1": "3,4-methylenedioxymethamphetamine",
    "entity2": "SERT"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "To determine whether 3,4-methylenedioxymethamphetamine (<protein> MDMA </protein>)-induced reductions in <chemical> SERT </chemical> density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.",
    "original_text": "To determine whether 3,4-methylenedioxymethamphetamine ( MDMA )-induced reductions in  SERT  density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.",
    "entity1": "MDMA",
    "entity2": "SERT"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "However, only <protein> MDMA </protein> reduced <chemical> SERT </chemical> density.",
    "original_text": "However, only  MDMA  reduced  SERT  density.",
    "entity1": "MDMA",
    "entity2": "SERT"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "This observation suggests that <protein> MDMA </protein>-induced reductions in <chemical> SERT </chemical> density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA.",
    "original_text": "This observation suggests that  MDMA -induced reductions in  SERT  density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA.",
    "entity1": "MDMA",
    "entity2": "SERT"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pharmacological properties of <protein> lorglumide </protein> as a member of a new class of <chemical> cholecystokinin </chemical> antagonists.",
    "original_text": "Pharmacological properties of  lorglumide  as a member of a new class of  cholecystokinin  antagonists.",
    "entity1": "lorglumide",
    "entity2": "cholecystokinin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Derivatives of <protein> 5-(dipentylamino)-5-oxo-pentanoic acid </protein> are a new class of non-peptide cholecystokinin (<chemical> CCK </chemical>) antagonists.",
    "original_text": "Derivatives of  5-(dipentylamino)-5-oxo-pentanoic acid  are a new class of non-peptide cholecystokinin ( CCK ) antagonists.",
    "entity1": "5-(dipentylamino)-5-oxo-pentanoic acid",
    "entity2": "CCK"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Derivatives of <protein> 5-(dipentylamino)-5-oxo-pentanoic acid </protein> are a new class of non-peptide <chemical> cholecystokinin </chemical> (CCK) antagonists.",
    "original_text": "Derivatives of  5-(dipentylamino)-5-oxo-pentanoic acid  are a new class of non-peptide  cholecystokinin  (CCK) antagonists.",
    "entity1": "5-(dipentylamino)-5-oxo-pentanoic acid",
    "entity2": "cholecystokinin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The most potent compound, <protein> D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid </protein> (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent <chemical> CCK </chemical> antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
    "original_text": "The most potent compound,  D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid  (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent  CCK  antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
    "entity1": "D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid",
    "entity2": "CCK"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (<protein> lorglumide </protein>, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent <chemical> CCK </chemical> antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
    "original_text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid ( lorglumide , CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent  CCK  antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
    "entity1": "lorglumide",
    "entity2": "CCK"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, <protein> CR 1409 </protein>), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent <chemical> CCK </chemical> antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
    "original_text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide,  CR 1409 ), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent  CCK  antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
    "entity1": "CR 1409",
    "entity2": "CCK"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In vivo <protein> lorglumide </protein> antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. <chemical> CCK-8 </chemical> or ceruletide (caerulein).",
    "original_text": "In vivo  lorglumide  antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v.  CCK-8  or ceruletide (caerulein).",
    "entity1": "lorglumide",
    "entity2": "CCK-8"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to <protein> clonidine </protein> and endogenous clonidine-displacing substance(s), and may serve as markers of <chemical> imidazoline receptors </chemical> in humans.",
    "original_text": "These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to  clonidine  and endogenous clonidine-displacing substance(s), and may serve as markers of  imidazoline receptors  in humans.",
    "entity1": "clonidine",
    "entity2": "imidazoline receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Effects of <protein> ORF 17583 </protein>, other <chemical> histamine H2-receptor </chemical> antagonists and omeprazole on gastric acid secretory states in rats and dogs.",
    "original_text": "Effects of  ORF 17583 , other  histamine H2-receptor  antagonists and omeprazole on gastric acid secretory states in rats and dogs.",
    "entity1": "ORF 17583",
    "entity2": "histamine H2-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> ORF 17583 </protein>, a <chemical> histamine H2-receptor </chemical> antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.).",
    "original_text": " ORF 17583 , a  histamine H2-receptor  antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.).",
    "entity1": "ORF 17583",
    "entity2": "histamine H2-receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "This study examined the inward transport of <protein> l-[(14)C]alanine </protein>, an <chemical> ASCT2 </chemical> preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.",
    "original_text": "This study examined the inward transport of  l-[(14)C]alanine , an  ASCT2  preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.",
    "entity1": "l-[(14)C]alanine",
    "entity2": "ASCT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the presence of the system L inhibitor BCH, Na(+)-dependent <protein> l-alanine </protein> uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through <chemical> ASCT2 </chemical>.",
    "original_text": "In the presence of the system L inhibitor BCH, Na(+)-dependent  l-alanine  uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through  ASCT2 .",
    "entity1": "l-alanine",
    "entity2": "ASCT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with <protein> amino acid </protein> transport through <chemical> ASCT2 </chemical>.",
    "original_text": "In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with  amino acid  transport through  ASCT2 .",
    "entity1": "amino acid",
    "entity2": "ASCT2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Differences in magnitude of <protein> Na(+) </protein>-dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in <chemical> ASCT2 </chemical> protein expression, this being more abundant in WKY PTE cells.",
    "original_text": "Differences in magnitude of  Na(+) -dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in  ASCT2  protein expression, this being more abundant in WKY PTE cells.",
    "entity1": "Na(+)",
    "entity2": "ASCT2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Differences in magnitude of Na(+)-dependent <protein> l-alanine </protein> uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in <chemical> ASCT2 </chemical> protein expression, this being more abundant in WKY PTE cells.",
    "original_text": "Differences in magnitude of Na(+)-dependent  l-alanine  uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in  ASCT2  protein expression, this being more abundant in WKY PTE cells.",
    "entity1": "l-alanine",
    "entity2": "ASCT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Differences in magnitude of Na(+)-dependent <protein> l-alanine </protein> uptake through <chemical> ASCT2 </chemical> between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells.",
    "original_text": "Differences in magnitude of Na(+)-dependent  l-alanine  uptake through  ASCT2  between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells.",
    "entity1": "l-alanine",
    "entity2": "ASCT2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity <protein> Na(+) </protein>-dependent amino acid transporter, with functional features of <chemical> ASCT2 </chemical> transport.",
    "original_text": "In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity  Na(+) -dependent amino acid transporter, with functional features of  ASCT2  transport.",
    "entity1": "Na(+)",
    "entity2": "ASCT2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent <protein> amino acid </protein> transporter, with functional features of <chemical> ASCT2 </chemical> transport.",
    "original_text": "In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent  amino acid  transporter, with functional features of  ASCT2  transport.",
    "entity1": "amino acid",
    "entity2": "ASCT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In conclusion, immortalized SHR and WKY PTE cells take up <protein> l-alanine </protein> mainly through a high-affinity <chemical> Na(+)-dependent amino acid transporter </chemical>, with functional features of ASCT2 transport.",
    "original_text": "In conclusion, immortalized SHR and WKY PTE cells take up  l-alanine  mainly through a high-affinity  Na(+)-dependent amino acid transporter , with functional features of ASCT2 transport.",
    "entity1": "l-alanine",
    "entity2": "Na(+)-dependent amino acid transporter"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In conclusion, immortalized SHR and WKY PTE cells take up <protein> l-alanine </protein> mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of <chemical> ASCT2 </chemical> transport.",
    "original_text": "In conclusion, immortalized SHR and WKY PTE cells take up  l-alanine  mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of  ASCT2  transport.",
    "entity1": "l-alanine",
    "entity2": "ASCT2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Brain but not spinal <protein> NR2B </protein> receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist <chemical> CP-101,606 </chemical> in a rat chronic constriction injury model.",
    "original_text": "Brain but not spinal  NR2B  receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist  CP-101,606  in a rat chronic constriction injury model.",
    "entity1": "NR2B",
    "entity2": "CP-101,606"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an <protein> NR2B </protein> subunit-selective antagonist <chemical> CP-101,606 </chemical> in a rat chronic constriction injury model.",
    "original_text": "Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an  NR2B  subunit-selective antagonist  CP-101,606  in a rat chronic constriction injury model.",
    "entity1": "NR2B",
    "entity2": "CP-101,606"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In order to examine the site of action of an <protein> NR2B </protein> subtype-selective NMDA antagonist <chemical> CP-101,606 </chemical>, we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.",
    "original_text": "In order to examine the site of action of an  NR2B  subtype-selective NMDA antagonist  CP-101,606 , we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.",
    "entity1": "NR2B",
    "entity2": "CP-101,606"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In order to examine the site of action of an NR2B subtype-selective <protein> NMDA </protein> antagonist <chemical> CP-101,606 </chemical>, we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.",
    "original_text": "In order to examine the site of action of an NR2B subtype-selective  NMDA  antagonist  CP-101,606 , we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.",
    "entity1": "NMDA",
    "entity2": "CP-101,606"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In contrast, intrathecal injection of a non-selective <protein> NMDA </protein> antagonist, <chemical> memantine </chemical>, significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist.",
    "original_text": "In contrast, intrathecal injection of a non-selective  NMDA  antagonist,  memantine , significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist.",
    "entity1": "NMDA",
    "entity2": "memantine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Omega class GSTs </protein> have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of <chemical> monomethylarsonate </chemical>, an intermediate in the pathway of arsenic biotransformation.",
    "original_text": " Omega class GSTs  have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of  monomethylarsonate , an intermediate in the pathway of arsenic biotransformation.",
    "entity1": "Omega class GSTs",
    "entity2": "monomethylarsonate"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "It is not yet clear whether <protein> tamoxifen </protein> can reduce breast cancer incidence in women with BRCA1 and <chemical> BRCA2 </chemical> mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation.",
    "original_text": "It is not yet clear whether  tamoxifen  can reduce breast cancer incidence in women with BRCA1 and  BRCA2  mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation.",
    "entity1": "tamoxifen",
    "entity2": "BRCA2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "It is not yet clear whether <protein> tamoxifen </protein> can reduce breast cancer incidence in women with BRCA1 and BRCA2 mutations, although preliminary evidence favors benefit for at least those with a <chemical> BRCA2 </chemical> mutation.",
    "original_text": "It is not yet clear whether  tamoxifen  can reduce breast cancer incidence in women with BRCA1 and BRCA2 mutations, although preliminary evidence favors benefit for at least those with a  BRCA2  mutation.",
    "entity1": "tamoxifen",
    "entity2": "BRCA2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "The positive correlation between <protein> vitamin A </protein> and <chemical> immunoglobulin A </chemical> concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis.",
    "original_text": "The positive correlation between  vitamin A  and  immunoglobulin A  concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis.",
    "entity1": "vitamin A",
    "entity2": "immunoglobulin A"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "The positive correlation between <protein> vitamin A </protein> and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during <chemical> immunoglobulins A </chemical> synthesis.",
    "original_text": "The positive correlation between  vitamin A  and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during  immunoglobulins A  synthesis.",
    "entity1": "vitamin A",
    "entity2": "immunoglobulins A"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "The positive correlation between vitamin A and <protein> immunoglobulin A </protein> concentrations might be the result of the <chemical> vitamin A </chemical> inductive effect during immunoglobulins A synthesis.",
    "original_text": "The positive correlation between vitamin A and  immunoglobulin A  concentrations might be the result of the  vitamin A  inductive effect during immunoglobulins A synthesis.",
    "entity1": "immunoglobulin A",
    "entity2": "vitamin A"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "The positive correlation between vitamin A and immunoglobulin A concentrations might be the result of the <protein> vitamin A </protein> inductive effect during <chemical> immunoglobulins A </chemical> synthesis.",
    "original_text": "The positive correlation between vitamin A and immunoglobulin A concentrations might be the result of the  vitamin A  inductive effect during  immunoglobulins A  synthesis.",
    "entity1": "vitamin A",
    "entity2": "immunoglobulins A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Specifically, <protein> all-trans-13,14-dihydroretinol </protein> is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by <chemical> Cyp26 </chemical> enzymes.",
    "original_text": "Specifically,  all-trans-13,14-dihydroretinol  is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by  Cyp26  enzymes.",
    "entity1": "all-trans-13,14-dihydroretinol",
    "entity2": "Cyp26"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Unlike mouse RetSat (mRetSat), <protein> zRetSat A </protein> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of <chemical> all-trans-retinol </chemical> to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively.",
    "original_text": "Unlike mouse RetSat (mRetSat),  zRetSat A  had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of  all-trans-retinol  to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively.",
    "entity1": "zRetSat A",
    "entity2": "all-trans-retinol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> zRetSat A </protein> also saturated the 13-14 or 7-8 double bonds of <chemical> all-trans-3,4-didehydroretinol </chemical> (vitamin A2), a second endogenous form of vitamin A in zebrafish.",
    "original_text": " zRetSat A  also saturated the 13-14 or 7-8 double bonds of  all-trans-3,4-didehydroretinol  (vitamin A2), a second endogenous form of vitamin A in zebrafish.",
    "entity1": "zRetSat A",
    "entity2": "all-trans-3,4-didehydroretinol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> zRetSat A </protein> also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (<chemical> vitamin A2 </chemical>), a second endogenous form of vitamin A in zebrafish.",
    "original_text": " zRetSat A  also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol ( vitamin A2 ), a second endogenous form of vitamin A in zebrafish.",
    "entity1": "zRetSat A",
    "entity2": "vitamin A2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the <protein> GluR3 flop </protein> splice variant and suggested that <chemical> lithium </chemical> might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function. J. Neurophysiol., 81 (1999) 1506-1512).",
    "original_text": "Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the  GluR3 flop  splice variant and suggested that  lithium  might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function. J. Neurophysiol., 81 (1999) 1506-1512).",
    "entity1": "GluR3 flop",
    "entity2": "lithium"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Moreover, BH(4) treatment of the <protein> fructose </protein>-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <chemical> nuclear factor-kappaB </chemical> and activating protein-1, which were increased in fructose-fed rats.",
    "original_text": "Moreover, BH(4) treatment of the  fructose -fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors,  nuclear factor-kappaB  and activating protein-1, which were increased in fructose-fed rats.",
    "entity1": "fructose",
    "entity2": "nuclear factor-kappaB"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Moreover, BH(4) treatment of the <protein> fructose </protein>-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <chemical> activating protein-1 </chemical>, which were increased in fructose-fed rats.",
    "original_text": "Moreover, BH(4) treatment of the  fructose -fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and  activating protein-1 , which were increased in fructose-fed rats.",
    "entity1": "fructose",
    "entity2": "activating protein-1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <protein> nuclear factor-kappaB </protein> and activating protein-1, which were increased in <chemical> fructose </chemical>-fed rats.",
    "original_text": "Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors,  nuclear factor-kappaB  and activating protein-1, which were increased in  fructose -fed rats.",
    "entity1": "nuclear factor-kappaB",
    "entity2": "fructose"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <protein> activating protein-1 </protein>, which were increased in <chemical> fructose </chemical>-fed rats.",
    "original_text": "Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and  activating protein-1 , which were increased in  fructose -fed rats.",
    "entity1": "activating protein-1",
    "entity2": "fructose"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Moreover, <protein> BH(4) </protein> treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <chemical> nuclear factor-kappaB </chemical> and activating protein-1, which were increased in fructose-fed rats.",
    "original_text": "Moreover,  BH(4)  treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors,  nuclear factor-kappaB  and activating protein-1, which were increased in fructose-fed rats.",
    "entity1": "BH(4)",
    "entity2": "nuclear factor-kappaB"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Moreover, <protein> BH(4) </protein> treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <chemical> activating protein-1 </chemical>, which were increased in fructose-fed rats.",
    "original_text": "Moreover,  BH(4)  treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and  activating protein-1 , which were increased in fructose-fed rats.",
    "entity1": "BH(4)",
    "entity2": "activating protein-1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "It has been claimed that <protein> hCTR1 </protein>, the human high affinity copper transporter, is the major entry pathway for <chemical> cDDP </chemical> and related drugs via a mechanism that mimics copper.",
    "original_text": "It has been claimed that  hCTR1 , the human high affinity copper transporter, is the major entry pathway for  cDDP  and related drugs via a mechanism that mimics copper.",
    "entity1": "hCTR1",
    "entity2": "cDDP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "It has been claimed that hCTR1, the <protein> human high affinity copper transporter </protein>, is the major entry pathway for <chemical> cDDP </chemical> and related drugs via a mechanism that mimics copper.",
    "original_text": "It has been claimed that hCTR1, the  human high affinity copper transporter , is the major entry pathway for  cDDP  and related drugs via a mechanism that mimics copper.",
    "entity1": "human high affinity copper transporter",
    "entity2": "cDDP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We confirm the correlation between higher <protein> hCTR1 </protein> levels and higher <chemical> Pt </chemical>-drug uptake in tumor cells sensitive to the drug.",
    "original_text": "We confirm the correlation between higher  hCTR1  levels and higher  Pt -drug uptake in tumor cells sensitive to the drug.",
    "entity1": "hCTR1",
    "entity2": "Pt"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In the DRN, <protein> brexpiprazole </protein> completely inhibited the firing of 5-HT neurons via <chemical> 5-HT1A </chemical> agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug/kg, respectively).",
    "original_text": "In the DRN,  brexpiprazole  completely inhibited the firing of 5-HT neurons via  5-HT1A  agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug/kg, respectively).",
    "entity1": "brexpiprazole",
    "entity2": "5-HT1A"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In the DRN, brexpiprazole completely inhibited the firing of 5-HT neurons via <protein> 5-HT1A </protein> agonism and was more potent than <chemical> aripiprazole </chemical> (ED50 = 230 and 700 mug/kg, respectively).",
    "original_text": "In the DRN, brexpiprazole completely inhibited the firing of 5-HT neurons via  5-HT1A  agonism and was more potent than  aripiprazole  (ED50 = 230 and 700 mug/kg, respectively).",
    "entity1": "5-HT1A",
    "entity2": "aripiprazole"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential <protein> 5-HT2A </protein> receptor agonist <chemical> DOI </chemical> (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.",
    "original_text": "In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential  5-HT2A  receptor agonist  DOI  (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.",
    "entity1": "5-HT2A",
    "entity2": "DOI"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential <protein> 5-HT2A </protein> receptor agonist DOI (<chemical> 2,5-dimethoxy-4-iodoamphetamine </chemical>) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.",
    "original_text": "In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential  5-HT2A  receptor agonist DOI ( 2,5-dimethoxy-4-iodoamphetamine ) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.",
    "entity1": "5-HT2A",
    "entity2": "2,5-dimethoxy-4-iodoamphetamine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Brexpiprazole reversed the inhibitory effect of the DA agonist <protein> apomorphine </protein> on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on <chemical> D2 receptors </chemical>.",
    "original_text": "Brexpiprazole reversed the inhibitory effect of the DA agonist  apomorphine  on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on  D2 receptors .",
    "entity1": "apomorphine",
    "entity2": "D2 receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the lateral geniculate nucleus, <protein> brexpiprazole </protein> displayed <chemical> alpha1B-adrenoceptor </chemical> antagonistic action.",
    "original_text": "In the lateral geniculate nucleus,  brexpiprazole  displayed  alpha1B-adrenoceptor  antagonistic action.",
    "entity1": "brexpiprazole",
    "entity2": "alpha1B-adrenoceptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The enzyme <protein> dimethylarginine dimethylaminohydrolase </protein> (DDAH) specifically hydrolyzes these asymmetrically methylated <chemical> arginine </chemical> residues to citrulline and methylamines.",
    "original_text": "The enzyme  dimethylarginine dimethylaminohydrolase  (DDAH) specifically hydrolyzes these asymmetrically methylated  arginine  residues to citrulline and methylamines.",
    "entity1": "dimethylarginine dimethylaminohydrolase",
    "entity2": "arginine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The enzyme dimethylarginine dimethylaminohydrolase (<protein> DDAH </protein>) specifically hydrolyzes these asymmetrically methylated <chemical> arginine </chemical> residues to citrulline and methylamines.",
    "original_text": "The enzyme dimethylarginine dimethylaminohydrolase ( DDAH ) specifically hydrolyzes these asymmetrically methylated  arginine  residues to citrulline and methylamines.",
    "entity1": "DDAH",
    "entity2": "arginine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Previously we have proposed that regulation of asymmetric <protein> methylarginine </protein> concentration by <chemical> DDAH </chemical> may provide a novel mechanism for the regulation of NOS activity in vivo.",
    "original_text": "Previously we have proposed that regulation of asymmetric  methylarginine  concentration by  DDAH  may provide a novel mechanism for the regulation of NOS activity in vivo.",
    "entity1": "methylarginine",
    "entity2": "DDAH"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Leukotriene A(4) hydrolase (<protein> LTA(4)H </protein>) is a cystolic enzyme that stereospecifically catalyzes the transformation of <chemical> LTA(4) </chemical> to LTB(4).",
    "original_text": "Leukotriene A(4) hydrolase ( LTA(4)H ) is a cystolic enzyme that stereospecifically catalyzes the transformation of  LTA(4)  to LTB(4).",
    "entity1": "LTA(4)H",
    "entity2": "LTA(4)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Leukotriene A(4) hydrolase </protein> (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of <chemical> LTA(4) </chemical> to LTB(4).",
    "original_text": " Leukotriene A(4) hydrolase  (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of  LTA(4)  to LTB(4).",
    "entity1": "Leukotriene A(4) hydrolase",
    "entity2": "LTA(4)"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Also in contrast to effects of multiple <protein> METH </protein> injections, 1) MDMA caused little or no decrease in binding of the <chemical> DAT </chemical> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.",
    "original_text": "Also in contrast to effects of multiple  METH  injections, 1) MDMA caused little or no decrease in binding of the  DAT  ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.",
    "entity1": "METH",
    "entity2": "DAT"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the <protein> DAT </protein> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the <chemical> MDMA </chemical>-induced reduction in plasmalemmal DA transport.",
    "original_text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the  DAT  ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the  MDMA -induced reduction in plasmalemmal DA transport.",
    "entity1": "DAT",
    "entity2": "MDMA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the <protein> DAT </protein> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal <chemical> DA </chemical> transport.",
    "original_text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the  DAT  ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal  DA  transport.",
    "entity1": "DAT",
    "entity2": "DA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the <protein> DAT </protein> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of <chemical> DA </chemical> prevented the MDMA-induced reduction in plasmalemmal DA transport.",
    "original_text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the  DAT  ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of  DA  prevented the MDMA-induced reduction in plasmalemmal DA transport.",
    "entity1": "DAT",
    "entity2": "DA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In addition to affecting <protein> DAT </protein> function, MDMA rapidly decreased vesicular <chemical> DA </chemical> transport as assessed in striatal vesicles prepared from treated rats.",
    "original_text": "In addition to affecting  DAT  function, MDMA rapidly decreased vesicular  DA  transport as assessed in striatal vesicles prepared from treated rats.",
    "entity1": "DAT",
    "entity2": "DA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Concentration-dependent inhibitory effects of baicalin on the metabolism of <protein> dextromethorphan </protein>, a dual probe of <chemical> CYP2D </chemical> and CYP3A, in rats.",
    "original_text": "Concentration-dependent inhibitory effects of baicalin on the metabolism of  dextromethorphan , a dual probe of  CYP2D  and CYP3A, in rats.",
    "entity1": "dextromethorphan",
    "entity2": "CYP2D"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Concentration-dependent inhibitory effects of baicalin on the metabolism of <protein> dextromethorphan </protein>, a dual probe of CYP2D and <chemical> CYP3A </chemical>, in rats.",
    "original_text": "Concentration-dependent inhibitory effects of baicalin on the metabolism of  dextromethorphan , a dual probe of CYP2D and  CYP3A , in rats.",
    "entity1": "dextromethorphan",
    "entity2": "CYP3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of <protein> dextromethorphan </protein> (DXM), a dual probe substrate of <chemical> CYP2D </chemical> and CYP3A, in rats.",
    "original_text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of  dextromethorphan  (DXM), a dual probe substrate of  CYP2D  and CYP3A, in rats.",
    "entity1": "dextromethorphan",
    "entity2": "CYP2D"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of <protein> dextromethorphan </protein> (DXM), a dual probe substrate of CYP2D and <chemical> CYP3A </chemical>, in rats.",
    "original_text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of  dextromethorphan  (DXM), a dual probe substrate of CYP2D and  CYP3A , in rats.",
    "entity1": "dextromethorphan",
    "entity2": "CYP3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (<protein> DXM </protein>), a dual probe substrate of <chemical> CYP2D </chemical> and CYP3A, in rats.",
    "original_text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan ( DXM ), a dual probe substrate of  CYP2D  and CYP3A, in rats.",
    "entity1": "DXM",
    "entity2": "CYP2D"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (<protein> DXM </protein>), a dual probe substrate of CYP2D and <chemical> CYP3A </chemical>, in rats.",
    "original_text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan ( DXM ), a dual probe substrate of CYP2D and  CYP3A , in rats.",
    "entity1": "DXM",
    "entity2": "CYP3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Taken together, these data demonstrate that baicalin inhibits the metabolism of <protein> DXM </protein> in a concentration-dependent manner in rats, possibly through inhibiting hepatic <chemical> CYP2D </chemical> and CYP3A activities.",
    "original_text": "Taken together, these data demonstrate that baicalin inhibits the metabolism of  DXM  in a concentration-dependent manner in rats, possibly through inhibiting hepatic  CYP2D  and CYP3A activities.",
    "entity1": "DXM",
    "entity2": "CYP2D"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Taken together, these data demonstrate that baicalin inhibits the metabolism of <protein> DXM </protein> in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and <chemical> CYP3A </chemical> activities.",
    "original_text": "Taken together, these data demonstrate that baicalin inhibits the metabolism of  DXM  in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and  CYP3A  activities.",
    "entity1": "DXM",
    "entity2": "CYP3A"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Identification of a novel <protein> benzimidazole </protein> derivative as a highly potent <chemical> NPY Y5 receptor </chemical> antagonist with an anti-obesity profile.",
    "original_text": "Identification of a novel  benzimidazole  derivative as a highly potent  NPY Y5 receptor  antagonist with an anti-obesity profile.",
    "entity1": "benzimidazole",
    "entity2": "NPY Y5 receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The beta(2)-adrenoceptor (<protein> beta(2)-AR </protein>) agonists <chemical> clenbuterol </chemical> and fenoterol have similar beneficial effects in animal models of heart failure.",
    "original_text": "The beta(2)-adrenoceptor ( beta(2)-AR ) agonists  clenbuterol  and fenoterol have similar beneficial effects in animal models of heart failure.",
    "entity1": "beta(2)-AR",
    "entity2": "clenbuterol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The <protein> beta(2)-adrenoceptor </protein> (beta(2)-AR) agonists <chemical> clenbuterol </chemical> and fenoterol have similar beneficial effects in animal models of heart failure.",
    "original_text": "The  beta(2)-adrenoceptor  (beta(2)-AR) agonists  clenbuterol  and fenoterol have similar beneficial effects in animal models of heart failure.",
    "entity1": "beta(2)-adrenoceptor",
    "entity2": "clenbuterol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The beta(2)-adrenoceptor (<protein> beta(2)-AR </protein>) agonists clenbuterol and <chemical> fenoterol </chemical> have similar beneficial effects in animal models of heart failure.",
    "original_text": "The beta(2)-adrenoceptor ( beta(2)-AR ) agonists clenbuterol and  fenoterol  have similar beneficial effects in animal models of heart failure.",
    "entity1": "beta(2)-AR",
    "entity2": "fenoterol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The <protein> beta(2)-adrenoceptor </protein> (beta(2)-AR) agonists clenbuterol and <chemical> fenoterol </chemical> have similar beneficial effects in animal models of heart failure.",
    "original_text": "The  beta(2)-adrenoceptor  (beta(2)-AR) agonists clenbuterol and  fenoterol  have similar beneficial effects in animal models of heart failure.",
    "entity1": "beta(2)-adrenoceptor",
    "entity2": "fenoterol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> beta(1)-Adrenoceptor </protein> antagonism (10 mg kg(-1) <chemical> bisoprolol </chemical>) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551).",
    "original_text": " beta(1)-Adrenoceptor  antagonism (10 mg kg(-1)  bisoprolol ) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551).",
    "entity1": "beta(1)-Adrenoceptor",
    "entity2": "bisoprolol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The mouse <protein> CYP2J </protein> subfamily includes members that have wide tissue distribution and are active in the metabolism of <chemical> arachidonic acid </chemical> (AA), linoleic acid (LA), and other lipids and xenobiotics.",
    "original_text": "The mouse  CYP2J  subfamily includes members that have wide tissue distribution and are active in the metabolism of  arachidonic acid  (AA), linoleic acid (LA), and other lipids and xenobiotics.",
    "entity1": "CYP2J",
    "entity2": "arachidonic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The mouse <protein> CYP2J </protein> subfamily includes members that have wide tissue distribution and are active in the metabolism of arachidonic acid (AA), <chemical> linoleic acid </chemical> (LA), and other lipids and xenobiotics.",
    "original_text": "The mouse  CYP2J  subfamily includes members that have wide tissue distribution and are active in the metabolism of arachidonic acid (AA),  linoleic acid  (LA), and other lipids and xenobiotics.",
    "entity1": "CYP2J",
    "entity2": "linoleic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> CPT I </protein> (carnitine palmitoyltransferase I) catalyses the conversion of <chemical> palmitoyl-CoA </chemical> into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.",
    "original_text": " CPT I  (carnitine palmitoyltransferase I) catalyses the conversion of  palmitoyl-CoA  into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.",
    "entity1": "CPT I",
    "entity2": "palmitoyl-CoA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "CPT I (<protein> carnitine palmitoyltransferase I </protein>) catalyses the conversion of <chemical> palmitoyl-CoA </chemical> into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.",
    "original_text": "CPT I ( carnitine palmitoyltransferase I ) catalyses the conversion of  palmitoyl-CoA  into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.",
    "entity1": "carnitine palmitoyltransferase I",
    "entity2": "palmitoyl-CoA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Cholesterol </protein> uptake from <chemical> lipoproteins </chemical>, intracellular vesicle transport and lipid transfer are also modified by oxysterols.",
    "original_text": " Cholesterol  uptake from  lipoproteins , intracellular vesicle transport and lipid transfer are also modified by oxysterols.",
    "entity1": "Cholesterol",
    "entity2": "lipoproteins"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment of the tissues with combined <protein> 5-HT1 </protein>/5-HT2 antagonists, <chemical> methysergide </chemical> (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
    "original_text": "Pretreatment of the tissues with combined  5-HT1 /5-HT2 antagonists,  methysergide  (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
    "entity1": "5-HT1",
    "entity2": "methysergide"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment of the tissues with combined 5-HT1/<protein> 5-HT2 </protein> antagonists, <chemical> methysergide </chemical> (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
    "original_text": "Pretreatment of the tissues with combined 5-HT1/ 5-HT2  antagonists,  methysergide  (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
    "entity1": "5-HT2",
    "entity2": "methysergide"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment of the tissues with combined <protein> 5-HT1 </protein>/5-HT2 antagonists, methysergide (1 microM) or <chemical> methiothepin </chemical> (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
    "original_text": "Pretreatment of the tissues with combined  5-HT1 /5-HT2 antagonists, methysergide (1 microM) or  methiothepin  (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
    "entity1": "5-HT1",
    "entity2": "methiothepin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment of the tissues with combined 5-HT1/<protein> 5-HT2 </protein> antagonists, methysergide (1 microM) or <chemical> methiothepin </chemical> (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
    "original_text": "Pretreatment of the tissues with combined 5-HT1/ 5-HT2  antagonists, methysergide (1 microM) or  methiothepin  (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
    "entity1": "5-HT2",
    "entity2": "methiothepin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment with <protein> tropisetron </protein> (1 microM), a <chemical> 5-HT3 </chemical> antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",
    "original_text": "Pretreatment with  tropisetron  (1 microM), a  5-HT3  antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",
    "entity1": "tropisetron",
    "entity2": "5-HT3"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, <protein> ketanserin </protein> (10 microM), a <chemical> 5-HT2 </chemical> antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",
    "original_text": "Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist,  ketanserin  (10 microM), a  5-HT2  antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",
    "entity1": "ketanserin",
    "entity2": "5-HT2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, <protein> thioperamide </protein> (10 microM), a <chemical> histamine H3 </chemical> antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",
    "original_text": "Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist,  thioperamide  (10 microM), a  histamine H3  antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",
    "entity1": "thioperamide",
    "entity2": "histamine H3"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Chlorpheniramine </protein> (10 microM), another <chemical> histamine H1 receptor </chemical> antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction.",
    "original_text": " Chlorpheniramine  (10 microM), another  histamine H1 receptor  antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction.",
    "entity1": "Chlorpheniramine",
    "entity2": "histamine H1 receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These results suggest that <protein> epinastine </protein>, although identified as a 5-HT antagonist, acts as a <chemical> 5-HT1 </chemical> agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves.",
    "original_text": "These results suggest that  epinastine , although identified as a 5-HT antagonist, acts as a  5-HT1  agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves.",
    "entity1": "epinastine",
    "entity2": "5-HT1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "It is possible that <protein> vitamin C </protein>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of <chemical> I-\u03baB\u03b5 </chemical> and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.",
    "original_text": "It is possible that  vitamin C , an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of  I-\u03baB\u03b5  and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.",
    "entity1": "vitamin C",
    "entity2": "I-\u03baB\u03b5"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding, <protein> I-\u03baB\u03b5 </protein> degradation and c-Rel nuclear translocation in cells pretreated with <chemical> vitamin C </chemical>.",
    "original_text": "We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding,  I-\u03baB\u03b5  degradation and c-Rel nuclear translocation in cells pretreated with  vitamin C .",
    "entity1": "I-\u03baB\u03b5",
    "entity2": "vitamin C"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the <protein> isoprenaline </protein> responses of the atria and the pA2 values were 8.60 and 8.98 at the <chemical> beta 1-adrenoceptors </chemical> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",
    "original_text": "Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the  isoprenaline  responses of the atria and the pA2 values were 8.60 and 8.98 at the  beta 1-adrenoceptors  of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",
    "entity1": "isoprenaline",
    "entity2": "beta 1-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Labetalol </protein> (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the <chemical> beta 1-adrenoceptors </chemical> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",
    "original_text": " Labetalol  (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the  beta 1-adrenoceptors  of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",
    "entity1": "Labetalol",
    "entity2": "beta 1-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Labetalol (> or = 3 x 10(-8) M) and <protein> dilevalol </protein> (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the <chemical> beta 1-adrenoceptors </chemical> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",
    "original_text": "Labetalol (> or = 3 x 10(-8) M) and  dilevalol  (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the  beta 1-adrenoceptors  of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",
    "entity1": "dilevalol",
    "entity2": "beta 1-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The isoprenaline attenuation responses of the portal vein were inhibited by labetalol and dilevalol (both at > or = 10(-7) M) and the pA2 value for the <protein> labetalol </protein> at <chemical> beta 2-adrenoceptors </chemical> was 7.59.",
    "original_text": "The isoprenaline attenuation responses of the portal vein were inhibited by labetalol and dilevalol (both at > or = 10(-7) M) and the pA2 value for the  labetalol  at  beta 2-adrenoceptors  was 7.59.",
    "entity1": "labetalol",
    "entity2": "beta 2-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "It is concluded that <protein> labetalol </protein> and dilevalol are <chemical> beta 1-adrenoceptor </chemical> selective antagonists.",
    "original_text": "It is concluded that  labetalol  and dilevalol are  beta 1-adrenoceptor  selective antagonists.",
    "entity1": "labetalol",
    "entity2": "beta 1-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "It is concluded that labetalol and <protein> dilevalol </protein> are <chemical> beta 1-adrenoceptor </chemical> selective antagonists.",
    "original_text": "It is concluded that labetalol and  dilevalol  are  beta 1-adrenoceptor  selective antagonists.",
    "entity1": "dilevalol",
    "entity2": "beta 1-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of <protein> flumazenil </protein> (5.0 mg/kg) - a <chemical> BDZ receptor </chemical> antagonist, immediately induced BDZ withdrawal signs in these animals.",
    "original_text": "The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of  flumazenil  (5.0 mg/kg) - a  BDZ receptor  antagonist, immediately induced BDZ withdrawal signs in these animals.",
    "entity1": "flumazenil",
    "entity2": "BDZ receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The non-selective <protein> adenosine receptor </protein> antagonist (<chemical> caffeine </chemical>), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.",
    "original_text": "The non-selective  adenosine receptor  antagonist ( caffeine ), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.",
    "entity1": "adenosine receptor",
    "entity2": "caffeine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The non-selective adenosine receptor antagonist (caffeine), and the selective <protein> adenosine A1 receptor </protein> antagonist (<chemical> DPCPX </chemical>), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.",
    "original_text": "The non-selective adenosine receptor antagonist (caffeine), and the selective  adenosine A1 receptor  antagonist ( DPCPX ), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.",
    "entity1": "adenosine A1 receptor",
    "entity2": "DPCPX"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cross-inhibition of <protein> SR-BI </protein>- and ABCA1-mediated <chemical> cholesterol </chemical> transport by the small molecules BLT-4 and glyburide.",
    "original_text": "Cross-inhibition of  SR-BI - and ABCA1-mediated  cholesterol  transport by the small molecules BLT-4 and glyburide.",
    "entity1": "SR-BI",
    "entity2": "cholesterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cross-inhibition of SR-BI- and <protein> ABCA1 </protein>-mediated <chemical> cholesterol </chemical> transport by the small molecules BLT-4 and glyburide.",
    "original_text": "Cross-inhibition of SR-BI- and  ABCA1 -mediated  cholesterol  transport by the small molecules BLT-4 and glyburide.",
    "entity1": "ABCA1",
    "entity2": "cholesterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> SR-BI </protein> is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of <chemical> cholesteryl esters </chemical> from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL.",
    "original_text": " SR-BI  is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of  cholesteryl esters  from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL.",
    "entity1": "SR-BI",
    "entity2": "cholesteryl esters"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> SR-BI </protein> is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of cholesteryl esters from lipid-rich HDL to cells and the efflux of unesterified <chemical> cholesterol </chemical> from cells to HDL.",
    "original_text": " SR-BI  is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of cholesteryl esters from lipid-rich HDL to cells and the efflux of unesterified  cholesterol  from cells to HDL.",
    "entity1": "SR-BI",
    "entity2": "cholesterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> ABCA1 </protein> mediates the efflux of unesterified <chemical> cholesterol </chemical> and phospholipids from cells to lipid-poor apolipoprotein A-I (apoA-I).",
    "original_text": " ABCA1  mediates the efflux of unesterified  cholesterol  and phospholipids from cells to lipid-poor apolipoprotein A-I (apoA-I).",
    "entity1": "ABCA1",
    "entity2": "cholesterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked <protein> ABCA1 </protein>-mediated <chemical> cholesterol </chemical> efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).",
    "original_text": "Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked  ABCA1 -mediated  cholesterol  efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).",
    "entity1": "ABCA1",
    "entity2": "cholesterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Aldo-keto reductases </protein> (AKRs) metabolize a wide range of substrates, including <chemical> polycyclic aromatic hydrocarbons </chemical> (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "original_text": " Aldo-keto reductases  (AKRs) metabolize a wide range of substrates, including  polycyclic aromatic hydrocarbons  (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "entity1": "Aldo-keto reductases",
    "entity2": "polycyclic aromatic hydrocarbons"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Aldo-keto reductases (<protein> AKRs </protein>) metabolize a wide range of substrates, including <chemical> polycyclic aromatic hydrocarbons </chemical> (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "original_text": "Aldo-keto reductases ( AKRs ) metabolize a wide range of substrates, including  polycyclic aromatic hydrocarbons  (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "entity1": "AKRs",
    "entity2": "polycyclic aromatic hydrocarbons"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Aldo-keto reductases </protein> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<chemical> PAHs </chemical>), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "original_text": " Aldo-keto reductases  (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons ( PAHs ), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "entity1": "Aldo-keto reductases",
    "entity2": "PAHs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Aldo-keto reductases (<protein> AKRs </protein>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<chemical> PAHs </chemical>), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "original_text": "Aldo-keto reductases ( AKRs ) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons ( PAHs ), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "entity1": "AKRs",
    "entity2": "PAHs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Aldo-keto reductases </protein> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (<chemical> o-quinones </chemical>) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "original_text": " Aldo-keto reductases  (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites ( o-quinones ) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "entity1": "Aldo-keto reductases",
    "entity2": "o-quinones"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Aldo-keto reductases (<protein> AKRs </protein>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (<chemical> o-quinones </chemical>) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "original_text": "Aldo-keto reductases ( AKRs ) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites ( o-quinones ) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "entity1": "AKRs",
    "entity2": "o-quinones"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Despite the importance of <protein> AKRs </protein> in <chemical> PAHs </chemical> metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs).",
    "original_text": "Despite the importance of  AKRs  in  PAHs  metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs).",
    "entity1": "AKRs",
    "entity2": "PAHs"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The pretreatment with 20\u00a0mg\u2009L(-1) <protein> La(III) </protein> could alleviate the effects of UV-B radiation on the activities of <chemical> nitrate reductase </chemical>, glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",
    "original_text": "The pretreatment with 20\u00a0mg\u2009L(-1)  La(III)  could alleviate the effects of UV-B radiation on the activities of  nitrate reductase , glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",
    "entity1": "La(III)",
    "entity2": "nitrate reductase"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The pretreatment with 20\u00a0mg\u2009L(-1) <protein> La(III) </protein> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, <chemical> glutamine synthetase </chemical>, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",
    "original_text": "The pretreatment with 20\u00a0mg\u2009L(-1)  La(III)  could alleviate the effects of UV-B radiation on the activities of nitrate reductase,  glutamine synthetase , glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",
    "entity1": "La(III)",
    "entity2": "glutamine synthetase"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The pretreatment with 20\u00a0mg\u2009L(-1) <protein> La(III) </protein> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, <chemical> glutamate synthase </chemical>, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",
    "original_text": "The pretreatment with 20\u00a0mg\u2009L(-1)  La(III)  could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase,  glutamate synthase , and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",
    "entity1": "La(III)",
    "entity2": "glutamate synthase"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The pretreatment with 20\u00a0mg\u2009L(-1) <protein> La(III) </protein> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and <chemical> glutamate dehydrogenase </chemical>, promoting amino acid conversion and protein synthesis in soybean seedlings.",
    "original_text": "The pretreatment with 20\u00a0mg\u2009L(-1)  La(III)  could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and  glutamate dehydrogenase , promoting amino acid conversion and protein synthesis in soybean seedlings.",
    "entity1": "La(III)",
    "entity2": "glutamate dehydrogenase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> TAS-102 </protein> is a novel drug containing trifluorothymidine, which is phosphorylated by <chemical> TK-1 </chemical> to its active monophosphated form, that in turn can inhibit TS.",
    "original_text": " TAS-102  is a novel drug containing trifluorothymidine, which is phosphorylated by  TK-1  to its active monophosphated form, that in turn can inhibit TS.",
    "entity1": "TAS-102",
    "entity2": "TK-1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "TAS-102 is a novel drug containing <protein> trifluorothymidine </protein>, which is phosphorylated by <chemical> TK-1 </chemical> to its active monophosphated form, that in turn can inhibit TS.",
    "original_text": "TAS-102 is a novel drug containing  trifluorothymidine , which is phosphorylated by  TK-1  to its active monophosphated form, that in turn can inhibit TS.",
    "entity1": "trifluorothymidine",
    "entity2": "TK-1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "However, recent clinical studies have shown that a single low-dose injection of <protein> ketamine </protein>, an <chemical> N-methyl d-aspartate receptor </chemical> (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.",
    "original_text": "However, recent clinical studies have shown that a single low-dose injection of  ketamine , an  N-methyl d-aspartate receptor  (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.",
    "entity1": "ketamine",
    "entity2": "N-methyl d-aspartate receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "However, recent clinical studies have shown that a single low-dose injection of <protein> ketamine </protein>, an N-methyl d-aspartate receptor (<chemical> NMDAR </chemical>) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.",
    "original_text": "However, recent clinical studies have shown that a single low-dose injection of  ketamine , an N-methyl d-aspartate receptor ( NMDAR ) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.",
    "entity1": "ketamine",
    "entity2": "NMDAR"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Doxorubicin </protein> is mainly excreted into the bile via <chemical> P-glycoprotein </chemical> (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.",
    "original_text": " Doxorubicin  is mainly excreted into the bile via  P-glycoprotein  (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.",
    "entity1": "Doxorubicin",
    "entity2": "P-glycoprotein"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Doxorubicin </protein> is mainly excreted into the bile via P-glycoprotein (<chemical> P-gp </chemical>) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.",
    "original_text": " Doxorubicin  is mainly excreted into the bile via P-glycoprotein ( P-gp ) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.",
    "entity1": "Doxorubicin",
    "entity2": "P-gp"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Doxorubicin </protein> is mainly excreted into the bile via P-glycoprotein (P-gp) and <chemical> multidrug resistance-associated protein 2 </chemical> (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.",
    "original_text": " Doxorubicin  is mainly excreted into the bile via P-glycoprotein (P-gp) and  multidrug resistance-associated protein 2  (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.",
    "entity1": "Doxorubicin",
    "entity2": "multidrug resistance-associated protein 2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Doxorubicin </protein> is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (<chemical> Mrp2 </chemical>) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.",
    "original_text": " Doxorubicin  is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 ( Mrp2 ) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.",
    "entity1": "Doxorubicin",
    "entity2": "Mrp2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Doxorubicin </protein> is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via <chemical> cytochrome P450 (CYP) 3A </chemical> subfamily.",
    "original_text": " Doxorubicin  is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via  cytochrome P450 (CYP) 3A  subfamily.",
    "entity1": "Doxorubicin",
    "entity2": "cytochrome P450 (CYP) 3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic <protein> CYP3A </protein> subfamily-mediated metabolism (21.9% decrease) of <chemical> doxorubicin </chemical>.",
    "original_text": "The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic  CYP3A  subfamily-mediated metabolism (21.9% decrease) of  doxorubicin .",
    "entity1": "CYP3A",
    "entity2": "doxorubicin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Conversely, opioid antagonists such as <protein> naloxone </protein> and naltrexone (which bind to non-selectively <chemical> opioid receptors </chemical>) have been shown to decrease alcohol consumption under various experimental conditions.",
    "original_text": "Conversely, opioid antagonists such as  naloxone  and naltrexone (which bind to non-selectively  opioid receptors ) have been shown to decrease alcohol consumption under various experimental conditions.",
    "entity1": "naloxone",
    "entity2": "opioid receptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Adenylosuccinate synthetase (<protein> AdSS </protein>) catalyzes the <chemical> Mg2+ </chemical> dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP.",
    "original_text": "Adenylosuccinate synthetase ( AdSS ) catalyzes the  Mg2+  dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP.",
    "entity1": "AdSS",
    "entity2": "Mg2+"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> Na(+)/Ca(2+) exchanger </protein> (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings <chemical> Ca(2+) </chemical> into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.",
    "original_text": "The  Na(+)/Ca(2+) exchanger  (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings  Ca(2+)  into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.",
    "entity1": "Na(+)/Ca(2+) exchanger",
    "entity2": "Ca(2+)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> Na(+)/Ca(2+) exchanger </protein> (NCX) is a bidirectional transporter that normally extrudes <chemical> Ca(2+) </chemical> from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.",
    "original_text": "The  Na(+)/Ca(2+) exchanger  (NCX) is a bidirectional transporter that normally extrudes  Ca(2+)  from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.",
    "entity1": "Na(+)/Ca(2+) exchanger",
    "entity2": "Ca(2+)"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> HSYA </protein> treatment also decreased <chemical> NF-\u03baB </chemical> p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).",
    "original_text": " HSYA  treatment also decreased  NF-\u03baB  p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).",
    "entity1": "HSYA",
    "entity2": "NF-\u03baB"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> HSYA </protein> treatment also decreased NF-\u03baB <chemical> p65 </chemical> nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).",
    "original_text": " HSYA  treatment also decreased NF-\u03baB  p65  nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).",
    "entity1": "HSYA",
    "entity2": "p65"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Block of human NaV1.5 <protein> sodium channels </protein><chemical> sodium </chemical> channels by novel alpha-hydroxyphenylamide analogues of phenytoin.",
    "original_text": "Block of human NaV1.5  sodium channels  sodium  channels by novel alpha-hydroxyphenylamide analogues of phenytoin.",
    "entity1": "sodium channels",
    "entity2": "sodium"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Block of <protein> human NaV1.5 </protein> <chemical> sodium </chemical> channels by novel alpha-hydroxyphenylamide analogues of phenytoin.",
    "original_text": "Block of  human NaV1.5   sodium  channels by novel alpha-hydroxyphenylamide analogues of phenytoin.",
    "entity1": "human NaV1.5",
    "entity2": "sodium"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Voltage-gated sodium (Na) channels </protein><chemical> Na </chemical>) channels are a critical component of electrically excitable cells.",
    "original_text": " Voltage-gated sodium (Na) channels  Na ) channels are a critical component of electrically excitable cells.",
    "entity1": "Voltage-gated sodium (Na) channels",
    "entity2": "Na"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Voltage-gated sodium (Na) channels </protein><chemical> sodium </chemical> (Na) channels are a critical component of electrically excitable cells.",
    "original_text": " Voltage-gated sodium (Na) channels  sodium  (Na) channels are a critical component of electrically excitable cells.",
    "entity1": "Voltage-gated sodium (Na) channels",
    "entity2": "sodium"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Phenytoin (diphenylhydantoin, DPH) is an established <protein> sodium channel </protein><chemical> sodium </chemical> channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.",
    "original_text": "Phenytoin (diphenylhydantoin, DPH) is an established  sodium channel  sodium  channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.",
    "entity1": "sodium channel",
    "entity2": "sodium"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit <protein> human Na(V)1.5 </protein> <chemical> sodium </chemical> channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",
    "original_text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit  human Na(V)1.5   sodium  channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",
    "entity1": "human Na(V)1.5",
    "entity2": "sodium"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 <protein> sodium channels </protein><chemical> sodium </chemical> channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",
    "original_text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5  sodium channels  sodium  channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",
    "entity1": "sodium channels",
    "entity2": "sodium"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "This information may be useful in the development of more potent <protein> sodium channel </protein><chemical> sodium </chemical> channel blockers.",
    "original_text": "This information may be useful in the development of more potent  sodium channel  sodium  channel blockers.",
    "entity1": "sodium channel",
    "entity2": "sodium"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Effects of a <protein> serotonin 5-HT(4) receptor </protein> antagonist <chemical> SB-207266 </chemical> on gastrointestinal motor and sensory function in humans.",
    "original_text": "Effects of a  serotonin 5-HT(4) receptor  antagonist  SB-207266  on gastrointestinal motor and sensory function in humans.",
    "entity1": "serotonin 5-HT(4) receptor",
    "entity2": "SB-207266"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "METHODS: Part A compared the effects of placebo to four doses of a <protein> 5-HT(4) </protein> receptor antagonist (SB-207266) on the <chemical> cisapride </chemical> mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.",
    "original_text": "METHODS: Part A compared the effects of placebo to four doses of a  5-HT(4)  receptor antagonist (SB-207266) on the  cisapride  mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.",
    "entity1": "5-HT(4)",
    "entity2": "cisapride"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "METHODS: Part A compared the effects of placebo to four doses of a <protein> 5-HT(4) </protein> receptor antagonist (<chemical> SB-207266 </chemical>) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.",
    "original_text": "METHODS: Part A compared the effects of placebo to four doses of a  5-HT(4)  receptor antagonist ( SB-207266 ) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.",
    "entity1": "5-HT(4)",
    "entity2": "SB-207266"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (<protein> SB-207266 </protein>) on the cisapride mediated increase in plasma aldosterone (a <chemical> 5-HT(4) </chemical> mediated response) and orocaecal transit in 18 subjects.",
    "original_text": "METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist ( SB-207266 ) on the cisapride mediated increase in plasma aldosterone (a  5-HT(4)  mediated response) and orocaecal transit in 18 subjects.",
    "entity1": "SB-207266",
    "entity2": "5-HT(4)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Spermidine/spermine N1-acetyltransferase </protein> (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of <chemical> spermidine </chemical> and spermine triggers export or degradation.",
    "original_text": " Spermidine/spermine N1-acetyltransferase  (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of  spermidine  and spermine triggers export or degradation.",
    "entity1": "Spermidine/spermine N1-acetyltransferase",
    "entity2": "spermidine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Spermidine/spermine N1-acetyltransferase </protein> (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and <chemical> spermine </chemical> triggers export or degradation.",
    "original_text": " Spermidine/spermine N1-acetyltransferase  (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and  spermine  triggers export or degradation.",
    "entity1": "Spermidine/spermine N1-acetyltransferase",
    "entity2": "spermine"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Treatment of C57 BL/6 mice with <protein> bleomycin </protein> increased fibroblast viability and collagen production and significantly downregulated <chemical> Nrf2 </chemical>.",
    "original_text": "Treatment of C57 BL/6 mice with  bleomycin  increased fibroblast viability and collagen production and significantly downregulated  Nrf2 .",
    "entity1": "bleomycin",
    "entity2": "Nrf2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "To confirm this novel mechanism of <protein> bleomycin </protein>-induced fibrogenesis, we attempted to upregulate <chemical> Nrf2 </chemical> and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.",
    "original_text": "To confirm this novel mechanism of  bleomycin -induced fibrogenesis, we attempted to upregulate  Nrf2  and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.",
    "entity1": "bleomycin",
    "entity2": "Nrf2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Cardiac effects of the <protein> beta 3-adrenoceptor </protein> agonist <chemical> BRL35135 </chemical> in man.",
    "original_text": "Cardiac effects of the  beta 3-adrenoceptor  agonist  BRL35135  in man.",
    "entity1": "beta 3-adrenoceptor",
    "entity2": "BRL35135"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The aim of the present study was to evaluate the cardiac effects of the <protein> beta 3-adrenoceptor </protein> agonist <chemical> BRL35135 </chemical>, and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man.",
    "original_text": "The aim of the present study was to evaluate the cardiac effects of the  beta 3-adrenoceptor  agonist  BRL35135 , and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man.",
    "entity1": "beta 3-adrenoceptor",
    "entity2": "BRL35135"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective <protein> beta 2-adrenoceptor </protein> agonist <chemical> salbutamol </chemical> 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",
    "original_text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective  beta 2-adrenoceptor  agonist  salbutamol  8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",
    "entity1": "beta 2-adrenoceptor",
    "entity2": "salbutamol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective <protein> beta 2-adrenoceptor </protein> agonist salbutamol 8 mg (<chemical> SAL </chemical>), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",
    "original_text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective  beta 2-adrenoceptor  agonist salbutamol 8 mg ( SAL ), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",
    "entity1": "beta 2-adrenoceptor",
    "entity2": "SAL"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), <protein> bisoprolol </protein> 5 mg (B5) as a selective <chemical> beta 1-adrenoceptor </chemical> antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",
    "original_text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL),  bisoprolol  5 mg (B5) as a selective  beta 1-adrenoceptor  antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",
    "entity1": "bisoprolol",
    "entity2": "beta 1-adrenoceptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by <protein> TCDD </protein>, siRNA-mediated <chemical> Cx43 </chemical> knock-down was not sufficient to stimulate proliferation in contact-inhibited cells.",
    "original_text": "Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by  TCDD , siRNA-mediated  Cx43  knock-down was not sufficient to stimulate proliferation in contact-inhibited cells.",
    "entity1": "TCDD",
    "entity2": "Cx43"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "BACKGROUND: Histamine synthesized by <protein> histidine decarboxylase </protein> (HDC) from <chemical> L-histidine </chemical> is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.",
    "original_text": "BACKGROUND: Histamine synthesized by  histidine decarboxylase  (HDC) from  L-histidine  is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.",
    "entity1": "histidine decarboxylase",
    "entity2": "L-histidine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "BACKGROUND: Histamine synthesized by histidine decarboxylase (<protein> HDC </protein>) from <chemical> L-histidine </chemical> is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.",
    "original_text": "BACKGROUND: Histamine synthesized by histidine decarboxylase ( HDC ) from  L-histidine  is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.",
    "entity1": "HDC",
    "entity2": "L-histidine"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and <protein> HDC </protein> mRNA induced by TDI in <chemical> TDI </chemical>-sensitized rats.",
    "original_text": "Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and  HDC  mRNA induced by TDI in  TDI -sensitized rats.",
    "entity1": "HDC",
    "entity2": "TDI"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Mibefradil </protein> is a <chemical> T-type Ca2+ channel </chemical> antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels.",
    "original_text": " Mibefradil  is a  T-type Ca2+ channel  antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels.",
    "entity1": "Mibefradil",
    "entity2": "T-type Ca2+ channel"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Risperidone </protein> is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the <chemical> cytochrome P450 </chemical> enzymes CYP2D6 and 3A4.",
    "original_text": " Risperidone  is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the  cytochrome P450  enzymes CYP2D6 and 3A4.",
    "entity1": "Risperidone",
    "entity2": "cytochrome P450"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Both <protein> risperidone </protein> and 9-hydroxyrisperidone are substrates of <chemical> P-glycoprotein </chemical> (P-gp), a transport protein involved in drug absorption, distribution, and elimination.",
    "original_text": "Both  risperidone  and 9-hydroxyrisperidone are substrates of  P-glycoprotein  (P-gp), a transport protein involved in drug absorption, distribution, and elimination.",
    "entity1": "risperidone",
    "entity2": "P-glycoprotein"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Both <protein> risperidone </protein> and 9-hydroxyrisperidone are substrates of P-glycoprotein (<chemical> P-gp </chemical>), a transport protein involved in drug absorption, distribution, and elimination.",
    "original_text": "Both  risperidone  and 9-hydroxyrisperidone are substrates of P-glycoprotein ( P-gp ), a transport protein involved in drug absorption, distribution, and elimination.",
    "entity1": "risperidone",
    "entity2": "P-gp"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Both risperidone and <protein> 9-hydroxyrisperidone </protein> are substrates of <chemical> P-glycoprotein </chemical> (P-gp), a transport protein involved in drug absorption, distribution, and elimination.",
    "original_text": "Both risperidone and  9-hydroxyrisperidone  are substrates of  P-glycoprotein  (P-gp), a transport protein involved in drug absorption, distribution, and elimination.",
    "entity1": "9-hydroxyrisperidone",
    "entity2": "P-glycoprotein"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Both risperidone and <protein> 9-hydroxyrisperidone </protein> are substrates of P-glycoprotein (<chemical> P-gp </chemical>), a transport protein involved in drug absorption, distribution, and elimination.",
    "original_text": "Both risperidone and  9-hydroxyrisperidone  are substrates of P-glycoprotein ( P-gp ), a transport protein involved in drug absorption, distribution, and elimination.",
    "entity1": "9-hydroxyrisperidone",
    "entity2": "P-gp"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of <protein> BW-1 </protein>, acted as substrate for <chemical> PAO </chemical>.",
    "original_text": "bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of  BW-1 , acted as substrate for  PAO .",
    "entity1": "BW-1",
    "entity2": "PAO"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Flecainide </protein> block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (<chemical> DeltaKPQ </chemical>) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",
    "original_text": " Flecainide  block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted ( DeltaKPQ ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",
    "entity1": "Flecainide",
    "entity2": "DeltaKPQ"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the <protein> long QT syndrome 3 (LQT3) sodium channel alpha </protein><chemical> sodium </chemical> channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",
    "original_text": "Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the  long QT syndrome 3 (LQT3) sodium channel alpha  sodium  channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",
    "entity1": "long QT syndrome 3 (LQT3) sodium channel alpha",
    "entity2": "sodium"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Both <protein> 5'-AMN </protein> and 5'-MABN had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and <chemical> \u03bc-receptor </chemical> antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.",
    "original_text": "Both  5'-AMN  and 5'-MABN had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and  \u03bc-receptor  antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.",
    "entity1": "5'-AMN",
    "entity2": "\u03bc-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Both 5'-AMN and <protein> 5'-MABN </protein> had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and <chemical> \u03bc-receptor </chemical> antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.",
    "original_text": "Both 5'-AMN and  5'-MABN  had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and  \u03bc-receptor  antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.",
    "entity1": "5'-MABN",
    "entity2": "\u03bc-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Plerixafor </protein>, a <chemical> CXCR4 </chemical> antagonist for the mobilization of hematopoietic stem cells.",
    "original_text": " Plerixafor , a  CXCR4  antagonist for the mobilization of hematopoietic stem cells.",
    "entity1": "Plerixafor",
    "entity2": "CXCR4"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Suppression of <protein> Src </protein>/ERK and GSK-3/\u03b2-catenin signaling by <chemical> pinosylvin </chemical> inhibits the growth of human colorectal cancer cells.",
    "original_text": "Suppression of  Src /ERK and GSK-3/\u03b2-catenin signaling by  pinosylvin  inhibits the growth of human colorectal cancer cells.",
    "entity1": "Src",
    "entity2": "pinosylvin"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Suppression of Src/<protein> ERK </protein> and GSK-3/\u03b2-catenin signaling by <chemical> pinosylvin </chemical> inhibits the growth of human colorectal cancer cells.",
    "original_text": "Suppression of Src/ ERK  and GSK-3/\u03b2-catenin signaling by  pinosylvin  inhibits the growth of human colorectal cancer cells.",
    "entity1": "ERK",
    "entity2": "pinosylvin"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Suppression of Src/ERK and <protein> GSK-3 </protein>/\u03b2-catenin signaling by <chemical> pinosylvin </chemical> inhibits the growth of human colorectal cancer cells.",
    "original_text": "Suppression of Src/ERK and  GSK-3 /\u03b2-catenin signaling by  pinosylvin  inhibits the growth of human colorectal cancer cells.",
    "entity1": "GSK-3",
    "entity2": "pinosylvin"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Suppression of Src/ERK and GSK-3/<protein> \u03b2-catenin </protein> signaling by <chemical> pinosylvin </chemical> inhibits the growth of human colorectal cancer cells.",
    "original_text": "Suppression of Src/ERK and GSK-3/ \u03b2-catenin  signaling by  pinosylvin  inhibits the growth of human colorectal cancer cells.",
    "entity1": "\u03b2-catenin",
    "entity2": "pinosylvin"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of <chemical> p21 </chemical>(WAF1/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of  p21 (WAF1/CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "p21"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(<chemical> WAF1 </chemical>/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21( WAF1 /CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "WAF1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/<chemical> CIP1 </chemical>) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/ CIP1 ) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "CIP1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and <chemical> p53 </chemical>.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and  p53 .",
    "entity1": "Pinosylvin",
    "entity2": "p53"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of <chemical> cyclin D1 </chemical>, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of  cyclin D1 , cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "cyclin D1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, <chemical> cyclin E </chemical>, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1,  cyclin E , cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "cyclin E"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, <chemical> cyclin A </chemical>, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E,  cyclin A , cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "cyclin A"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, <chemical> cyclin dependent kinase 2 </chemical> (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A,  cyclin dependent kinase 2  (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "cyclin dependent kinase 2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (<chemical> CDK2 </chemical>), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 ( CDK2 ), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "CDK2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), <chemical> CDK4 </chemical>, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2),  CDK4 , c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "CDK4"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, <chemical> c-Myc </chemical>, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4,  c-Myc , and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "c-Myc"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and <chemical> retinoblastoma protein </chemical> (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and  retinoblastoma protein  (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "retinoblastoma protein"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Pinosylvin </protein> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (<chemical> pRb </chemical>), and the upregulation of p21(WAF1/CIP1) and p53.",
    "original_text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein ( pRb ), and the upregulation of p21(WAF1/CIP1) and p53.",
    "entity1": "Pinosylvin",
    "entity2": "pRb"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "At a low pH (pH 7.4), but not pH 7.9, <protein> ifenprodil </protein> reduces the mean open time of <chemical> GluN1 </chemical>/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.",
    "original_text": "At a low pH (pH 7.4), but not pH 7.9,  ifenprodil  reduces the mean open time of  GluN1 /GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.",
    "entity1": "ifenprodil",
    "entity2": "GluN1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "At a low pH (pH 7.4), but not pH 7.9, <protein> ifenprodil </protein> reduces the mean open time of GluN1/<chemical> GluN2B </chemical> receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.",
    "original_text": "At a low pH (pH 7.4), but not pH 7.9,  ifenprodil  reduces the mean open time of GluN1/ GluN2B  receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.",
    "entity1": "ifenprodil",
    "entity2": "GluN2B"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "High <protein> glucose </protein> (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates <chemical> tuberin </chemical> and activates mTOR.",
    "original_text": "High  glucose  (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates  tuberin  and activates mTOR.",
    "entity1": "glucose",
    "entity2": "tuberin"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Systemic administration of <protein> beta2-adrenoceptor </protein> agonists, <chemical> formoterol </chemical> and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.",
    "original_text": "Systemic administration of  beta2-adrenoceptor  agonists,  formoterol  and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.",
    "entity1": "beta2-adrenoceptor",
    "entity2": "formoterol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Systemic administration of <protein> beta2-adrenoceptor </protein> agonists, formoterol and <chemical> salmeterol </chemical>, elicit skeletal muscle hypertrophy in rats at micromolar doses.",
    "original_text": "Systemic administration of  beta2-adrenoceptor  agonists, formoterol and  salmeterol , elicit skeletal muscle hypertrophy in rats at micromolar doses.",
    "entity1": "beta2-adrenoceptor",
    "entity2": "salmeterol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Two beta(2)-agonists, <protein> formoterol </protein> and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater <chemical> beta(2)-adrenoceptor </chemical> selectivity.",
    "original_text": "Two beta(2)-agonists,  formoterol  and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater  beta(2)-adrenoceptor  selectivity.",
    "entity1": "formoterol",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Two beta(2)-agonists, formoterol and <protein> salmeterol </protein>, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater <chemical> beta(2)-adrenoceptor </chemical> selectivity.",
    "original_text": "Two beta(2)-agonists, formoterol and  salmeterol , are approved for treating asthma and have an extended duration of action and increased safety, associated with greater  beta(2)-adrenoceptor  selectivity.",
    "entity1": "salmeterol",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "A dose of 25 microg kg(-1) day(-1) of <protein> formoterol </protein> elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar <chemical> beta-adrenoceptor </chemical> downregulation.",
    "original_text": "A dose of 25 microg kg(-1) day(-1) of  formoterol  elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar  beta-adrenoceptor  downregulation.",
    "entity1": "formoterol",
    "entity2": "beta-adrenoceptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "A dose of 25 microg kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than <protein> salmeterol </protein>, but resulted in similar <chemical> beta-adrenoceptor </chemical> downregulation.",
    "original_text": "A dose of 25 microg kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than  salmeterol , but resulted in similar  beta-adrenoceptor  downregulation.",
    "entity1": "salmeterol",
    "entity2": "beta-adrenoceptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "On phosphorylation of <protein> Ser40 </protein> by <chemical> protein kinase A </chemical>, the affinity for H4biopterin increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03).",
    "original_text": "On phosphorylation of  Ser40  by  protein kinase A , the affinity for H4biopterin increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03).",
    "entity1": "Ser40",
    "entity2": "protein kinase A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4-Hydroxynonenal (<protein> 4-HNE </protein>) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several <chemical> glutathione S-transferase </chemical> (GST) isoforms.",
    "original_text": "4-Hydroxynonenal ( 4-HNE ) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several  glutathione S-transferase  (GST) isoforms.",
    "entity1": "4-HNE",
    "entity2": "glutathione S-transferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4-Hydroxynonenal (<protein> 4-HNE </protein>) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (<chemical> GST </chemical>) isoforms.",
    "original_text": "4-Hydroxynonenal ( 4-HNE ) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase ( GST ) isoforms.",
    "entity1": "4-HNE",
    "entity2": "GST"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> 4-Hydroxynonenal </protein> (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several <chemical> glutathione S-transferase </chemical> (GST) isoforms.",
    "original_text": " 4-Hydroxynonenal  (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several  glutathione S-transferase  (GST) isoforms.",
    "entity1": "4-Hydroxynonenal",
    "entity2": "glutathione S-transferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> 4-Hydroxynonenal </protein> (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (<chemical> GST </chemical>) isoforms.",
    "original_text": " 4-Hydroxynonenal  (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase ( GST ) isoforms.",
    "entity1": "4-Hydroxynonenal",
    "entity2": "GST"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4-Hydroxynonenal (4-HNE) is a mutagenic <protein> alpha,beta-unsaturated aldehyde </protein> produced during oxidative injury that is conjugated by several <chemical> glutathione S-transferase </chemical> (GST) isoforms.",
    "original_text": "4-Hydroxynonenal (4-HNE) is a mutagenic  alpha,beta-unsaturated aldehyde  produced during oxidative injury that is conjugated by several  glutathione S-transferase  (GST) isoforms.",
    "entity1": "alpha,beta-unsaturated aldehyde",
    "entity2": "glutathione S-transferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4-Hydroxynonenal (4-HNE) is a mutagenic <protein> alpha,beta-unsaturated aldehyde </protein> produced during oxidative injury that is conjugated by several glutathione S-transferase (<chemical> GST </chemical>) isoforms.",
    "original_text": "4-Hydroxynonenal (4-HNE) is a mutagenic  alpha,beta-unsaturated aldehyde  produced during oxidative injury that is conjugated by several glutathione S-transferase ( GST ) isoforms.",
    "entity1": "alpha,beta-unsaturated aldehyde",
    "entity2": "GST"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The alpha class <protein> human GSTA4-4 </protein> enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward <chemical> 4-HNE </chemical> conjugation.",
    "original_text": "The alpha class  human GSTA4-4  enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward  4-HNE  conjugation.",
    "entity1": "human GSTA4-4",
    "entity2": "4-HNE"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The alpha class human GSTA4-4 enzyme (<protein> hGSTA4-4 </protein>) has a particularly high catalytic efficiency toward <chemical> 4-HNE </chemical> conjugation.",
    "original_text": "The alpha class human GSTA4-4 enzyme ( hGSTA4-4 ) has a particularly high catalytic efficiency toward  4-HNE  conjugation.",
    "entity1": "hGSTA4-4",
    "entity2": "4-HNE"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "HepG2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high <protein> GST-4 </protein><chemical> 4-HNE </chemical> catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells.",
    "original_text": "HepG2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high  GST-4  4-HNE  catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells.",
    "entity1": "GST-4",
    "entity2": "4-HNE"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Specifically, <protein> hGSTA4 </protein> cells had significantly higher GSH concentrations when exposed to 5-15 microM <chemical> 4-HNE </chemical>, but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE.",
    "original_text": "Specifically,  hGSTA4  cells had significantly higher GSH concentrations when exposed to 5-15 microM  4-HNE , but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE.",
    "entity1": "hGSTA4",
    "entity2": "4-HNE"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Specifically, <protein> hGSTA4 </protein> cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM <chemical> 4-HNE </chemical>, suggesting extensive GSH utilization at high concentrations of 4-HNE.",
    "original_text": "Specifically,  hGSTA4  cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM  4-HNE , suggesting extensive GSH utilization at high concentrations of 4-HNE.",
    "entity1": "hGSTA4",
    "entity2": "4-HNE"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In summary, our data indicates that over-expression of hGSTA4 at levels conferring high <protein> GST </protein>-<chemical> 4-HNE </chemical> conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury.",
    "original_text": "In summary, our data indicates that over-expression of hGSTA4 at levels conferring high  GST - 4-HNE  conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury.",
    "entity1": "GST",
    "entity2": "4-HNE"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, the loss of proliferative capacity of <protein> hGSTA4 </protein> cells challenged with levels of <chemical> 4-HNE </chemical> associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and/or GSH-electrophile transporter proteins, in providing full cellular protection against 4-HNE toxicity.",
    "original_text": "However, the loss of proliferative capacity of  hGSTA4  cells challenged with levels of  4-HNE  associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and/or GSH-electrophile transporter proteins, in providing full cellular protection against 4-HNE toxicity.",
    "entity1": "hGSTA4",
    "entity2": "4-HNE"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "OBJECTIVE: Preclinical evaluation of <protein> DRF 2655 </protein>, a peroxisome proliferator-activated receptor alpha (PPARalpha) and <chemical> PPARgamma </chemical> agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",
    "original_text": "OBJECTIVE: Preclinical evaluation of  DRF 2655 , a peroxisome proliferator-activated receptor alpha (PPARalpha) and  PPARgamma  agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",
    "entity1": "DRF 2655",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "OBJECTIVE: Preclinical evaluation of <protein> DRF 2655 </protein>, a <chemical> peroxisome proliferator-activated receptor alpha </chemical> (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",
    "original_text": "OBJECTIVE: Preclinical evaluation of  DRF 2655 , a  peroxisome proliferator-activated receptor alpha  (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",
    "entity1": "DRF 2655",
    "entity2": "peroxisome proliferator-activated receptor alpha"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "OBJECTIVE: Preclinical evaluation of <protein> DRF 2655 </protein>, a peroxisome proliferator-activated receptor alpha (<chemical> PPARalpha </chemical>) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",
    "original_text": "OBJECTIVE: Preclinical evaluation of  DRF 2655 , a peroxisome proliferator-activated receptor alpha ( PPARalpha ) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",
    "entity1": "DRF 2655",
    "entity2": "PPARalpha"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "db/db mice treated with <protein> DRF 2655 </protein> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes <chemical> carnitine palmitoyltransferase </chemical> and carnitine acetyltransferase, respectively.",
    "original_text": "db/db mice treated with  DRF 2655  showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes  carnitine palmitoyltransferase  and carnitine acetyltransferase, respectively.",
    "entity1": "DRF 2655",
    "entity2": "carnitine palmitoyltransferase"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "db/db mice treated with <protein> DRF 2655 </protein> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and <chemical> carnitine acetyltransferase </chemical>, respectively.",
    "original_text": "db/db mice treated with  DRF 2655  showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and  carnitine acetyltransferase , respectively.",
    "entity1": "DRF 2655",
    "entity2": "carnitine acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The enzyme <protein> cyclo-oxygenase </protein> catalyses the oxygenation of <chemical> arachidonic acid </chemical>, leading to the formation of prostaglandins.",
    "original_text": "The enzyme  cyclo-oxygenase  catalyses the oxygenation of  arachidonic acid , leading to the formation of prostaglandins.",
    "entity1": "cyclo-oxygenase",
    "entity2": "arachidonic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> hCOX-1 </protein> had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for <chemical> arachidonate </chemical> and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme.",
    "original_text": " hCOX-1  had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for  arachidonate  and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme.",
    "entity1": "hCOX-1",
    "entity2": "arachidonate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas <protein> hCOX-2 </protein> had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for <chemical> arachidonate </chemical> and a Vmax. of 1090 nmol of O2/nmol of enzyme.",
    "original_text": "hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas  hCOX-2  had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for  arachidonate  and a Vmax. of 1090 nmol of O2/nmol of enzyme.",
    "entity1": "hCOX-2",
    "entity2": "arachidonate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the <protein> glycine decarboxylase complex </protein> (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with <chemical> glycine </chemical> (Gly) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the  glycine decarboxylase complex  (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with  glycine  (Gly) as one-carbon (1-C) source.",
    "entity1": "glycine decarboxylase complex",
    "entity2": "glycine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (<protein> GDC </protein>, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with <chemical> glycine </chemical> (Gly) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex ( GDC , EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with  glycine  (Gly) as one-carbon (1-C) source.",
    "entity1": "GDC",
    "entity2": "glycine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, <protein> EC 2.1.1.10 </protein>) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with <chemical> glycine </chemical> (Gly) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC,  EC 2.1.1.10 ) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with  glycine  (Gly) as one-carbon (1-C) source.",
    "entity1": "EC 2.1.1.10",
    "entity2": "glycine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and <protein> serine hydroxymethyltransferase </protein> (SHMT, EC 2.1.2.1) with <chemical> glycine </chemical> (Gly) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  serine hydroxymethyltransferase  (SHMT, EC 2.1.2.1) with  glycine  (Gly) as one-carbon (1-C) source.",
    "entity1": "serine hydroxymethyltransferase",
    "entity2": "glycine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (<protein> SHMT </protein>, EC 2.1.2.1) with <chemical> glycine </chemical> (Gly) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase ( SHMT , EC 2.1.2.1) with  glycine  (Gly) as one-carbon (1-C) source.",
    "entity1": "SHMT",
    "entity2": "glycine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, <protein> EC 2.1.2.1 </protein>) with <chemical> glycine </chemical> (Gly) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT,  EC 2.1.2.1 ) with  glycine  (Gly) as one-carbon (1-C) source.",
    "entity1": "EC 2.1.2.1",
    "entity2": "glycine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the <protein> glycine decarboxylase complex </protein> (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<chemical> Gly </chemical>) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the  glycine decarboxylase complex  (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine ( Gly ) as one-carbon (1-C) source.",
    "entity1": "glycine decarboxylase complex",
    "entity2": "Gly"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (<protein> GDC </protein>, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<chemical> Gly </chemical>) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex ( GDC , EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine ( Gly ) as one-carbon (1-C) source.",
    "entity1": "GDC",
    "entity2": "Gly"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, <protein> EC 2.1.1.10 </protein>) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<chemical> Gly </chemical>) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC,  EC 2.1.1.10 ) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine ( Gly ) as one-carbon (1-C) source.",
    "entity1": "EC 2.1.1.10",
    "entity2": "Gly"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and <protein> serine hydroxymethyltransferase </protein> (SHMT, EC 2.1.2.1) with glycine (<chemical> Gly </chemical>) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  serine hydroxymethyltransferase  (SHMT, EC 2.1.2.1) with glycine ( Gly ) as one-carbon (1-C) source.",
    "entity1": "serine hydroxymethyltransferase",
    "entity2": "Gly"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (<protein> SHMT </protein>, EC 2.1.2.1) with glycine (<chemical> Gly </chemical>) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase ( SHMT , EC 2.1.2.1) with glycine ( Gly ) as one-carbon (1-C) source.",
    "entity1": "SHMT",
    "entity2": "Gly"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, <protein> EC 2.1.2.1 </protein>) with glycine (<chemical> Gly </chemical>) as one-carbon (1-C) source.",
    "original_text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT,  EC 2.1.2.1 ) with glycine ( Gly ) as one-carbon (1-C) source.",
    "entity1": "EC 2.1.2.1",
    "entity2": "Gly"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "An alternative THF-dependent pathway involves the <protein> C1-THF synthase </protein>/SHMT activities with <chemical> formate </chemical> as 1-C source.",
    "original_text": "An alternative THF-dependent pathway involves the  C1-THF synthase /SHMT activities with  formate  as 1-C source.",
    "entity1": "C1-THF synthase",
    "entity2": "formate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "An alternative THF-dependent pathway involves the C1-THF synthase/<protein> SHMT </protein> activities with <chemical> formate </chemical> as 1-C source.",
    "original_text": "An alternative THF-dependent pathway involves the C1-THF synthase/ SHMT  activities with  formate  as 1-C source.",
    "entity1": "SHMT",
    "entity2": "formate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Firstly, transgenic plants overexpressing <protein> formate dehydrogenase </protein> (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in <chemical> formate </chemical> metabolism.",
    "original_text": "Firstly, transgenic plants overexpressing  formate dehydrogenase  (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in  formate  metabolism.",
    "entity1": "formate dehydrogenase",
    "entity2": "formate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Firstly, transgenic plants overexpressing formate dehydrogenase (<protein> FDH </protein>, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in <chemical> formate </chemical> metabolism.",
    "original_text": "Firstly, transgenic plants overexpressing formate dehydrogenase ( FDH , EC 1.2.1.2) were used to continue our previous studies on the function of FDH in  formate  metabolism.",
    "entity1": "FDH",
    "entity2": "formate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, <protein> EC 1.2.1.2 </protein>) were used to continue our previous studies on the function of FDH in <chemical> formate </chemical> metabolism.",
    "original_text": "Firstly, transgenic plants overexpressing formate dehydrogenase (FDH,  EC 1.2.1.2 ) were used to continue our previous studies on the function of FDH in  formate  metabolism.",
    "entity1": "EC 1.2.1.2",
    "entity2": "formate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of <protein> FDH </protein> in <chemical> formate </chemical> metabolism.",
    "original_text": "Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of  FDH  in  formate  metabolism.",
    "entity1": "FDH",
    "entity2": "formate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of <protein> formate </protein> to CO(2) by the <chemical> FDH </chemical> reaction is the primary and preferred fate of the organic acid in Arabidopsis.",
    "original_text": "We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of  formate  to CO(2) by the  FDH  reaction is the primary and preferred fate of the organic acid in Arabidopsis.",
    "entity1": "formate",
    "entity2": "FDH"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The ratio between the <protein> GDC </protein>/SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from <chemical> [alpha-(13)C]Gly </chemical> and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.",
    "original_text": "The ratio between the  GDC /SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from  [alpha-(13)C]Gly  and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.",
    "entity1": "GDC",
    "entity2": "[alpha-(13)C]Gly"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The ratio between the GDC/SHMT and <protein> C1-THF synthase </protein>/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and <chemical> [(13)C]formate </chemical>, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.",
    "original_text": "The ratio between the GDC/SHMT and  C1-THF synthase /SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and  [(13)C]formate , respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.",
    "entity1": "C1-THF synthase",
    "entity2": "[(13)C]formate"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the <protein> endothelin ET(B) receptor </protein> antagonist <chemical> RES 701-1 </chemical>, by indomethacin, or by glibenclamide.",
    "original_text": "The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the  endothelin ET(B) receptor  antagonist  RES 701-1 , by indomethacin, or by glibenclamide.",
    "entity1": "endothelin ET(B) receptor",
    "entity2": "RES 701-1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the <protein> thromboxane A2 receptor </protein> antagonists <chemical> GR32191 </chemical> and ridogrel.",
    "original_text": "The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the  thromboxane A2 receptor  antagonists  GR32191  and ridogrel.",
    "entity1": "thromboxane A2 receptor",
    "entity2": "GR32191"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the <protein> thromboxane A2 receptor </protein> antagonists GR32191 and <chemical> ridogrel </chemical>.",
    "original_text": "The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the  thromboxane A2 receptor  antagonists GR32191 and  ridogrel .",
    "entity1": "thromboxane A2 receptor",
    "entity2": "ridogrel"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A novel class of <protein> quinoxalines </protein> has been discovered as antagonists of the <chemical> IgG </chemical>:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.",
    "original_text": "A novel class of  quinoxalines  has been discovered as antagonists of the  IgG :FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.",
    "entity1": "quinoxalines",
    "entity2": "IgG"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A novel class of <protein> quinoxalines </protein> has been discovered as antagonists of the IgG:<chemical> FcRn </chemical> protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.",
    "original_text": "A novel class of  quinoxalines  has been discovered as antagonists of the IgG: FcRn  protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.",
    "entity1": "quinoxalines",
    "entity2": "FcRn"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Agmatine </protein>, locally synthesized, is an endogenous agonist at <chemical> imidazoline receptors </chemical>, a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter.",
    "original_text": " Agmatine , locally synthesized, is an endogenous agonist at  imidazoline receptors , a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter.",
    "entity1": "Agmatine",
    "entity2": "imidazoline receptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of <protein> serotonin </protein>, possibly by facilitating the interaction of serotonin with transport-ready conformations of <chemical> SERT </chemical> when concentrations of serotonin were low and rate limiting.",
    "original_text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of  serotonin , possibly by facilitating the interaction of serotonin with transport-ready conformations of  SERT  when concentrations of serotonin were low and rate limiting.",
    "entity1": "serotonin",
    "entity2": "SERT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of <protein> serotonin </protein> with transport-ready conformations of <chemical> SERT </chemical> when concentrations of serotonin were low and rate limiting.",
    "original_text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of  serotonin  with transport-ready conformations of  SERT  when concentrations of serotonin were low and rate limiting.",
    "entity1": "serotonin",
    "entity2": "SERT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of serotonin with transport-ready conformations of <protein> SERT </protein> when concentrations of <chemical> serotonin </chemical> were low and rate limiting.",
    "original_text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of serotonin with transport-ready conformations of  SERT  when concentrations of  serotonin  were low and rate limiting.",
    "entity1": "SERT",
    "entity2": "serotonin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (<protein> NifS </protein>) that is involved in the activation of sulphur from <chemical> l-cysteine </chemical>, and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed.",
    "original_text": "Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme ( NifS ) that is involved in the activation of sulphur from  l-cysteine , and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed.",
    "entity1": "NifS",
    "entity2": "l-cysteine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> [6]-gingerol </protein>: a novel <chemical> AT\u2081 </chemical> antagonist for the treatment of cardiovascular disease.",
    "original_text": " [6]-gingerol : a novel  AT\u2081  antagonist for the treatment of cardiovascular disease.",
    "entity1": "[6]-gingerol",
    "entity2": "AT\u2081"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> [6]-Gingerol </protein> derived from Zingiber officinale Roscoe (ginger) was identified as a novel <chemical> angiotensin II type 1 receptor </chemical> antagonist, with an IC50 value of 8.173 \u00b5M.",
    "original_text": " [6]-Gingerol  derived from Zingiber officinale Roscoe (ginger) was identified as a novel  angiotensin II type 1 receptor  antagonist, with an IC50 value of 8.173 \u00b5M.",
    "entity1": "[6]-Gingerol",
    "entity2": "angiotensin II type 1 receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> N(5)-Substituted H(4)biopterin </protein> derivatives were not oxidized to products serving as substrates for <chemical> dihydropteridine reductase </chemical> and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.",
    "original_text": " N(5)-Substituted H(4)biopterin  derivatives were not oxidized to products serving as substrates for  dihydropteridine reductase  and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.",
    "entity1": "N(5)-Substituted H(4)biopterin",
    "entity2": "dihydropteridine reductase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Mitochondrial arginase II </protein> modulates nitric-oxide synthesis through nonfreely exchangeable <chemical> L-arginine </chemical> pools in human endothelial cells.",
    "original_text": " Mitochondrial arginase II  modulates nitric-oxide synthesis through nonfreely exchangeable  L-arginine  pools in human endothelial cells.",
    "entity1": "Mitochondrial arginase II",
    "entity2": "L-arginine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <protein> L-arginine </protein>, the common substrate of <chemical> constitutive nitric-oxide synthase </chemical> (NOS) and cytosolic arginase I and mitochondrial arginase II.",
    "original_text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of  L-arginine , the common substrate of  constitutive nitric-oxide synthase  (NOS) and cytosolic arginase I and mitochondrial arginase II.",
    "entity1": "L-arginine",
    "entity2": "constitutive nitric-oxide synthase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <protein> L-arginine </protein>, the common substrate of constitutive nitric-oxide synthase (<chemical> NOS </chemical>) and cytosolic arginase I and mitochondrial arginase II.",
    "original_text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of  L-arginine , the common substrate of constitutive nitric-oxide synthase ( NOS ) and cytosolic arginase I and mitochondrial arginase II.",
    "entity1": "L-arginine",
    "entity2": "NOS"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <protein> L-arginine </protein>, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic <chemical> arginase I </chemical> and mitochondrial arginase II.",
    "original_text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of  L-arginine , the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic  arginase I  and mitochondrial arginase II.",
    "entity1": "L-arginine",
    "entity2": "arginase I"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <protein> L-arginine </protein>, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and <chemical> mitochondrial arginase II </chemical>.",
    "original_text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of  L-arginine , the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and  mitochondrial arginase II .",
    "entity1": "L-arginine",
    "entity2": "mitochondrial arginase II"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Addition of <protein> putrescine </protein> restored the induction of apoptosis as indicated by an increase in the number of detached cells and <chemical> caspase 3 </chemical> activity.",
    "original_text": "Addition of  putrescine  restored the induction of apoptosis as indicated by an increase in the number of detached cells and  caspase 3  activity.",
    "entity1": "putrescine",
    "entity2": "caspase 3"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "On the other hand, in patients with a mean serum <protein> carvedilol </protein> level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start ofcarvedilol therapy, the degree of reduction in the <chemical> BNP </chemical> value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l.",
    "original_text": "On the other hand, in patients with a mean serum  carvedilol  level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start ofcarvedilol therapy, the degree of reduction in the  BNP  value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l.",
    "entity1": "carvedilol",
    "entity2": "BNP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Interestingly, the allele of PRO1 was shown to enhance the activities of <protein> gamma-glutamyl kinase </protein> and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from <chemical> L-glutamate </chemical> and which together may form a complex in vivo.",
    "original_text": "Interestingly, the allele of PRO1 was shown to enhance the activities of  gamma-glutamyl kinase  and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from  L-glutamate  and which together may form a complex in vivo.",
    "entity1": "gamma-glutamyl kinase",
    "entity2": "L-glutamate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and <protein> gamma-glutamyl phosphate reductase </protein>, both of which catalyze the first two steps of L-proline synthesis from <chemical> L-glutamate </chemical> and which together may form a complex in vivo.",
    "original_text": "Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and  gamma-glutamyl phosphate reductase , both of which catalyze the first two steps of L-proline synthesis from  L-glutamate  and which together may form a complex in vivo.",
    "entity1": "gamma-glutamyl phosphate reductase",
    "entity2": "L-glutamate"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Terbutaline (Bricanyl) and its prodrug <protein> Bambuterol </protein> (Bambec) are highly potent <chemical> beta(2)-adrenoceptor </chemical> agonists often used in asthma patients.",
    "original_text": "Terbutaline (Bricanyl) and its prodrug  Bambuterol  (Bambec) are highly potent  beta(2)-adrenoceptor  agonists often used in asthma patients.",
    "entity1": "Bambuterol",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Terbutaline (Bricanyl) and its prodrug Bambuterol (<protein> Bambec </protein>) are highly potent <chemical> beta(2)-adrenoceptor </chemical> agonists often used in asthma patients.",
    "original_text": "Terbutaline (Bricanyl) and its prodrug Bambuterol ( Bambec ) are highly potent  beta(2)-adrenoceptor  agonists often used in asthma patients.",
    "entity1": "Bambec",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Terbutaline </protein> (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent <chemical> beta(2)-adrenoceptor </chemical> agonists often used in asthma patients.",
    "original_text": " Terbutaline  (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent  beta(2)-adrenoceptor  agonists often used in asthma patients.",
    "entity1": "Terbutaline",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Terbutaline (<protein> Bricanyl </protein>) and its prodrug Bambuterol (Bambec) are highly potent <chemical> beta(2)-adrenoceptor </chemical> agonists often used in asthma patients.",
    "original_text": "Terbutaline ( Bricanyl ) and its prodrug Bambuterol (Bambec) are highly potent  beta(2)-adrenoceptor  agonists often used in asthma patients.",
    "entity1": "Bricanyl",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> (+/-)-tamsulosin </protein>, an <chemical> alpha 1A-adrenoceptor </chemical> antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart.",
    "original_text": " (+/-)-tamsulosin , an  alpha 1A-adrenoceptor  antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart.",
    "entity1": "(+/-)-tamsulosin",
    "entity2": "alpha 1A-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The influence of <protein> (+/-)-tamsulosin </protein>, a selective <chemical> alpha 1A-adrenoceptor </chemical> antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium.",
    "original_text": "The influence of  (+/-)-tamsulosin , a selective  alpha 1A-adrenoceptor  antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium.",
    "entity1": "(+/-)-tamsulosin",
    "entity2": "alpha 1A-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of <protein> phenylephrine </protein> even after inactivation of <chemical> alpha 1B-adrenoceptors </chemical> by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",
    "original_text": "(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of  phenylephrine  even after inactivation of  alpha 1B-adrenoceptors  by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",
    "entity1": "phenylephrine",
    "entity2": "alpha 1B-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> (+/-)-Tamsulosin </protein> effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of <chemical> alpha 1B-adrenoceptors </chemical> by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",
    "original_text": " (+/-)-Tamsulosin  effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of  alpha 1B-adrenoceptors  by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",
    "entity1": "(+/-)-Tamsulosin",
    "entity2": "alpha 1B-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> (+/-)-Tamsulosin </protein>, over the range of concentrations at which it antagonized the positive inotropic effect mediated by <chemical> alpha 1-adrenoceptors </chemical>, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine.",
    "original_text": " (+/-)-Tamsulosin , over the range of concentrations at which it antagonized the positive inotropic effect mediated by  alpha 1-adrenoceptors , did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine.",
    "entity1": "(+/-)-Tamsulosin",
    "entity2": "alpha 1-adrenoceptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and <protein> oxymetazoline </protein>-sensitive subtype of <chemical> alpha 1-adrenoceptors </chemical>, is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",
    "original_text": "These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and  oxymetazoline -sensitive subtype of  alpha 1-adrenoceptors , is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",
    "entity1": "oxymetazoline",
    "entity2": "alpha 1-adrenoceptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "These results indicate that the positive inotropic effect, mediated via <protein> (+/-)-tamsulosin </protein>- and oxymetazoline-sensitive subtype of <chemical> alpha 1-adrenoceptors </chemical>, is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",
    "original_text": "These results indicate that the positive inotropic effect, mediated via  (+/-)-tamsulosin - and oxymetazoline-sensitive subtype of  alpha 1-adrenoceptors , is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",
    "entity1": "(+/-)-tamsulosin",
    "entity2": "alpha 1-adrenoceptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the present study, we have evaluated possible participation of <protein> monocarboxylate transporters </protein> (MCTs) responsible for the bidirectional membrane transport of <chemical> pyruvate </chemical> in the cytoprotective property in osteoblasts.",
    "original_text": "In the present study, we have evaluated possible participation of  monocarboxylate transporters  (MCTs) responsible for the bidirectional membrane transport of  pyruvate  in the cytoprotective property in osteoblasts.",
    "entity1": "monocarboxylate transporters",
    "entity2": "pyruvate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the present study, we have evaluated possible participation of monocarboxylate transporters (<protein> MCTs </protein>) responsible for the bidirectional membrane transport of <chemical> pyruvate </chemical> in the cytoprotective property in osteoblasts.",
    "original_text": "In the present study, we have evaluated possible participation of monocarboxylate transporters ( MCTs ) responsible for the bidirectional membrane transport of  pyruvate  in the cytoprotective property in osteoblasts.",
    "entity1": "MCTs",
    "entity2": "pyruvate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Mammalian ALDH1B1 </protein>, another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing <chemical> acetaldehyde </chemical> but has a tissue distribution and pattern of activity distinct from that of ALDH2.",
    "original_text": " Mammalian ALDH1B1 , another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing  acetaldehyde  but has a tissue distribution and pattern of activity distinct from that of ALDH2.",
    "entity1": "Mammalian ALDH1B1",
    "entity2": "acetaldehyde"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with <protein> ALDH2 </protein>, is also capable of metabolizing <chemical> acetaldehyde </chemical> but has a tissue distribution and pattern of activity distinct from that of ALDH2.",
    "original_text": "Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with  ALDH2 , is also capable of metabolizing  acetaldehyde  but has a tissue distribution and pattern of activity distinct from that of ALDH2.",
    "entity1": "ALDH2",
    "entity2": "acetaldehyde"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Evidence has accumulated in the last few years that the expression of the <protein> microsomal/peroxidase antigen </protein> (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular <chemical> cAMP </chemical> accumulation and protein synthesis.",
    "original_text": "Evidence has accumulated in the last few years that the expression of the  microsomal/peroxidase antigen  (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular  cAMP  accumulation and protein synthesis.",
    "entity1": "microsomal/peroxidase antigen",
    "entity2": "cAMP"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Evidence has accumulated in the last few years that the expression of the microsomal/peroxidase antigen (<protein> M/TPO-Ag </protein>) in thyroid cells is induced by TSH, through pathways which involve intracellular <chemical> cAMP </chemical> accumulation and protein synthesis.",
    "original_text": "Evidence has accumulated in the last few years that the expression of the microsomal/peroxidase antigen ( M/TPO-Ag ) in thyroid cells is induced by TSH, through pathways which involve intracellular  cAMP  accumulation and protein synthesis.",
    "entity1": "M/TPO-Ag",
    "entity2": "cAMP"
  }
]